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Part I
Introduction

Chapter 1
General introduction, aims and outline
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Stroke in young adults
Stroke is one of the leading causes of death with an annual 6 million fatal events 
worldwide.1 In the Netherlands, 200,000 men and women have a history of stroke, 
36,000 are newly diagnosed with stroke each year and 10,000 die from stroke 
annually.2 Stroke accounts for more than 4% of direct health-care expenditure 
in developed countries and is one of the ten most expensive diseases in the 
Netherlands.3, 4  Stroke is clinically defined by an acute neurological deficit (for 
example one sided weakness, aphasia, hemianopia) that can best be explained by 
an occlusion or rupture of the cerebral blood vessels. 
Figure 1 shows that, although stroke mainly affects elderly people, still approximately 
10% occurs in patients younger than 50 years. Before the age of 35 years stroke is 
more frequent in women, but among those young stroke patients after the age of 35 
years, men outnumber women.5, 6 
Figure 1 Cumulative age-specific contribution to total stroke incidence in the 
Netherlands
Figure 1 Cumulative age-specific contribution to total stroke incidence in the Netherlands. (Source: Nationaal 
Kompas Volksgezondheid. Bilthoven: RIVM)
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There is no uniform definition of young stroke. Stroke is an umbrella term for both 
short (TIA) and longer lasting periods of cerebral ischemia, but also intracerebral 
hemorrhage (ICH), however most studies hardly include any outcome data on 
these, other than ischemic stroke. Furthermore, age limits vary; lower age limit in 
studies on young stroke is generally 15 or 18 years old, whereas the upper age limit 
varies between 40 and 55 years. For the studies described in this thesis, we defined 
young stroke as a TIA, ischemic stroke or intracerebral hemorrhage in adults aged 
18 through 50. 
Although the overall incidence of stroke is declining, the incidence of stroke in adults 
younger than 55 years is increasing (Figure 2).7 
This increase is suggested to be mainly attributable to a growing prevalence of 
”traditional” vascular risk factors, including smoking, diabetes, hypertension, 
hypercholesterolemia, and obesity in young adults over time.7 This challenges the 
traditional view that young stroke is often caused by “rare” causes.8
Figure 2 Age-specific incidence rate by calendar-year for first-ever stroke 
in the White population of the Greater Cincinatti/Northern Kentucky 
region in the United States
Based on Kissela et al. 20127
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Risk factors for stroke in young adults
Diseases and risk factors that have traditionally been considered to be important 
in the etiology of stroke in young adults include non-atherosclerotic arteriopathy’s 
(mainly dissections), cardiac causes, migraine,  coagulation disorders, pregnancy and 
puerperium, use of oral contraceptives, substance abuse and some monogenetic 
disorders.8 However, for most of these risk factors, evidence of a causal relationship 
with young stroke is only weak, since it is mainly based on case-reports and case-
series.  Moreover, evidence, and more important, awareness  is increasing that 
traditional vascular risk factors are rather common in young adults with stroke and 
thus may explain a considerable proportion of young stroke.6, 7, 9-14
The identification of a high risk young stroke subpopulation may offer opportunities 
for long-term secondary prevention strategy. However, risk factors that emerge after 
a young stroke often may go undetected in many patients as current protocols and 
guidelines only recommend screening of young stroke patients in the acute phase 
and only few months thereafter.
Long-term prognosis after stroke in young adults
Despite the considerable proportion of young adults among stroke patients, only 
very limited data exist on long-term prognosis after stroke in adults aged 18-50 
years.13, 15-20 Young stroke patients face many uncertainties about their future, and 
it is exactly this long-term prognosis that is particularly important in adults in these 
ages, given that they have a long life expectancy during a demanding period of life in 
which they start to form families, have an active social life and make decisive career 
moves. Prognosis of young stroke in terms of mortality is generally considered to 
be benign, given that short-term mortality and is lower compared to older stroke 
patients. However, it is to be questioned whether this is a relevant comparison as 
these older patients obviously have a much higher a priori mortality rate, simply 
because of their age.
Stroke at young age has a major and long-lasting impact on a patient’s quality of 
life, but this impact is not solely determined by the index stroke, but also by future 
(cerebro)vascular events and early death after the initial stroke. There are only very 
limited data on risk of recurrent vascular events or mortality beyond 5 years after 
the initial stroke in the young and these studies show much of variation which might 
be due to only modest number of patients involved.13, 16, 17, 19  
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Studies that investigated risk factors or that identified subgroups of patients 
associated with long-term mortality or risk of recurrent vascular events in a time-
dependent way are even more sparse.18, 19, 21
Aim of the thesis and study design
The aim of this thesis was to investigate the long-term prognosis after stroke in 
young adults aged 18-50 years. The studies presented in this thesis are based on 
the Follow-Up of Transient ischemic attack and stroke patients and Unelucidated 
Risk factor Evaluation (FUTURE)-study, a prospective cohort study designed to 
investigate etiologies and long-term consequences of a young stroke. The FUTURE 
study comprises all patients aged 18-50 years with a TIA, ischemic stroke, or ICH, 
admitted to the Radboud University Medical Centre Nijmegen from January 1, 1980 
until November 1, 2010. 
Exclusion criteria were traumatic hemorrhagic stroke, hemorrhage in known cerebral 
metastasis or primary brain tumor, cerebral venous sinus thrombosis, subarachnoid 
hemorrhage or ICH attributable to known ruptured aneurysm, and retinal infarction.
Patients alive were invited for an extensive follow-up assessment between November 
1, 2009 and January 1, 2012.
Outline of the thesis
In part I of this thesis, chapter 2 describes the rationale and design of the FUTURE 
study.
Part II of this thesis reports on risk factors that are associated with young stroke and 
recurrent vascular events. First the prevalence of Fabry Disease is reported (Chapter 
3), followed by a critical discussion of previous studies and a recommendation for 
future studies that investigate the prevalence of Fabry Disease in young stroke 
patients. Chapter 4 reports on the long-term incidence of diabetes after young 
stroke and the association of diabetes and impaired fasting glucose with recurrent 
vascular events.
Part III of the thesis reports on the long-term prognosis after stroke. In Chapter 5 the 
long-term risk of death is investigated and compared with the general population 
with similar age and sex characteristics. Subsequently we investigated the causes 
that underlie this long-term risk of death (Chapter 6). In chapter 7 the long-term risk 
of recurrent vascular events is reported. 
16
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Chapter 8 describes the clinical characteristics of intracerebral hemorrhage in young 
adults. Furthermore, the clinical determinants of short- and long-term prognosis are 
reported.
In part IV of this thesis, chapter 9 provides a long-term perspective on stroke in 
young adults. This chapter provides a critical overview on the etiology of young 
ischemic stroke and addresses its long-term prognosis, including cardiovascular risk, 
functional outcome and psychosocial consequences.
 In part V of this thesis, the main results from the studies presented in the preceding 
chapters are summarized (Chapter 10) and discussed (Chapter 11). In addition, 
possible clinical implications and suggestions for future research are put forward.
17
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Chapter 2
The FUTURE study: 
 a prospective cohort study. 
 Study rationale and protocol.
Published as
Rutten-Jacobs LC, Maaijwee NA, Arntz RM, Van Alebeek ME, Schaapsmeerders P, 
Schoonderwaldt HC, Dorresteijn LD, Overeem S, Drost G, Janssen MC, van Heerde 
WL, Kessels RP, Zwiers MP, Norris DG, van der Vlugt MJ, van Dijk EJ, de Leeuw FE. 
Risk factors and prognosis of young stroke. The FUTURE study: a prospective cohort 
study. Study rationale and protocol. 
BMC Neurol. 2011; 11:109
Abstract
Background and objectives
Young stroke can have devastating consequences with respect to quality of life, the 
ability to work, plan or run a family, and participate in social life. Better insight into 
risk factors and the long-term prognosis is extremely important, especially in young 
stroke patients with a life expectancy of decades. To date, detailed information on 
risk factors and the long-term prognosis in young stroke patients, and more specific 
risk of mortality or recurrent vascular events, remains scarce.
Methods/Design
The FUTURE study is a prospective cohort study on risk factors and prognosis of 
young ischemic and hemorrhagic stroke among 1008 patients, aged 18-50 years, 
included in our study database between 1-1-1980 and 1-11-2010. Follow-up visits 
at our research centre take place from the end of 2009 until the end of 2011. 
Control subjects will be recruited among the patients’ spouses, relatives or social 
environment. Information on mortality and incident vascular events will be retrieved 
via structured questionnaires. In addition, participants are invited to the research 
centre to undergo an extensive sub study including MRI.
Discussion
The FUTURE study has the potential to make an important contribution to increase 
the knowledge on risk factors and long-term prognosis in young stroke patients. 
Our study differs from previous studies by having a maximal follow-up of more than 
30 years, including not only TIA and ischemic stroke but also hemorrhagic stroke, 
the addition of healthy controls and prospectively collect data during an extensive 
follow-up visit. Completion of the FUTURE study may provide better information for 
treating physicians and patients with respect to the prognosis of young stroke.
21
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Introduction
Up to 12% of all strokes occur in patients between 18-50 years (“young” stroke), 
13 affecting about 5000 patients each year in the Netherlands and about 2 million 
young people each year worldwide. In a substantial proportion of roughly one third 
the etiology remains unelucidated. In terms of prognosis a “young” stroke has a 
dramatic influence on independency and quality of life as it occurs in the period 
of life that people start to form families, make decisive career moves, and have an 
active social life. Uncertainty about long term prognosis affects choices and planning 
affiliated with these life events.
Whereas risk factors and prognosis in patients who develop a stroke at higher ages 
(usually over 70 years) are among the best studied topics in clinical medicine, this 
does not hold true for young stroke. At higher ages, almost all risk factors have 
atherosclerosis in their final common pathway. However, this cannot simply be 
extrapolated to young stroke as the underlying cause of stroke is usually different 
from that in elderly and may therefore also have a different prognosis both with 
respect to functional stroke outcome as to risks of recurrent stroke or other major 
vascular events. Even more, the identification of risk factors for young stroke so far 
has often been based on the occurrence of presumed risk factors in consecutive 
series of young stroke patients, without methodological sound comparison with 
controls.
The “long-term” perspective in an on average over 70 years “old” stroke patient 
differs from that of a 30 years “young” stroke patient, and particularly studies with 
a long-term follow-up of more than 10 years are lacking in the young stroke field. 
Studies thus far, usually with a mean follow-up duration of less than 7 years, report 
highly variable post-stroke mortality and risk of incident vascular disease.10, 13, 21-
24 These large differences across studies are well explained because young stroke 
is a heterogeneous disease and most studies were small, had different selection 
criteria, did not investigate patients in person but relied on telephone interviews 
and outcome assessments and follow-up planning was not uniform and often 
suboptimal. Although stroke includes both ischemic and hemorrhagic stroke, almost 
all studies have excluded the investigation of etiology and prognosis of young 
hemorrhagic stroke.
Except for recurrent vascular disease and persistent motor and language 
impairments, post-“young” stroke quality of life will most likely also be determined 
by cognitive dysfunction, depressive symptoms, fatigue, and specific post-stroke 
complications such as epilepsy, because those determine the ability to (return to) 
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work and to have a normal family and social life. Data on those aspects in the very 
long-term follow-up of young stroke patients are even more scarce.
Although the absolute number of young stroke is lower than stroke among the 
elderly, the total number of years that young stroke patients as a whole will live 
with the consequences of the stroke exceeds that of older stroke survivors due to 
far longer survival.
This justifies a properly designed and executed study on risk factors and prognosis 
of young stroke, compared with controls. We therefore set up the FUTURE study 
(Follow-Up of Transient ischemic attack and stroke patients and Unelucidated Risk 
factor Evaluation study), the largest single-centre prospective cohort study on risk 
factors and prognosis of young TIA, ischemic stroke and hemorrhagic stroke patients 
(n=1008) and controls.
Methods/Design
The FUTURE study is a prospective cohort study that aims to investigate the causes 
and consequences of a young stroke. The Medical Review Ethics Committee region 
Arnhem-Nijmegen approved the study.
Patients
The department of neurology has a long-standing interest in the etiology and 
prognosis of young stroke and therefore maintains a prospective registry of all 
consecutive young stroke patients with a standardized collection of baseline and 
clinical characteristics (see baseline) since the 1970’ies.25 For the current FUTURE-
study, all consecutive TIA, ischemic stroke patients with presumed arterial origin 
or those with an intracerebral hemorrhage that sought medical attention for these 
disorders at the department of neurology of the Radboud University Nijmegen 
Medical Centre between 1-1-1980 and 1-11-2010 will be eligible for participation 
in the study.
Inclusion criteria. 
• TIA, ischemic stroke of presumed arterial origin or intracerebral hemorrhage
• Date of onset between 1-1-1980 and 1-11-2010
• Age 18-50 at onset
23
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Exclusion criteria
• Traumatic hemorrhagic stroke
• Intracerebral hemorrhage in known cerebral metastasis or primary brain tumor
• Ischemic/hemorrhagic stroke due to cerebral venous sinus thrombosis
• Intracerebral hemorrhage due to ruptured cerebral aneurysm
• Any subarachnoid hemorrhage 
• Retinal infarct
TIA was defined as a rapidly evolving focal neurological deficit with no other than 
a vascular cause lasting less than 24 hours. Stroke was defined similarly, but with 
symptoms lasting more than 24 hours. On the basis of radiological findings, stroke 
was further subdivided into hemorrhagic and ischemic stroke.
As the diagnostic process may have changed during more than 30-year period 
all initial diagnoses were reviewed by a panel of two experts from a pool of four 
(FEdL, EvD, RA, LJD) and in cases of disagreement a consensus meeting was held to 
adjudicate the event.
Controls. Control subjects will be recruited among the patients’ spouses, relatives or 
social environment. They have to be at least 18 years old without a history of any TIA 
or stroke before the age of 50 at the moment of inclusion.
Baseline.
At baseline (during the occurrence of the qualifying event for the study) a minimal 
dataset has been collected that consists of demographics, stroke subtype, risk 
factors and additional investigations (table 1). The completeness of the baseline 
dataset varies among patients due to changes in standard diagnostic procedures 
over the last thirty years.
Current common rating scales for the severity and cause of stroke did not exist at 
the time when a substantial proportion of our patients experienced their qualifying 
event. Therefore a rating of both the severity (NIHSS) and cause (TOAST) was done 
for all cases retrospectively by a validated approach.26
Follow-up 
Information on the vital status will be available either from hospital data or through 
coupling of patient records with data from the municipality registry. All patients alive 
will be approached for the follow-up assessment according to a two-step approach.
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First, all patients will be contacted by letter to inform them about the study; 
subsequently they will be contacted by phone. In case the patient has moved, the 
municipality register of the last known residence will be contacted to trace the 
patient. In cases of an invalid phone number, a second letter will be sent asking 
the patient to contact our centre to provide a correct phone number. Subsequently, 
when a patient does not respond to the second letter, the last known general 
practitioner will be contacted to provide us with updated contact details. The patient 
will be considered lost to follow-up when known alive, but when untraceable via the 
procedure described above.
Subsequently, patients will be given the opportunity to participate in an extensive 
sub study. If they agree to do so, they will be invited to visit our research 
centre for additional investigations including a structured interview, cognitive 
assessment, physical and neurological examination, an extensive MRI protocol, 
an electrocardiogram and an ultrasonography of the carotid arteries (Table 1). In 
addition, blood samples (serum/plasma/DNA) will be taken for future analysis. 
When patients are not able to visit our research centre the same investigations 
will be performed at their homes, except for the ultrasonography of the carotid 
arteries, electrocardiogram and MRI scan. Controls will undergo the same protocol 
as patients.
The follow-up has started at the end of 2009 and is planned to finish at the end of 
2011.  All these participants signed an informed consent.
Outcome events
The primary outcome of the study will be all-cause mortality and the composite 
endpoint of death from all vascular causes; non-fatal stroke, non-fatal (silent) 
myocardial infarction, cardiovascular procedures (coronary artery bypass grafting, 
percutaneous transluminal coronary angioplasty, carotid endarterectomy and other 
arterial revascularization procedures), whichever occurred first. We will perform 
separate analysis for the occurrence of fatal or non-fatal stroke. Causes of death will 
be categorized into ischemic stroke, intracerebral hemorrhage, cardiac causes, other 
vascular causes or non-vascular causes. If we cannot obtain information about the 
cause of death, the event will be classified as unspecified.
Secondary outcomes are seizures (classified according to the ILAE 27) and dementia 
(according to DSM-IV). Whenever an outcome event is suspected with the aid of a 
standardized, structured questionnaire, information retrieved will be verified and 
adjudicated by physicians from the appropriate specialty. In case a patient has died, 
25
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this information will be retrieved from their general practitioner or a relative. If 
there is no information available, the event will be classified as a possible event.
Assessment of variables during follow-up
Demographics and life style
Standardized questionnaires on demographics, education (classified using seven 
categories; one being less than primary school and seven reflecting an academic 
degree),28 marital status, living conditions, and life style habits (alcohol consumption, 
smoking, exercise) will be administered. Alcohol consumption will be defined as 
units per day and the age at which alcohol consumption had started (and ended if 
stopped) will be noted. Cigarette smoking behavior will be defined as never, former 
and current. Subsequently, former and current smoking behavior will be quantified 
as the number of pack-years, calculated as the number of packs of cigarettes smoked 
per day multiplied by the number of years a participant had smoked. Exercise 
will be expressed in the metabolic equivalent value (MET) according to accepted 
standards.29
Medical history
Structured, standardized questionnaires will be used to assess participants history of 
hypertension, diabetes mellitus, atrial fibrillation, TIA, stroke, myocardial infarction, 
coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, 
carotid endarterectomy and other arterial revascularization procedures, 30-33 
migraine with or without aura,34 pregnancy and malignancy. Whenever a primary or 
secondary outcome event is suspected with the aid of this standardized, structured 
questionnaire, information retrieved will be verified and adjudicated by physicians 
from the appropriate specialty (see outcome events). The presence of a family 
history of myocardial infarction, cerebrovascular disease and diabetes mellitus in 
next of kin will be recorded.
Epilepsy
Each patient will be evaluated for a history of epilepsy by means of a standardized, 
structured questionnaire. Whenever epilepsy is suspected, information will be 
retrieved from the treating physician and verified and adjudicated by a neurologist 
(FEdL). Epilepsy will be classified according to the ILAE criteria.27 Post-stroke epilepsy 
will be subdivided into early (£ 7 days post-stroke) and late (> 7 days) post-stroke 
epilepsy.
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Current medication
Current medication use and the age at which medication use started will be noted 
and classified according to the Anatomical Therapeutic Chemical (ATC) classification 
system. (World Health Organization, WHO Collaborating Centre for drug statistics 
and methodology, http://www.whocc.no/atcddd/)
Neuropsychological assessment
We will administer an extensive neuropsychological test battery that encompasses 
items from other large-scale epidemiological studies covering the main cognitive 
domains. 35, 36 Global cognitive function will be assessed using the Mini Mental 
State Examination (MMSE).37 Verbal episodic memory function will be assessed by 
the three-trial version of the Rey Auditory Verbal Learning Test (RAVLT) that also 
includes a delayed free-recall and recognition trial, a test used to evaluate the 
ability to acquire and retain new verbal information.38 Visuospatial episodic memory 
will be administered by the Rey Complex Figure Test (RCFT), that consists of three 
trials: a copy trial, an immediate recall trial after 3 minutes and a delayed-recall 
trial after 30 minutes.39 To evaluate speed of information processing and executive 
function, two tests will be used; the abbreviated Stroop Color Word Test (three 
subtasks, the interference trial measuring response inhibition)40 and the Symbol-
Digit Substitution Task, which is a modified version of the Symbol Digit Modalities 
Test.41 A verbal fluency task in which as many animals as possible have to be named 
within 60 seconds will be used to test semantic memory and executive functioning 
(response generation). To assess working memory, the Paper and Pencil Memory 
Scanning Task (four subtasks)42 will be used. To evaluate attention, the verbal series 
attention test (VSAT) will be used. 43 To register subjective cognitive failures we will 
administer the modified Cognitive Failures Questionnaire (CFQ).44 The assessments 
will be carried out under standard circumstances in quiet rooms.
A standardized structured questionnaire used in previous large-scale epidemiological 
studies will be used to assess the history of depressive symptoms; normal reactions 
to stressful events or normal grief will carefully be excluded.45 In case of a depressive 
episode, age of onset, the medical advice and medication use will be registered. We 
defined ‘depression’ as those depressive episodes that have required attention of 
a general practitioner, psychologist, or psychiatrist. This definition includes minor 
depression, as well as more severe depression syndromes such as major depression 
and bipolar depression.45
In addition participants will be screened for current depressive symptoms by means 
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of the Mini International Neuropsychiatric Interview (MINI), part A, which is a short 
diagnostic structured interview based on the DSM IV.46 Additionally, presence of 
actual depressive symptoms will be assessed by two self report questionnaires, the 
Centre of Epidemiologic Studies Depression Scale (CES-D)47 and the Hospital Anxiety 
and Depression Scale (HADS).48
Physical and Neurological Examination
Height and weight will be measured without shoes in light clothing. The body mass 
index (BMI) will be calculated as weight divided by height (in meters) squared. The 
maximal waist circumference will be measured without shirt, in standing position, 
between the lowest rib and the iliac crest, at the end of normal expiration.49 Blood 
pressure and pulse rate will be measured in triplicate in supine position after 5 
minutes rest. Subsequently one measurement is performed after 1 minute in upright 
position.32
The strength of the biceps, hand grip, iliopsoas, quadriceps and foot extensor 
muscles on both sides will be scored according to the medical research council scale 
(MRC).
The sensory system will be assessed by a quantitative measurement by vibration 
tuning fork (Rydel-Seiffer®) on both first toes and both medial malleolus, also 
registering ankle edema and the ankle jerk reflex.
Gait and balance
We will use a widely used modified version of the original Tinetti test with 17 items: 
9 for body balance (score 0-16) and 8 for gait (score 0-12), with a maximum score of 
28.50 It grades balance while sitting, standing with eyes open and closed, nudging and 
turning, gait initiation, stride length and width and symmetry. Functional mobility 
will be classified by using the widely-used TUG-test which is a timed test during 
which the participant is asked to rise from a standard armchair, walk 3 m, turn, walk 
back and sit down again.51 Each participant will perform the test three times.
Functional performance
As a measure of disability the Barthel Index and modified Ranking Scale will be 
used.52 The activities of daily living will be assessed by the instrumental activities of 
daily living questionnaire.53
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Additional Self-report questionnaires
Several primary sleep disorders are addressed using a number of screening 
questions. The presence of possible sleep disordered breathing is based on a history 
of snoring, witnessed sleep-related apneas and non-restorative sleep. Non-REM and 
REM parasomnias are addressed based on a history of sleepwalking, dream-enacting 
behavior. Excessive daytime sleepiness will be assessed based on the presence of 
continuous feelings of sleepiness, sleep attacks or a combination of both. Finally, the 
presence of sleep-onset and/or sleep-maintenance insomnia is recorded. 
For the assessment of fatigue we will use the Checklist on Individual Strength 
(CIS20R).54 The overall health status (quality of life) will be assessed with the Short 
Form 36 (SF-36).55, 56, the EQ-5D57 and the Stroke Impact Scale 3.58
Adverse life events will be assessed with the 12-item List of Threatening Events 
(LTE), 6 months before the index event and subsequently the period after the index 
event. 59
Patients will be asked for their employment status in the month before their index 
event, within the first year after their index event and at time of the follow-up visit. 
Each period includes a description of occupation, working hours a week, adjustments 
in tasks, use of supporting devices and reasons for not working.
Ancillary Investigations
MRI protocol. MRI scanning will be performed on a 1.5-Tesla Magnetom scanner 
(Siemens, Erlangen, Germany). The scanning protocol includes whole brain 3D 
T1 magnetization-prepared rapid gradient-echo (MPRAGE) sequence (TR/TE/
TI 2730/2.95/1000ms; flip angle 7°; voxel size 1.0x1.0x1.0mm); FLAIR pulse 
sequences (TR/TE/TI 12220/85/2200 ms; voxel size 1.0x1.2x3.0mm; slice gap 0.6 
mm); transversal T2-weighted turbo spin echo sequence (TR/TE 7440/96ms; voxel 
size 0.9x0.9x3.0 mm; slice gap 0.6 mm); Multi-slab 3D time of flight angiography 
sequence (TR/TE 24/7ms; voxel size 0.8x0.5x1.0mm) will be made of the carotid 
arteries and the circle of Willis. Gradient echo susceptibility weighted imaging 
sequence (TR/TE 49/40ms; voxel size 0.8x0.7x1.0mm); DTI (TR/TE 9100/98ms; voxel 
size 2.2x2.2x2.2mm; 7 unweighted scans, 61 diffusion weighted scans, with non 
co-linear orientation of the diffusion-weighting gradient, and b value 1000s/mm²) 
and resting state imaging using a gradient echo EPI (TR/TE 1870/35ms; voxel size 
3.5x3.5x3.0 mm; slice gap 0.5mm). During resting state, participants will be told not 
to concentrate on any particular subject, but just to relax with their eyes closed. The 
complete scanning protocol takes approximately 60 minutes.
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ECG. An electrocardiogram (ECG) will be performed and evaluated by a standardized 
assessment by an experienced cardiologist, registering frequency, cardiac rhythm, 
cardiac ectopias, cardiac axis, conduction time over the PQ, QRS and QTC intervals, 
conduction disturbances, left ventricle hypertrophy, pathologic Qs, infarction, 
repolarisation disturbances and acute ischemia. A final diagnosis is defined as 
normal, abnormal without clinical significance, abnormal with clinical consequences 
or pathologic ECG with immediate consultation of a cardiologist when necessary.
Carotid ultrasound. A carotid ultrasound assessment will be performed at which the 
intima media thickness (IMT) will be measured in the distal (near the bulbus) left and 
right common carotid artery. All measurements will be performed using a phased 
array real-time scanner (Philips i-u22, The Netherlands) with a 17-5 MHz broadband 
linear transducer. The IMT will be automatically measured by QLab® qualification 
software (V. 4.2.1.) according to previously described procedures.60 All ultrasound 
measurements will be performed by three experienced and specific trained clinical 
neurophysiology technicians.
Vena puncture. Fasting blood samples will be taken. Immediate analysis will include 
glucose, creatinine, lipid profile and complete blood count. Additional serum, 
plasma and DNA will be stored (-80°C) for future biochemical and genetic analyses.
Statistical analysis
Cumulative risk of primary and secondary outcomes will be estimated with Kaplan-
Meier analysis. In the analysis of vascular events, patients who had died from 
other than the defined fatal endpoints will be censored at the time of death. Cox 
proportional hazard models will be used to calculate the risk of suffering from any 
of the primary or secondary outcomes in the follow-up period, with adjustments 
for the necessary covariates. The relative risk (hazards ratios) will be calculated with 
their corresponding 95% confidence intervals.
Cross-sectional analysis (for example in the comparison between patients and 
controls of data acquired during the follow-up) of continuous variables will be done 
with Student’s t test or analysis of variance or in case of skewed distributions which 
cannot be normalized corresponding nonparametric tests will be used. Chi-squared 
test will be used for cross-sectional analysis of categorical variables.
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Table 1 Schedule of assessments in the FUTURE study
Assessment Baseline Follow-up
Demographics
Ethnicity X
Education X
Marital status X
Social/living status X
Stroke Characteristics
Qualifying event X
Symptoms at onset X
Discharge date and destination X
TOAST X
NIHSS at admission and at discharge X
Modified Ranking Scale at discharge X
Medical History
History of any cardiovascular disease X X*
Cardiovascular risk factors X X*
Family history of cardiovascular disease X X
Medication use X X*
Stroke related surgical procedures X X*
Epilepsy X X*
Neuropsychologic examination
Global cognitive function
Mini Mental State Examination (MMSE) X X
Verbal memory function
Rey Auditory Verbal Learning Test X
Visuospatial memory
Rey’s Complex Figure Test X
Speed of information processing
Symbol-Digit Substitution Task X
Stroop test X
* Variables were collected both for the period before and after the index event.
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Table 1 Schedule of assessments in the FUTURE study (continued)
Assessment Baseline Follow-up
Working memory
Paper and Pencil Memory Scanning Tasks X
Executive functioning
Animal Fluency task X
Attention
Verbal series attention test X
Subjective cognitive failures
Cognitive failures questionnaire X
Depressive symptoms
Structured questionnaire depressive symptoms X*
Mini International Neuropsychiatric Interview 
(MINI)
X
Center of Epidemiological Studies Depression Scale 
(CES-D)
X
Hospital Anxiety and Depression Scale (HADS) X
Physical examination
Length and weight X X
Waist circumference X
Blood pressure X X
Heart rate X X
Neurological examination
Babinsky sign X
Sensory system
Quantitative measurement by vibration tuning fork X
Muscle strength 
Medical Research Council Scale (MRC) X
Mobility and activities of daily living
TUG-test X
Exercise expressed in metabolic equivalent value X*
* Variables were collected both for the period before and after the index event.
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Table 1 Schedule of assessments in the FUTURE study (continued)
Assessment Baseline Follow-up
Tinetti test (body balance and gait) X
Modified Ranking Scale (MRS) X X
Barthel Index X
Instrumental activities of daily living questionnaire 
(IADL)
X
Additional questionnaires
Fatigue
CIS20R X
Health related quality of life
Short Form 36 X
EQ-5D X
Stroke impact scale 3.0 X
Other
Sleep disturbances X*
List of Threatening Experiences (LTE) X*
Work X*
Radiological examination
Confirmation of index event (CT or MRI) X
Angiography X
MRI
T1 magnetization-prepared rapid gradient echo X
FLAIR pulse sequences X
Transversal T2* weighted gradient echo sequence X
Diffusion Tensor imaging X
Resting state imaging X
Time-of-flight angiography X
Ancillary investigation
Electrocardiogram X X
Ultrasonography of the carotid arteries X X
* Variables were collected both for the period before and after the index event.
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Results
1008 patients who had sought medical attention at our University Medical Center 
between January 1, 1980 and November 1, 2010 fulfilled inclusion and exclusion 
criteria for our study. Characteristics of our baseline population (at the time of their 
qualifying event) are reported in table 2.
Discussion
Detailed information on risk factors and the long-term prognosis in young stroke 
patients, and more specific the risk of mortality and recurrent vascular events, 
remains scarce. These data are often derived from selected patients (often with 
the exclusion of TIA and hemorrhagic stroke patients) in small sized studies with 
short follow-up without in person assessment of risk factors and outcomes. We 
therefore performed the FUTURE study, designed to investigate risk factors and to 
prospectively assess prognosis in a large cohort of young stroke patients.
Strong elements of our study are the inclusion of both TIA and hemorrhagic and 
ischemic stroke patients, the very long follow-up (up to 30 years), its sample size of 
over 1000 potential participants and the availability of baseline data of all consecutive 
patients in a single university medical centre. In addition, the extensive investigation 
during a follow-up visit, including advanced neuroimaging has the potential of major 
contributions to the field. Our study differs from many other young stroke studies 
due to the inclusion of controls that enable us to compare the frequency of some 
Table 2 Baseline population characteristics
 Total 
population
Time of index event
1980-1989 1990-1999 2000-2010
n 1008 223 250 535
Male, n (%) 471 (46.7) 109 (48.9) 129 (51.6) 233 (43.6)
Age at index event, 
mean (SD)
40.2 (8.0) 39.2 (8.3) 39.7 (8.7) 40.8 (7.4)
Index event
TIA, n (%) 276 (27.4) 53 (23.8) 40 (16.0) 183 (34.2)
Infarction, n (%) 632 (62.7) 144 (64.6) 190 (76.0) 298 (55.7)
Hemorrhage, n (%) 100 (9.9) 26 (11.7) 20 (8.0) 54 (10.1)
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presumed, but also unknown, risk factors between patients and controls. Detailed 
risk factor analysis can be done, not only for commonly documented risk factors but 
also for those that are rarely documented in medical records, like physical inactivity 
and sleep disturbances. Moreover, the inclusion of healthy controls provides the 
opportunity to distinguish consequences of a young stroke from other factors like 
aging effects.
We feel that completion of our study may contribute to a better understanding of the 
etiology of young stroke and may provide better information for treating physicians 
and patients with respect to the prognosis of young stroke.
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 Prevalence of Fabry disease in young adults with TIA or stroke.
Abstract
Background and objectives 
Data on the prevalence of Fabry disease (FD) in young stroke patients are 
controversial. The true prevalence may be obscured by including genetic variants 
of unknown significance (GVUS). Our objective was to investigate the prevalence of 
FD, including GVUS in young stroke patients and to examine the long-term risk of 
vascular events in these patients.
Methods
We determined the prevalence of FD in 442 patients with a transient ischemic attack 
(TIA), ischemic stroke, or intracerebral hemorrhage (ICH), aged 18-50 years admitted 
to our hospital between 1980 and 2010. All patients underwent assessment of 
α-Galactosidase A (α-GAL) activity in leukocytes and sequencing of the GLA gene. 
Long-term outcome (mean follow up 10.1 years (SD 8.3)) was any recurrent vascular 
event (stroke, myocardial infarction or cardiac or peripheral arterial revascularization 
procedures).
Results
No patient had a known GLA mutation causing FD. We detected two GVUS; p.D313Y 
(n=4) and a complex intronic haplotype (IVS0-10C>T [rs2071225], IVS4-16A>G 
[rs2071397], IVS6-22C>T [rs2071228]) (n=31). 5 patients with the haplotype, but 
no patient with p.D313Y had a recurrent vascular event. No patient with a recurrent 
event had a medical history or values of biochemical markers that were suggestive 
of FD. Long-term risk of any recurrent vascular did not differ between patients with 
and without GVUS. 
Conclusions
Our study suggests that the prevalence of FD in young stroke patients is very low. 
Moreover, the GVUS detected in our study are not likely to be FD causing variants, 
as long-term risk of vascular events was not increased.
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Introduction
Stroke mainly affects elderly people, yet approximately 10% of strokes occur in 
patients younger than 50 years.10 In a substantial proportion of roughly one third 
of young stroke patients, the etiology remains unknown. Previous studies have 
suggested that younger cases may have a stronger genetic predisposition to stroke 
than older cases.61, 62  
Variants and mutations in the α-galactosidase A gene (GLA), suggested to cause 
Fabry Disease (FD), an X-linked lysosomal disorder, have been reported in up to 0-4% 
of young cryptogenic stroke patients.63-70 Reduced activity of the α-galactosidase 
A (α-GAL) enzyme results in accumulation of globotriaosylceramide (Gb3) within 
lysosomes in many cell types and tissues, including vascular endothelial, smooth-
muscle, cardiac, renal and nerve cells. During the course of the disease several organs 
may be more or less severely affected, leading to a variable clinical presentation 
including stroke.71 
The discrepancy with respect to the prevalence of FD in young stroke patients 
between the  previous studies might have been caused by different inclusion criteria 
and definition of FD, but another possible explanation could be the inclusion of 
variants of not proven clinical significance,72 since not all studies have specified the 
mutations detected. 
Apart from 600 FD-causing GLA mutations that cause classical FD in which 
α-GAL activity in affected males is usually undetectable or <5% of controls, some 
genetic variants of unknown clinical significance (GVUS) result in reduced α-GAL 
activity (in the range of 5–35% of controls), which may be associated with milder 
phenotypes.73 Accordingly, it has been suggested that some GVUS found in young 
stroke patients, may cause a stroke-only variant of FD.70  Thus, although these GVUS 
do not cause classical FD, they might contribute to the risk of vascular disease. 74 
Long-term prospective monitoring of these patients with GVUS is one way to clarify 
the “unknown significance” and may be helpful in making a correct diagnosis.72 If 
these functional variants indeed are causally related to the development of vascular 
disease, we hypothesize that young stroke patients that carry these GVUS are at 
increased risk of vascular events at a relatively younger age during long-term follow-
up than those without these GVUS. However such long term follow-up studies have 
not been performed.
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The aim of the present study was to investigate the prevalence of FD in a cohort of 
young TIA, ischemic stroke and intracerebral hemorrhage (ICH) patients, irrespective 
of stroke subtype or sex. Furthermore, risk of recurrent vascular events during a 
mean follow-up of more than 10 years was assessed in patients with and without 
GVUS.
Methods
Patients and study design
This study is a part of the “Follow-Up of Transient ischemic attack and stroke patients 
and Unelucidated Risk factor Evaluation”-study (FUTURE study), a prospective 
cohort study that investigates causes and consequences of a young stroke. Details of 
the study have been described elsewhere.75 The Medical Review Ethics Committee 
region Arnhem-Nijmegen approved the study. Participants provided written 
informed consent. 
In short, the FUTURE study comprises all consecutive patients with a TIA, ischemic 
stroke or ICH, aged 18 – 50 years, admitted to the Radboud University Medical 
Centre Nijmegen from January 1, 1980 until November 1, 2010. Exclusion criteria 
were traumatic hemorrhagic stroke, ICH in known cerebral metastasis or primary 
brain tumor, cerebral venous sinus thrombosis, any subarachnoid hemorrhage or 
ICH due to known ruptured aneurysm and retinal infarction. 
TIA was defined as a rapidly evolving focal neurological deficit, without positive 
phenomena such as twitches, jerks or myoclonus, with vascular cause only, and 
persisting for a period less than 24 hours. Stroke was defined as focal neurological 
deficit persisting for more than 24 hours.76, 77 Stroke was subdivided into ICH and 
ischemic stroke on the basis of radiological findings.
Assessment of both the etiology (modified TOAST classification78) and severity 
(National Institutes of Health Stroke Scale (NIHSS)79) was performed retrospectively 
in all cases on the basis of medical records, because these scales did not exist 
when a substantial number of our patients experienced their index event. The 
NIHSS was scored using a validated approach as previously described.26, 80 A history 
of cardiovascular risk factors was defined as the presence of these risk factors, 
either in the patients’ medical history or when identified during admission.81 In the 
framework of our young stroke protocol, patients underwent imaging of intracranial 
and vertebral arteries, when appropriate, cardiac echography was also performed. 
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Follow-up
Information on the vital status was retrieved from hospital data or the Dutch 
Municipal Personal Records database. Patients alive were invited for a follow-up 
assessment between November 1, 2009 and January 1, 2012. Venous blood samples 
were taken from all patients for genetic and biochemical analysis.
The occurrence of any vascular event was defined as the composite event of fatal or 
non-fatal stroke (ischemic or hemorrhagic), fatal or non-fatal myocardial infarction, 
or cardiovascular procedures (coronary artery bypass grafting, percutaneous 
transluminal coronary angioplasty, carotid endarterectomy, or other peripheral 
arterial revascularization procedures), whichever occurred first.
Patients were evaluated for recurrent vascular events using a two staged approach. 
First, all patients alive were asked during a structured interview whether they had 
visited a because of a recurrent TIA or stroke, or because of any of the following 
(but not exclusively) symptoms that might raise the suspicion of the occurrence of 
a stroke: one-sided weakness in face, arm or leg, sensory loss, aphasia, diplopia, 
transient monocular blindness, hemianopsia, neglect, ataxia, dysarthria, dizziness, 
acute apraxia (trouble with dressing, brushing teeth, geographical disorientation etc). 
Furthermore patients were asked whether they ever had visited a physician because 
of a myocardial infarction, or whether they ever underwent coronary artery bypass 
grafting, percutaneous transluminal coronary angioplasty or any other peripheral 
arterial revascularization procedures. In case a patient had died, this information 
was retrieved from the general practitioner by the same structured questionnaires. 
Secondly, when patients (or their general practitioner) confirmed that they had 
a TIA or stroke after their index event, medical records were retrieved from their 
treating physicians and subsequently verified and adjudicated by physicians from 
the appropriate specialty (FEdL, EvD, MvdV). If information concerning a recurrent 
vascular event was not sufficient, it was considered as a possible event and not used 
in the analyses.
Genetic and biochemical analysis
All genetic and biochemical tests were performed blinded to clinical data. All patients 
were screened for FD mutations by direct di-deoxy-sequencing of the entire GLA 
exonic structures as well as the intron-exon boundaries to detect mutations in the 
GLA gene. DNA was extracted from peripheral blood (QIAamp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany) and 50ng of the DNA samples was subsequently used for 
PCR amplification of the GLA exons 1–7.  
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Levels of globotriaosylsphingosine (Lyso-Gb3) in blood were determined for patients 
in which a GLA variant was identified. 
Gradient HPLC method was used on a reversed phase column (ACE 3 C8, 50 x 2.1 
mm) for the determination of Lyso-Gb3. Lyso-ceramide trihexoside was used as 
reference items (Matreya LLC, USA; purity >98%) and lyso-lactosylceramid was used 
as internal standard. Genetic analyses and Lyso-Gb3 analysis of the blood samples 
were performed at the Albrecht-Kossel-Institute, Medical Faculty of the University 
Rostock, Germany. 
α-GAL activity was measured in leukocytes, extracted from heparinized whole 
blood. α-GAL activity was determined by a fluorometric assay, using the fluorescent 
substrate 4-methylumbellipheryl-α-d-galactoside.82
Fabry Disease
Definite FD was defined as patients having a known causative GLA mutation 
combined with deficient α-GAL activity for male patients (<5% of mean normal 
activity (< 2 nmol/h/mg protein)) and increased levels of plasma lyso-Gb3 (above 
the 95th percentile of healthy individuals).83 Possible FD was considered in patients 
carrying either the p.D313Y mutation or another GVUS in conjunction with α-GAL 
activity below the normal range (15-45 nmol/h/mg protein) and/or increased lyso-
Gb3 (above the 95th percentile of healthy individuals). Nonsynonymous variants 
were evaluated for pathogenicity by in silico mutation prediction tools, using three 
algorithms (PolyPhen-2,84 SIFT,85 and Mutation Taster86).
Statistical analysis
Person-years at risk were calculated for each patient from date of the index stroke 
until recurrent event or date of end of follow-up. Cumulative risk of vascular events 
was estimated by means of Kaplan-Meier analysis. Log-rank test was used to test for 
differences in cumulative risk of recurrent vascular events stratified by genotype. 
Cumulative risk of vascular events was compared between patients with and without 
GVUS. Two-sided P values of less than 0.05 were considered to indicate statistical 
significance. SPSS 20 was used for all statistical analysis.
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Results
442 patients (203 males, 239 females) with a mean age of 40.0 (SD 8.0) years were 
included in the present study (Figure 1).  Of them, 142 (32%) had a TIA, 267 (60%) 
an ischemic stroke and 33 (8%) an ICH. Mean follow-up duration of the total study 
population was 10.1 (SD 8.3) years. Follow-up survivors without DNA analysis (n=139) 
did not differ from follow-up survivors with DNA analysis with respect to subtype of 
stroke, age of onset, distribution of sex, TOAST subtype and stroke severity. 
Figure 1 Study population
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Table 1 Baseline characteristics stratified by genetic result.
 No 
mutation
p.D175E p.D313Y Intronic 
haplotype
n (% of total) 406 (100) 1 (0.2) 4 (0.9) 31 (7)
Mean age at event, years (SD) 39.9 (7.9) 49.7 41.0 (7.4) 40.0 (9.2)
Male 191 (47.0) 1 1 (25.0) 10 (32.3)
Stroke subtype
TIA 131 (32.3) 1 1 (25.0) 9 (29.0)
Ischemic stroke 244 (60.1) 0 3 (75.0) 20 (64.5)
ICH 31 (7.6) 0 0 2 (6.5)
TOAST    
Atherothrombotic stroke 30 (8.0) 0 0  1 (3.4)
Likely atherothrombotic stroke 62 (16.5) 0 1 (25.0)  5 (17.2)
Cardioembolic stroke 38 (10.1) 1 1 (25.0)  2 (6.9)
Lacunar stroke 41 (10.9) 0 0  3 (10.3)
Rare causes 55 (14.7) 0 0  4 (13.8)
Multiple causes 8 (2.1) 0 0  1 (3.4)
Unknown cause 141 (37.6) 0 2 (50.0)  13 (44.8)
Median NIHSS at admission 
(IQR)a
2 (0-6) 0 5 (2-6) 3 (1-6)
History of TIA or stroke 18 (4.4) 0 1 (25.0) 1 (3.2)
History of cardiovascular risk 
factors
    
Diabetes 19 (4.7) 0 0 0
Hypertension 103 (25.4) 0 0 9 (29.0)
Dyslipidemia 125 (30.8) 1 1 (25.0) 7 (22.6)
Atrial fibrillation 6 (1.5) 0 0 0
Smokingb 182 (46.1) 0 2 (50.0) 14 (46.7)
Excess drinkingc 20 (4.9) 1 1 (25.0) 3 (9.7)
Family history
Young stroke 59 (14.6) 1 0 5 (16.1)
Myocardial infarction (<55 
years)
103 (25.4) 1 0 7 (22.6)
Cardiac abnormalitiesd 98 (24.1) 0 2 (50.0) 5 (16.1)
Renal abnormalitiesd 52 (12.8%) 0 0 4 (12.9)
Abbreviations: IQR, interquartile range; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of ORG 
10172 in Acute Stroke Treatment; Numbers represent n (%) or otherwise stated
a Scores range from 0 to 42 with higher scores on the scale indicating worse stroke severity. NIHSS was missing 
in 1 patient.
b Smoking was defined as smoking at least 1 cigarette a day in the year prior to the event. Data on smoking 
habits were missing in 12 patients (2.7%)
c Excess alcohol consumption was defined as consuming more than 200 grams of pure alcohol per week
d Cardiac or renal abnormalities were defined as any cardiac or renal abnormalities that required treatment by 
a clinician
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 increased Lyso-Gb3.
Prevalence of Fabry Disease
 Patient 1 Patient 2 Patient 3
Genetic result p.D313Y intronic 
haplotype
intronic 
haplotype
Stroke subtype ischemic stroke ischemic stroke ischemic stroke
Age at event, yrs 48 50 28
Sex Female Male Female
α-GAL activity,  nmol/h/mg prot 30 22 34
TOAST subtype Likely-large 
artery
 Rare cause 
(dissection)
Cryptogenic
NIHSS at admission (IQR)a 4 2 3
Recurrent vascular event no no no
History of TIA or stroke no no no
History of vascular risk factors    
Diabetes no no no
Hypertension no yes no
Dyslipidemia yes yes yes
Atrial fibrillation no no no
Smokingb yes no no
Excess drinkingc no no no
Positive family history
Young stroke no yes no
Myocardial infarction (<55 yrs) no no no
Cardiac abnormalitiesd no no no
Renal abnormalitiesd no no no
Abbreviations: yrs, years; prot, protein; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of ORG 
10172 in Acute Stroke Treatment; 
a Scores range from 0 to 42 with higher scores on the scale indicating worse stroke severity. 
b Smoking was defined as smoking at least 1 cigarette a day in the year prior to the event. 
c Excess alcohol consumption was defined as consuming more than 200 grams of pure alcohol per week
d Cardiac or renal abnormalities were defined as any cardiac or renal abnormalities that required treatment by 
a clinician
48
Chapter 3
Demographic and clinical features of the study population stratified by genetic result 
are shown in Table 1.
Biochemical and genetic analyses
None of the patients had a known gene mutation responsible for classical FD. In 
one male, we found a nonsynonymous missense variant (c.525C>A; p.D175E), that 
to our knowledge was previously reported in one female without any biochemical 
or clinical signs of FD.87  Also in our patient α-GAL activity and lyso-Gb3 were within 
the normal range. Moreover, p.D175E is predicted to be tolerated as assessed by 
Polyphen-2, SIFT and MutationTaster. Four (0.9%) patients (three women, one man) 
had the variant p.D313Y and 31 (7.0%) patients had a previously reported GVUS, a 
complex intronic haplotype of unknown clinical relevance (IVS0-10C>T [rs2071225], 
IVS4-16A>G [rs2071397], IVS6-22C>T [rs2071228]).70, 88 Lyso-Gb3 was above normal 
values in one patient with p.D313Y and in two patients with the complex intronic 
haplotype. α-GAL activity was within the normal values for all these three patients. 
Clinical characteristics of these three patients are reported in table 2.
α-GAL activity was below the normal range in only 2 patients (12 and 14 nmol/h/mg 
protein), but well above 5% of normal activity. In addition, the lyso-Gb3 results were 
normal in these patients. Both these patients had the complex intronic haplotype. 
Vascular events
After a mean follow-up duration of 10.1 years (SD 8.3), 62 patients (15.3%) without 
any GLA variant and 5 patients with the complex intronic haplotype (16.1%) had 
a recurrent vascular event. No patient with p.D313Y or p.D175E had a recurrent 
event. Among the 5 patients with the complex intronic haplotype and a recurrent 
vascular event, all of them had normal lyso-Gb3 values and the index stroke was 
classified as likely or definite atherothrombotic stroke in 4 patients and rare cause 
(SLE) in one patient.
20-Year cumulative risk of any recurrent vascular event did not differ between 
patients with and without GVUS ((27.8% (95% CI 5.1%-50.6%) and 24.3% (95% CI 
17.9%-30.7%) respectively) (Figure 2).
49
II
Prevalence of Fabry Disease
Discussion
We did not identify any known FD mutation in our cohort of 442 young stroke 
patients. However, we did identify previously reported GVUS, but these genotypes 
were not associated with the risk of recurrent events.
In contrast to previous studies we did not limit screening for mutations to females 
or males with deficient α-GAL activity, but we screened all our patients to minimize 
misclassification. Moreover, we investigated the effect on long-term risk of vascular 
disease of GVUS in the GLA gene that were previously suggested to be possible 
causative FD variants,70 by relating them to risk of recurrent events after a mean 
follow-up duration of 10 years. Furthermore, collecting data all in one site allowed 
us to collect baseline and follow-up information according to identical procedures 
in all patients thereby reducing the risk of information bias. The ischemic stroke 
group in our study is slightly younger than in some previous studies.15, 18, 19 In line 
with epidemiologic data on young stroke, the proportion of women was significantly 
higher in our study than in those previous studies, indicating that our population 
Figure 2 Long-term risk of recurrent vascular events stratified by the presence  
  of a GVUS
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reflects a population with true young stroke.89 
One previous study reported a prevalence of FD in cryptogenic stroke of 4%, 
according to the authors based on biological significant mutations that prove the 
diagnosis of FD. However, information on the mutations was missing. Thereafter, 
several studies in young stroke, including the present study, failed to find such a high 
prevalence of FD in young stroke.63, 66-69. 
The largest study to date that investigated the prevalence of FD in young adults with 
stroke is the SIFAP study, a multicenter study in more than 5000 patients with TIA 
or stroke, aged 18-55.70  In this study, according to their methods, definite FD was 
diagnosed if a given mutation significantly reduced the enzyme activity, and was 
a known causative mutation, and a significant increase in at least 2 independent 
biochemical markers was detected (Gb3 in blood, lyso-Gb3 or Gb3-C24 in urine. 
Definite FD was identified in 0.5% of the patients (n=27), but case definition remained 
difficult as data on the criteria were not reported on an individual level and the 
numbers of patients with positive criteria did not add up to 27. Reporting these 
data on an individual level would be helpful to get insight in the FD phenotype of 
these individuals and to understand the pathogenic nature of the variants in the GLA 
gene in these individuals, since the diagnosis of FD is not always straightforward.90 
This is illustrated by a recent study that reported biochemical characteristics of the 
8 mutations that were reported as causative in the SIFAP study.87 A relatively high 
residual enzymatic activity in vitro in combination with normal lyso-Gb3 values was 
demonstrated for these 8 mutations and the authors suggested that biomarker data 
may be not accurate for milder cases of FD.   
In the SIFAP study another 0.4% of patients was classified as having possible FD 
which was defined by the presence of the p.D313Y mutation or the complex intronic 
haplotype, in combination with at least two increased biomarkers (Gb3 in blood, 
lyso-Gb3 or Gb3-24 in urine). In our study, 0.7% of our patients had either the 
p.D313Y mutation or the complex intronic haplotype in combination with increased 
lyso-Gb3, but α-GAL activity was within the reference range and these patients had 
no recurrent vascular events. The pathogenicity of p.D313Y has often been debated. 
Initially this mutation was described as causing classical FD.91 However, more recent 
studies showed that p.D313Y results in a decreased enzyme activity in plasma, though 
with remaining high residual enzyme activity and normal lyso-Gb3.92, 93 Therefore 
p.D313Y is now generally considered to result in so called pseudo-deficiency. 
In our study the complex intronic haplotype was not suggestive to be relevant to FD. 
Carriers of this haplotype had α-GAL activity within the reference range or slightly 
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below, but well above the 5% of mean normal activity. There were no differences in 
long-term risk of recurrent vascular events, between patients with this haplotype 
and those with no abnormal finding in the GLA gene. Moreover, patients with this 
haplotype that experienced a recurrent vascular event had normal lyso-Gb3 values, 
and had accompanying risk factors for vascular disease.  
Our study has some limitations, including that it may be that not all cases of young 
stroke in our catchment area were entered in our cohort, because our cohort is 
hospital-based, rather than community-based. Only those patients who sustained a 
fatal stroke, who were not admitted to our hospital, would not have been included 
in our study. Patients who survive usually visit a university medical center during the 
course of their disease. In addition there are no restrictions to be admitted to our 
hospital and we included all consecutive cases that were eligible for participation. 
We therefore presume that our study population is a representative sample of 
Dutch patients with young stroke, although formal data are lacking to prove this 
generalizability. Another limitation is that only survivors of young stroke are included 
in this study, possibly inducing survivor bias, which might have underestimated 
prevalence of FD in our study. 
To avoid controversial findings in future studies on FD in young stroke, studies should 
provide clear definitions of FD and detailed description of relevant findings that 
support a diagnosis of FD (e.g. mutations, levels of biomarkers, clinical findings).83, 
90 Moreover, before a definite diagnosis of FD is made and expensive treatment is 
initiated, confirmation of pathogenicity of GVUS is needed (cell culture experiments, 
computational modeling, prospective monitoring of patients including biopsies of 
affected organs to demonstrate significant substrate accumulation).72
In conclusion, our study suggests that the prevalence of FD in young stroke patients 
is very low and that the GVUS detected in our study are not very likely to be FD 
causing variants, as they were not associated with increased risk of incident vascular 
disease. The widespread screening for FD without any other clinical signs indicative 
of FD may not be justifiable in young stroke patients.
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Abstract
Background and objectives
Diabetes diagnosed prior to stroke in young adults is strongly associated with 
recurrent vascular events. The relevance of impaired fasting glucose (IFG) and 
incidence of diabetes after young stroke is unknown. We investigated the long-term 
incidence of diabetes after young stroke and evaluated the association of diabetes 
and impaired fasting glucose with recurrent vascular events.
Methods 
This study was part of the FUTURE study. All consecutive patients between January 
1, 1980, and November 1, 2010 with TIA or ischemic stroke, aged 18-50, were 
recruited. A follow-up assessment was performed in survivors between November 
1, 2009 and January 1, 2012 and included an evaluation for diabetes, fasting venous 
plasma glucose and recurrent vascular events. The association of diabetes and IFG 
with recurrent vascular events was assessed by logistic regression analysis, adjusted 
for age, sex and follow-up duration.
Results
427 survivors without a medical history of diabetes were included in the present 
analysis (mean follow-up of 10.1 (SD 8.4) years; age 40.3 (SD 7.9) years). The 
incidence rate of diabetes was 7.9 per 1000 person-years and the prevalence of IFG 
was 21.1%. Patients with diabetes and IFG were more likely to have experienced any 
vascular event than those with normal fasting glucose values (OR 3.5 (95%CI 1.5-8.4) 
for diabetes and OR 2.5 (95%CI 1.3-4.8) for IFG).
Conclusions 
Diabetes or IFG in young stroke survivors is frequent and is associated with recurrent 
vascular events. Regular screening for IFG and diabetes in this population, yields 
potential for secondary prevention.
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Background
Patients, who suffered a stroke at young age, are at high risk of recurrent vascular 
events and death.21, 81 Because of the young age of these patients, the initial stroke 
as well as possible recurrent vascular events has a large impact on number of years 
lost to ill-health, disability and early death. Previous studies reported that vascular 
risk factors are common in these young adults. 12, 14  Secondary prevention measures 
targeting these vascular risk factors may diminish the risk of recurrent vascular events. 
However, risk factors that emerge after a young stroke often may go undetected in 
many patients as current protocols and guidelines only recommend screening of 
young stroke patients in the acute phase and only few months thereafter.94
Risk of recurrent vascular events seems especially high in young stroke patients 
with a medical history of diabetes.95 In both the general population and in stroke 
patients over 65 years , also impaired fasting blood glucose (IFG) or impaired glucose 
tolerance, conditions that precede diabetes, have been associated with an increased 
risk of vascular events. 96, 97 Moreover, more than half of older stroke patients, 
who were not previously known to have diabetes, were diagnosed to have either 
impaired glucose tolerance or diabetes three months after stroke. 98 Analogous 
to these older stroke patients, young stroke patients without a medical history of 
diabetes at the time of their index event may still develop IFG or incident diabetes 
after their young stroke as well. Particularly since regular monitoring of glucose 
levels after the acute phase of stroke in young adults without diabetes is seldom 
performed. Glucose control in patients with IFG or incident diabetes could be an 
important way to reduce risk of recurrent vascular events.99 However, the incidence 
of diabetes and IFG after stroke in young adults is currently unknown. Moreover, 
we are not aware of any study that investigates the association between impaired 
fasting blood glucose and recurrent vascular events in young stroke patients.
Therefore, we investigated the incidence of diabetes after a mean follow-up of 
10 years in survivors of a young TIA or ischemic stroke. Secondly, we investigated 
whether impaired fasting blood glucose and diabetes at follow-up were associated 
with the occurrence of vascular events during follow-up. 
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Methods
Patients and study design
This study is a part of the “Follow-Up of Transient ischemic attack and stroke 
patients and Unelucidated Risk factor Evaluation” (FUTURE) study, a prospective 
cohort study of prognosis of stroke in young adults.75, 81 The Medical Review Ethics 
Committee region Arnhem-Nijmegen approved the study.
In short, the FUTURE study comprised all consecutive patients aged 18 through 
50 years with a TIA, ischemic stroke or intracerebral hemorrhage admitted to the 
Radboud university medical center from January 1, 1980 until November 1, 2010. 
Only patients with TIA or ischemic stroke without a medical history of diabetes, 
who survived until the follow-up assessment, were included in the present study. 
Exclusion criteria were cerebral venous sinus thrombosis and retinal infarct. 
To minimize bias resulting from changing diagnostic techniques, the World Health 
Organization definitions for TIA and stroke were used. 77, 100 The definition of TIA 
included a rapidly evolving focal neurologic deficit, without positive phenomena 
such as twitches, jerks or myoclonus, with vascular cause only and persisting for a 
period of less than 24 hours. Stroke was defined as focal neurologic deficit persisting 
for more than 24 hours. Stroke was subdivided into ischemic and hemorrhagic 
stroke, on the basis of radiological findings. 
Patients were identified through a prospective registry of all patients with 
young stroke that has been maintained at our centre, beginning in 1978,25 with 
a standardized data collection of baseline and clinical characteristics, including 
demographic data, stroke subtype and vascular risk factors.75 
Assessment of both the etiology (Trial of Org 10172 in Acute Stroke Treatment 
[TOAST] classification)78 and severity (National Institutes of Health Stroke Scale 
[NIHSS])79 was performed retrospectively in all cases on the basis of medical records, 
because these scales did not exist when a substantial number of our patients 
experienced their index event. In comparison to the original TOAST classification, 
101 the presently used classification has an additional category, “likely large-artery 
atherosclerosis”. 78 Atherothrombotic stroke is defined as patients with (1) an 
ipsilateral internal carotid stenosis >50% (in NASCET criteria), or (2) an ipsilateral 
stenosis >50% of another intra/extracranial artery, or (3) mobile thrombus in the 
aortic arch. Likely atherothrombotic stroke is defined as patients with no evidence 
of atherothrombotic stroke with (1) an ipsilateral internal carotid stenosis <50%, 
or (2) an ipsilateral stenosis <50% of another intra/extracranial artery, or (3) aortic 
arch plaques >4 mm in thickness without a mobile component, or (4) a history of 
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myocardial infarction or coronary revascularization, (5) a history of documented 
peripheral arterial disease, or (6) at least two risk factors for atherosclerotic disease: 
arterial hypertension (treated or known blood pressure before stroke >135/85 
mm Hg or hypertensive retinopathy), diabetes mellitus (treated or known blood 
fasting glucose >7 mmol/dl), current smoking (or smoking stopped within the last 
6 months), high cholesterol (treated or known low-density lipoprotein before the 
stroke >160 mg/dl). 
Patients alive were invited for follow-up assessment between November 1, 2009 
and January 1, 2012. Participants provided written informed consent.
Diabetes and impaired fasting glucose
Incidence of diabetes was the primary outcome measure, either diagnosed during 
follow-up or at the follow-up assessment. Secondary outcomes were the prevalence 
of IFG (fasting blood glucose 5.6-6.9 mmol/L at the follow-up assessment) and the 
occurrence of vascular events in relation to fasting blood glucose levels at the follow-
up assessment. 
The detection of incident diabetes during follow-up was done by a two step approach. 
First patients were asked whether diabetes was diagnosed during the follow-up 
period, by means of a standardized structured questionnaire. If so, patients’ general 
practitioner was contacted to verify the diagnosis systematically, and to ascertain 
information about the plasma glucose level, type of diagnosed diabetes and initiated 
treatment. 
Secondly, venous plasma samples were taken from all participants at the follow-up 
assessment after overnight fasting to measure plasma glucose. Whenever glucose 
was ≥5.6 mmol/L, the patient was sent to the general practitioner to obtain a second 
fasting venous plasma glucose. 
Incident diabetes was defined as: 1) treatment with antidiabetic medication or a 
diagnosis of diabetes (confirmed by a physician) during the follow-up period or 2) 
two consecutive fasting venous plasma glucose levels of ≥7.0 mmol/L at the follow-
up assessment. IFG was only assessed at the follow-up assessment, defined as a 
fasting blood glucose of 5.6 mmol/L-6.9 mmol/L.
Vascular events
Patients were evaluated for recurrent vascular events by means of a standardized, 
structured questionnaire.102 
58
Chapter 4
Whenever a recurrent event was suspected, information retrieved was verified and 
adjudicated by physicians from the appropriate specialty (FEdL, EvD, MvdV). 
A composite vascular event was defined as the combination of stroke (ischemic 
or hemorrhagic), myocardial infarction, and cardiovascular procedures (coronary 
artery bypass grafting, percutaneous transluminal coronary angioplasty, carotid 
endarterectomy or other peripheral arterial revascularization procedures), 
whichever occurred first. Separate analyses were done for stroke and other arterial 
events. 
Statistical analysis
The incidence rate of diabetes was calculated for stroke subtypes. Baseline 
characteristics were compared between patients without diabetes or impaired 
fasting glucose and patients with diabetes or impaired fasting glucose using 
Student’s t test, Mann-Whitney U test or chi-square-test whenever appropriate. 
Fasting blood glucose values at the follow-up assessment were categorized into 
normal fasting blood glucose (<5.6 mmol/L), impaired fasting blood glucose (5.6 
mmol/L-6.9 mmol/L) and diabetes (> 7.0 mmol/L). Odds ratios were calculated 
for the association between fasting blood glucose categories at the follow-up 
assessment and the occurrence during follow-up of the composite vascular event, 
other arterial events and stroke separately, adjusted for age of the index stroke, sex, 
and follow-up duration.
Analyses were done using IBM SPSS Statistics version 20. Two-sided P values of less 
than 0.05 were considered to indicate statistical significance.
Results
427 patients completed follow-up assessment (Figure 1). Baseline characteristics are 
presented in table 1. There were no differences in baseline characteristics between 
participants and non-participants (patients lost to follow-up, patients with no 
venipuncture or patients who refused), except for history of TIA (3.5% in participants 
and 0.7% in nonparticipants).
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After a mean follow-up of 10.1 years (SD 8.4), diabetes was diagnosed in 11 TIA 
patients (7.1%) and 23 ischemic stroke patients (8.5%), resulting in an incidence rate 
per 1000 person years of 7.9 and 7.8 respectively. Among those without diabetes at 
follow-up, 83 patients (21.1%) had an IFG (5.6-6.9 mmol/L) and 310 patients (78.9%) 
had normal blood glucose values. 
Figure 1 Flowchart of the study population
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Table 1 Baseline characteristics of patients
 Total TIA Ischemic 
stroke
n (% of total) 427 (100) 156 (36.5) 271 (63.5)
Mean age at event, years (SD) 40.3 (7.9) 41.3 (7.8) 39.9 (7.8)
Male 190 (44.5) 71 (45.5) 119 (43.9)
Median NIHSS at admission (IQR)a 2 (0-6) 0 (0-1) 4 (2-8)
Mean follow-up, years (SD) 10.1 (8.3) 8.9 (8.5) 10.9 (8.2)
TOAST    
Atherothrombotic stroke 33 (7.7) 9 (5.8) 24 (8.9)
Likely atherothrombotic stroke 61 (14.3) 27 (17.3) 34 (12.5)
Cardioembolic stroke 44 (10.3) 15 (9.6) 29 (10.7)
Small vessel occlusion 41 (9.6) 7 (4.5) 34 (12.5)
Rare causes 66 (15.5) 16 (10.3) 50 (18.5)
Multiple causes 10 (2.3) 3 (1.9) 7 (2.6)
Unknown cause 172 (40.3) 79 (50.6) 93 (34.3)
Risk factors in medical history    
Previous TIA 15 (3.5) 8 (5.1) 7 (2.6)
Previous stroke 6 (1.4) 2 (1.3) 4 (1.5)
Hypertension 101 (23.7) 46 (29.5) 55 (20.3)
Atrial fibrillation 6 (1.4) 2 (1.3) 4 (1.5)
Smokingb 196 (46.8) 55 (35.9) 141 (53.0)
Excess alcohol consumptionc 27 (6.3) 11 (7.1) 16 (5.9)
Family history of diabetesd 175 (41.4) 69 (45.1) 106 (39.3)
Abbreviations: TIA, transient ischemic attack; SD, standard deviation; NIHSS, National Institute of Health Stroke 
Scale; IQR, interquartile range; TOAST, Trial of Org 10172 in Acute Stroke Treatment. 
Data are given as number (percentage) or otherwise stated 
a Scores range from 0 to 42 with higher scores on the scale indicating worse stroke severity. 0.5% of NIHSS was 
missing.
b Smoking was defined as smoking at least 1 cigarette a day in the year prior to the event. 1.9% of data on 
smoking was missing.
c Excess alcohol consumption was defined as consuming more than 200 grams of pure alcohol per week
d First degree family member. 0.9% of data on family history of diabetes was missing.
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Compared with patients without IFG or incident diabetes at the follow-up 
assessment, patients with incident diabetes were at baseline more often older, 
had a longer mean follow-up duration , had a likely atherothrombotic stroke , a 
medical history of hypertension, a medical history of smoking and a family history 
of diabetes (Table 2). Compared with patients without IFG or incident diabetes at 
the follow-up assessment, patients with IFG at the follow-up assessment were at 
baseline more frequently men, had a higher age, a longer mean follow-up duration, 
a likely atherothrombotic stroke and a medical history of hypertension.
At follow-up, 12 patients with incident diabetes (35.3%) had experienced any 
vascular event (composite event) and 7 patients (20.6%) of them experienced more 
than one event; 4 patients (11.8%) had at least one stroke and 10 patients (29.4%) 
had experienced at least one other arterial event. Among patients with IFG at follow-
up, 21 patients (25.3%) had experienced any vascular event and 6 patients (7.2%) of 
them experienced more than one event; 10 patients (12.9%) had at least one stroke 
and 11 patients (13.3%) had experienced at least one other arterial event. Among 
patients with normal fasting blood glucose levels at follow-up, 30 patients (9.7%) had 
experienced any vascular event and 6 patients (1.9%) of them; 24 patients (7.7%) 
had experienced at least one stroke and 8 patients (2.6%) had experienced at least 
one other arterial event. In all three fasting blood glucose groups, the proportion 
of patients on antiplatelet medication at discharge did not differ between patients 
who experienced a recurrent vascular event compared with patients who did not 
experience a recurrent vascular event during follow-up.
After adjusting for age of index stroke, sex and follow-up duration, patients with 
diabetes and IFG were more likely to have experienced any vascular event during 
follow-up than those with normal fasting blood glucose values (OR 3.5 (95%CI 1.5-
8.4) for diabetes and OR 2.5 (95%CI 1.3-4.8) for IFG) . Risk for the recurrence of 
stroke was not different for patients with incident diabetes and IFG compared with 
those with normal fasting blood glucose values (OR 1.2 (95%CI 0.4-4.0) for diabetes 
and OR 1.4 (95%CI 0.6-3.3) for IFG). Risk of other arterial events was increased in 
patients with diabetes and IFG compared with those with normal fasting blood 
glucose levels (OR 8.4 (95% CI 2.7-26.4) for diabetes and (OR 3.6 (95%CI 1.3-9.6) for 
IFG).
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Table 2 Presence of baseline factors in patients with incident diabetes  
 or impaired fasting glucose at follow-up
 No 
diabetes 
or IFG
Diabetes pa IFG pb
n (% of total) 310 (72.6) 34 (8.0) 83 (19.4)
Mean age at event, years 
(SD)
39.2 (8.2) 44.5 (4.5) 0.002 42.8 (6.5) 0.001
Male 123 (39.7) 16 (47.1) 0.41 51 (61.4) <0.001
Median NIHSS at 
admission (IQR)c
2 (0-6) 2 (1-4) 0.82 3 (0-6) 0.31
Mean follow-up, years (SD) 8.7 (7.8) 16.7 (8.0) <0.001 12.6 (8.6) 0.001
TOAST   
Atherothrombotic stroke 20 (6.5) 5 (14.7) 0.08 8 (9.6) 0.32
Likely atherothrombotic 
stroke
30 (9.7) 14 (41.2) <0.001 17 (20.5) 0.007
Cardioembolic stroke 35 (11.3) 1 (2.9) 0.15 8 (9.6) 0.67
Small vessel occlusion 34 (11.0) 0 0.06 7 (8.4) 0.50
Rare causes 56 (18.1) 1 (2.9) 0.03 9 (10.8) 0.14
Multiple causes 7 (2.3) 1 (2.9) 1.00 2 (2.4) 1.00
Unknown cause 128 (41.3) 12 (35.3) 0.50 32 (38.6) 0.65
Risk factors in medical 
history
  
Previous TIA 10 (3.2) 1 (2.9) 1.00 4 (4.8) 0.51
Previous stroke 5 (1.6) 1 (2.9) 1.00 0 0.37
Hypertension 58 (18.7) 14 (41.2) 0.002 29 (34.9) 0.002
Smokingd 133 (43.6) 23 (67.6) 0.008 40 (50.0) 0.31
Excess alcohol 
consumptione
19 (6.1) 3 (8.8) 0.71 5 (6.0) 0.97
Family history diabetesf 124 (40.5) 20 (58.8) 0.04 31 (37.3) 0.60
Abbreviations: IFG, impaired fasting glucose; TIA, transient ischemic attack; SD, standard deviation; NIHSS, 
National Institute of Health Stroke Scale; IQR, interquartile range; TOAST, Trial of Org 10172 in Acute Stroke 
Treatment. 
Data are given as number (percentage) or otherwise stated 
a p values refer to a comparison between patients with incident diabetes and patients with no IFG or diabetes 
b p values refer to a comparison between patients with IFG and patients with no IFG or diabetes 
c Scores range from 0 to 42 with higher scores on the scale indicating worse stroke severity. 0.4% of NIHSS 
was missing.
d Smoking was defined as smoking at least 1 cigarette a day in the year prior to the event. 2.9% of data on 
smoking was missing.
e Excess alcohol consumption was defined as consuming more than 200 grams of pure alcohol per week
f First degree family member. 1.0% of data on family history of diabetes was missing.
63
II
Diabetes after stroke in young adults
Discussion
We demonstrated that 8% of young stroke survivors developed diabetes during a 
mean follow-up of 10 years after stroke, which is more than two times higher than 
expected compared with persons from a Dutch general practitioner registry with 
similar age and sex.103 Moreover, we showed that among those patients without 
diabetes at the follow-up assessment, 21% had impaired fasting blood glucose 
values. In our study, both patients with diabetes and patients with IFG at the follow-
up assessment were about three times more likely to experience any vascular event 
during follow-up than those with normal fasting blood glucose values. 
To our knowledge, our study is the first to evaluate the incidence of diabetes after 
stroke in young adults and to study the association between fasting blood glucose 
values and recurrent vascular events. Moreover, our study has the longest follow-
up period reported and one of the largest study populations in the field of young 
stroke. Collecting data all in one site allowed us to collect baseline and follow-up 
information according to identical procedures in all patients thereby reducing the 
risk of information bias. 
Our study has some limitations. First, it may be that not all cases of young stroke 
in our catchment area were included in our cohort, because our cohort is a single-
center, hospital-based study, rather than community-based. Only those patients 
who sustained a fatal stroke, who were not admitted to our hospital, would not have 
been included in our study. Patients who survive usually visit a university medical 
center during the course of their disease. In addition, there are no restrictions 
to be admitted to our hospital and we included all consecutive cases admitted. 
We therefore presume that our study population is a representative sample of 
Dutch patients with young stroke, although formal data are lacking to prove this 
generalizability.
Second, we investigated the association of IFG and diabetes with recurrent vascular 
events during follow-up in a cross-sectional analysis, on average 10 years after the 
index event in patients that survived until the follow-up assessment.
Thus the measurement of blood glucose values is done after a recurrent event 
occurred. This may have induced survivor bias. IFG and diabetes may be associated 
with the severity of the recurrent event and as a consequence, patients with IFG and 
diabetes may be underrepresented in survivors with recurrent events, which may 
have attenuated the association between IFG/diabetes and recurrent events. 
Furthermore, IFG was only measured at the follow-up assessment, whereas for 
diabetes also a diagnosis established during the follow-up period was taken in 
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account. Diabetes that developed during follow-up might otherwise have been 
missed at the follow-up assessment due to initiated treatment. 
Third, some patients were lost to follow-up or refused to participate, which 
potentially could have resulted in selection bias. However, non-participants did not 
differ in baseline characteristic from participants, making selection bias in this group 
unlikely. 
Fourth, our study has a long inclusion period, during which diagnostic equipment, 
acute treatment and secondary prevention have improved. However, this is an 
unavoidable feature of a long-term follow-up study. Furthermore, the long follow-up 
period might have resulted in recall bias with respect to vascular events. However, 
this probably would have underestimated the association between diabetes and 
recurrent vascular events, since the incidence of diabetes was strongly related to 
the number of follow-up years.
Fifth, secondary prevention might have influenced our results. In our study about 90% 
of all patients used secondary preventive medication at discharge. Consequently the 
shown risk of recurrent vascular events might be an underestimation attributable to 
the use of this preventive medication. Sixth, as is reflected by the wide CIs, estimates 
for some subgroups that contain only a few patients might be unstable and should 
therefore be interpreted with caution.
So far, the only studies reporting on epidemiology of diabetes in young stroke 
patients restricted their reports to diabetes diagnosed prior to stroke. The proportion 
of patients with a medical history of diabetes varied widely in these studies, ranging 
from 2-12%.20, 95, 104 Our observed prevalence of diabetes based on the medical 
history of 4.9% is in the middle of this range.  
We showed in univariate analysis that incident diabetes after TIA or ischemic 
stroke was associated with age, likely atherothrombotic stroke and family history of 
diabetes, which are among well established risk factors for diabetes in the general 
population. In addition, we showed that both patients with diabetes and patients 
with IFG were far more likely to have experienced any arterial event during follow-
up than those with normal fasting blood glucose values. These results suggest an 
intimate relationship in young stroke patients between pre-existent vulnerability 
to atherosclerosis and incident diabetes, which is an atherogenic risk factor itself. 
However, it is also possible that diabetes was already present but not revealed 
during the index event.
Incident diabetes or IFG was not associated with recurrent stroke. An explanation 
might be that diabetes needs to be present for many years to be a risk factor for 
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recurrent stroke. This is in line with a previous study in young adults with ischemic 
stroke that showed that among patients with type 1 diabetes, duration of diabetes 
was on average 10 years longer in those with recurrent stroke versus those without 
recurrent stroke.95 Another explanation for the lack of association might be the 
possibility of index event bias.105 In a study investigating recurrence, patients are 
included based on the occurrence of the first event that is similar to the recurrent 
event. This has an effect on the distribution of risk factors in this selected population 
and the associations of these risk factors with the outcome of interest.
The high incidence of diabetes during our long follow-up period, but also the high 
proportion of patients with IFG, emphasizes that young stroke survivors remain 
vulnerable to the development of (risk factors for) vascular disease, even decades 
after their initial stroke. Active screening for IFG and diabetes after stroke in young 
adults may allow for early diagnoses of IFG and diabetes and thereby provide a 
therapeutic window to lower the risk of recurrent vascular events. Similar to the 
general population, young stroke patients with a higher age, having other vascular 
risk factors or a family history of diabetes, might benefit the most from active 
screening. 
To conclude, IFG and diabetes after stroke in young patients may remain unnoticed 
in many patients. A regular screening for IFG and diabetes after young stroke, 
particularly in those with increasing age, having other vascular risk factors or a 
family history of diabetes, yields potential for secondary prevention. 
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Abstract
Background and objectives
Long-term data on mortality after first-ever stroke in adults aged 18-50 years are 
scarce and usually restricted to ischemic stroke. Moreover, expected mortality not 
related to first-ever stroke is not taken in account. Our objective was to investigate 
long-term mortality and cause of death after acute stroke in adults aged 18-50 years 
and to compare this with nationwide age and sex matched mortality rates
Methods
FUTURE study, a prospective cohort study on prognosis after ischemic or hemorrhagic 
stroke in adults, aged 18-50 years admitted to our hospital between 1-1-1980 till 
1-11-2010.We assessed at November 1, 2012 the survival status in 959 consecutive 
patients with a first-ever TIA (n=262), ischemic stroke (n=606) or intracerebral 
hemorrhage(n=91). Mean follow-up duration was 11.1 (8.7) years (median (IQR), 8.3 
(4.0-17.4)). Observed mortality was compared with the expected mortality, derived 
from mortality rates in the general population with similar age, sex and calendar-
year characteristics. 
Results 
At the end of the follow-up, 192 (20.0%) patients had died. Among 30-day survivors 
cumulative 20-year risk of death was 24.9% (95% CI 16.0-33.7), 26.8% (95% CI 
21.9-31.8) and 13.7% (95% CI 3.6-23.9) for TIA, ischemic stroke and intracerebral 
hemorrhage respectively. Observed mortality among TIA, ischemic stroke and 
intracerebral hemorrhage was increased compared to expected mortality 
(standardized mortality ratio (SMR) 2.6 (95% CI, 1.8-3.7), 3.9 (95% CI, 3.2-4.7) and 
3.9 (95% CI, 1.9-7.2) respectively). For ischemic stroke, cumulative mortality was 
higher in men than in women (33.7% (95% CI 26.1-41.3) versus 19.8% (95% CI 13.8-
25.9), whereas excess mortality was highest in women (SMR, 4.3 [95% CI, 3.2-5.6] 
for women; SMR, 3.6 [95% CI, 2.8-4.6] for men). 
For all etiological subtypes of ischemic stroke, observed mortality exceeded expected 
mortality.
Conclusions  
Among adults aged 18-50 years, 20-year mortality following acute stroke was 
relatively high compared with expected mortality.
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Introduction
Stroke is one of the leading causes of death with an annual 6 million fatal events 
worldwide. Stroke mainly affects elderly people, still approximately 10% occurs in 
patients younger than 50 years. Despite this considerable proportion, only very 
limited data exist on long-term prognosis after stroke in adults aged 18-50 years.13, 
15-20 It is exactly this long-term prognosis that is particularly important in adults in 
these ages, given that they have a long life expectancy during a demanding period of 
life in which they start to form families, have an active social life and make decisive 
career moves. To refer to a stroke that occurs in adults aged 18-50 years, the term 
“young stroke” is used.
Prognosis of young stroke is generally considered to be benign, given that short-
term mortality is lower compared to older stroke patients. Notably, these older 
patients have a much higher a priori mortality rate, simply because of their age. A 
more sensible approach would therefore be to compare the mortality in a young 
stroke population, with that of the age and sex matched general population in 
order to calculate the excess risk of dying in young stroke patients. So far, previous 
studies on mortality after young stroke only report absolute mortality rates within 
their population or relative to stroke at higher ages, without comparison to the age-
matched risk of dying. 
The few studies with extended follow-up (i.e. longer than 5 years) show much of 
variation which might be due to only modest number of patients involved.13, 16, 17, 
19 In addition, some important principles of study design are not always thoroughly 
described including diagnostic criteria, definition of outcomes, outcome surveillance, 
sources of data, statistical methods, efforts to address potential sources of bias and 
confounding.13, 16, 17, 19 Although stroke is an umbrella term for both short (TIA) and 
longer lasting periods of cerebral ischemia, but also intracerebral hemorrhage (ICH), 
most studies hardly include any outcome data on these, other than ischemic stroke. 
The aim of this study was to investigate long-term mortality and cause of death after 
first acute stroke in adults aged 18-50 years and to compare this with nationwide 
age and sex matched mortality rates. 
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Methods
Patients and study design
This study is a part of the “Follow-Up of Transient ischemic attack and stroke patients 
and Unelucidated Risk factor Evaluation”-study (FUTURE study), a prospective 
cohort study that investigates causes and consequences of a young stroke.75 
The Medical Review Ethics Committee region Arnhem-Nijmegen approved the study 
and granted a waiver of consent to collect information on vital status for those who 
had died. The report was prepared in accordance with the STROBE guidelines.106
In short, the FUTURE study comprised all consecutive patients with a TIA, ischemic 
stroke or ICH, between ages 18 – 50 years, admitted to the Radboud University 
Medical Centre Nijmegen from 1-1-1980 till 1-11-2010. Only patients with first-ever 
TIA or Stroke were included in the present study. Exclusion criteria were previous 
stroke or TIA, traumatic hemorrhagic stroke, hemorrhage in known cerebral 
metastasis or primary brain tumor, cerebral venous sinus thrombosis, subarachnoid 
hemorrhage or ICH due to known ruptured aneurysm and retinal infarction. 
To minimize bias due to changing diagnostic techniques, the World Health 
Organization definition for TIA and stroke was used.77, 100 TIA was defined as a rapidly 
evolving focal neurological deficit, without positive phenomena such as twitches, 
jerks or myoclonus, with no other than a vascular cause lasting less than 24 hours. 
Stroke was defined as focal neurological deficit persisting for more than 24 hours.77, 
100 On basis of radiological findings, stroke was subdivided into ICH and ischemic 
stroke. 
Patients were identified through a prospective registry of all consecutive young 
stroke patients that has been maintained at the department since the 1970’ies25 
with a standardized collection of baseline and clinical characteristics (including 
demographics, stroke subtype and vascular risk factors).75 In the frame work of our 
young stroke protocol, patients underwent imaging of intracranial and vertebral 
arteries and, when appropriate, cardiac echography was performed. The assessment 
of both the etiology (modified Trial of ORG 10172 in Acute Stroke Treatment (TOAST) 
classification 78) and severity (National Institutes of Health Stroke Scale (NIHSS)79 
and modified Rankin scale107) was done for all cases retrospectively by a validated 
approach,26, 80 as these scales did not exist at the time when a substantial proportion 
of our patients experienced their qualifying event. In comparison to the original 
TOAST classification,101 the presently used classification has an additional category 
“likely large-artery atherosclerosis”.78
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Mortality
The primary outcome was all-cause mortality. Information on the vital status was 
retrieved from the Dutch Municipal Personal Records database. Patients were 
followed until death or until November 1, 2012, whichever occurred first.
Information on cause of death was retrieved from the general practitioner or other 
treating physicians and medical records. Cause of death was missing for 4 (2.1%) 
patients.
Deaths were classified according to the International Classification of Diseases, 10th 
Revision.108 Causes were categorized into ischemic stroke, intracerebral hemorrhage, 
cardiac cause, other vascular, malignancies, infections and miscellaneous. Other 
vascular deaths were those that were not clearly non-vascular and did not meet the 
criteria for fatal stroke or cardiac cause. 
Statistical analysis
Case-fatality was defined as death within 30 days after the index stroke or TIA. 
Only patients surviving beyond these 30 days were included in survival analysis. 
Cumulative mortality and 95% CIs were estimated with Kaplan-Meier analysis by 
index event separately. Person-years at risk were calculated for each patient from 
date of the index stroke until death or date of end of follow-up. 
Patients who died or did not reach the endpoint were censored. For 36 (3.8%) 
patients follow-up was not complete. In our analyses, we took these patients into 
account until the last known recording of their survival status. Theoretically, the 
follow-up of these 36 patients could have contributed to a maximum of 538 person-
years. But on their last known survival status they contributed 199 person-years. 
This means that a maximum of 339 persons years out of in total 10960 person-years 
of follow up are missing, resulting in a follow up rate of 97%. 
To ensure that the provided Kaplan-Meier plots were reliable for all subgroups, 
survival plots were curtailed at 20 years, 109 all events were retained in subsequent 
analysis. 
Expected mortality was obtained from mortality data of the whole population of 
the Netherlands, stratified by age, sex and calendar year at risk,39 matched to the 
study population on these factors.110 Subsequently, expected cumulative mortality 
was compared with observed mortality per stroke subtype. Average annual risks 
of observed and expected mortality were calculated using the formula 1-[(1-I
c
)1/n], 
where I
c 
equals the cumulative mortality at n years, obtained by the Kaplan-Meier 
method. 111
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Age was divided into 3 groups: 18-29 years, 30-39 years and 40-50 years. To 
determine whether mortality after a TIA or ischemic stroke was different between 
the age categories and men versus women, cumulative mortality was estimated 
with Kaplan-Meier analysis for these subgroups. Subsequently, Kaplan-Meier 
curves were compared between the age categories and by sex using Log-rank test. 
Moreover, 20-year cumulative mortality with 95% CIs was calculated for the age 
categories and sex.
Standardized mortality ratios (SMRs) were calculated to compare risk of death in 
our population with that in the general population for each index event and for TIA 
and ischemic stroke also stratified by sex, age category and TOAST subtype. The 
standardized mortality ratio (SMR) was derived as the ratio of observed to expected 
deaths over the duration of the follow-up, and the exact 95% confidence interval 
was calculated according to the Poisson distribution. 
The absolute excess number of deaths was calculated as the difference between 
observed and expected deaths, divided by the number of person-years at risk and 
expressed per 1000 person-years.
We used Cox proportional hazard models to calculate hazard ratios (HRs) and 95% 
confidence intervals for age (continuous), sex and TOAST subtype. Subsequently 
these three variables were entered simultaneously in Cox proportional hazard 
model to quantify the relation between TOAST subtype and mortality adjusted for 
age and sex. 
A Cox proportional-hazards model was constructed with age, gender and period 
(1980-1989, 1990-1999 and 2000-2010), to evaluate whether a cohort or period 
effect could have influenced our mortality results, since the present study features 
a long inclusion period (1980-2010). Similarly, A Cox proportional-hazards model 
was constructed with age, gender and thrombolytic therapy, to evaluate the 
potential effect of thrombolytic therapy on our results. Schoenfeld residuals from 
the Cox proportional-hazards models were examined to assess possible departures 
from model assumptions. There were no indications that the proportional hazards 
assumption was violated.
Two-sided P values of less than 0.05 were considered to indicate statistical 
significance. As the analyses of the SMR were done for several subgroups, the 
threshold for significance in these analyses was set to a Bonferroni-adjusted p-value 
of 0.004. SPSS 18 was used for all statistical analysis.
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Results
Study population
Between 1-1-1980 and 1-11-2010, 959 patients with first-ever stroke/TIA were 
included. There were 262 (27.3%) patients with a TIA, 606 (63.2%) with an ischemic 
stroke and 91 (9.5%) with an ICH. The baseline characteristics of the study population 
are shown in Table 1. Mean follow-up was 11.1 (SD 8.7) years (median (IQR) = 8.3 
(4.0-17.4)).
Case-fatality
During follow-up, 192 (20.0%) patients had died. Forty-three of them died within the 
first 30 days after the index event, giving an overall 30 day case-fatality of 4.5%. For 
TIA, ischemic stroke and ICH, case-fatality was 0.4%, 3.6% and 22.0% respectively. 
Mortality in 30-day survivors
For young TIA patients, the 1 year cumulative mortality was 1.2% (95% CI 0.0-2.5) 
(Fig. 1A) In the subsequent years the annual mortality ranged between 0.4% and 
1.5% (Fig. 1B), resulting in a cumulative mortality of 2.5% (95% CI 0.5-4.4), 9.2% (95% 
CI 4.3-14.2) and 24.9% (95% CI 16.0-33.7) after 5, 10 and 20 years respectively.  
One year mortality after young ischemic stroke was 2.4% (95% CI 1.2-3.7) and 
thereafter the annual risk remained rather constant on a level ranging from 1.2%-
1.8%, resulting in a cumulative mortality of 5.8% (95% CI 3.9-7.8), 12.4% (95% CI 
9.4-15.5) and 26.8% (95% CI 21.9-31.8) after 5, 10 and 20 years respectively.
For ICH mortality at 1 year was 2.9% (95% CI 0.0-6.8); thereafter the annual risk 
ranged from 0.6%-2.9%, resulting in a cumulative mortality of 6.1% (95% CI 0.3-
11.9), 10.3% (95% CI 2.3-18.3) and 13.7% (95% CI 3.6-23.9) after 5, 10 and 20 years 
respectively.
Figure 1A shows that the observed mortality after ischemic stroke remained 
increased compared to the expected mortality during the whole follow-up (26.8% 
(95% CI 21.9-31.8) versus 7.6%). For TIA this was only true after 10 years follow-up 
(24.9% (95% CI 16.0-33.7) versus 8.5%). For ICH, the 95% confidence bound of the 
observed cumulative mortality and the expected mortality overlapped during the 
total follow-up period (13.7% (95% CI 3.6-23.9) versus 5.6%).
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Table 1 Baseline characteristics stratified by stroke subtype
 Total TIA Ischemic 
Stroke
ICH
n (% of total) 959 (100) 262 (27.3) 606 (63.2) 91 (9.5)
Mean age at event, 
years (SD)
40.1 (7.9) 40.3 (7.9) 40.3 (7.8) 38.1 (8.7)
Men, n (%) 446 (46.5) 115 (43.9) 287 (47.4) 40 (48.4)
Median follow-up, 
years (IQR)
8.3 (4.0-17.4) 6.9 (4.1-14.6) 10.0 (4.3-18.0) 6.1 (0.1-12.4)
>15 years FUP, n (%) 291 (30.3) 65 (24.8) 207 (34.2) 19 (20.9)
>20 years FUP, n (%) 186 (19.4) 48 (18.3) 124 (20.5) 14 (15.4)
TOAST     
Atherothrombotic 
stroke
89 (10.3) 14 (5.3) 75 (12.4)  
Likely athero-
thrombotic stroke
129 (14.9) 38 (14.5) 91 (15.0)  
Cardioembolic 
stroke
109 (12.6) 40 (15.3) 69 (11.4)  
Lacunar stroke 93 (10.7) 16 (6.1) 77 (12.7)  
Rare causes 132 (15.2) 25 (9.5) 107 (17.7)  
Coexisting cause 21 (2.4) 4 (1.5) 17 (2.8)  
Unknown cause 295 (34.0) 125 (47.7) 170 (28.1)  
Median NIHSS at 
admission (IQR)a
3 (1-8) 0 (0-1) 5 (2-10) 12 (3-16)
History of cardio-
vascular risk factors
    
Diabetes 50 (5.2) 8 (3.1) 40 (6.6) 2 (2.2)
Hypertension 262 (27.3) 71 (27.1) 170 (28.1) 21 (23.1)
Atrial fibrillation 15 (1.6) 6 (2.3) 9 (1.5) 0
Smokingb 469 (52.5) 115 (44.7) 329 (57.3) 25 (40.3)
Excess alcohol 
consumptionc
70 (7.3) 17 (6.5) 46 (7.6) 7 (7.7)
No classical vascular 
risk factors
331 (34.5) 102 (38.9) 177 (29.2) 52 (57.1)
Abbreviations: IQR, interquartile range; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of ORG 
10172 in Acute Stroke Treatment.
a Scores range from 0 to 42 with higher scores on the scale indicating worse stroke severity. 0.5% of NIHSS was 
missing, 
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Figure 2A shows the cumulative mortality after a TIA and ischemic stroke, stratified 
by sex. Cumulative mortality was increased in men compared to women in ischemic 
stroke patients (33.7% (95% CI 26.1-41.3) versus 19.8% (95% CI 13.8-25.9); (log-rank 
test, p=0.03)), but not in TIA patients (27.2% (95% CI 13.7-40.8) versus 22.6% (95% 
CI 11.2-34.0); ( log-rank test, p=NS) 
Figure 2B shows the cumulative mortality after a TIA or ischemic stroke, stratified 
by age at onset (18-29, 30-39 and 40-50). For ischemic stroke, cumulative mortality 
differed between groups (10.2% (95% CI 2.4-18.0), 23.9% (95% CI 14.6-33.2) and 
32.9% (95% CI 25.9-39.9) for 18-29, 30-39 and 40-50 years old respectively; (log-
rank test, p=0.002)). No differences were observed for TIA (17.0% (95% CI 0.0-35.8), 
27.0% (95% CI 9.0-44.9) and 25.5% (95% CI 13.9-37.1) for 18-29, 30-39 and 40-50 
respectively; log-rank test, p=NS)). 
Table 2 shows the SMRs for each index event and for ischemic stroke and TIA, 
stratified by sex, age category and TOAST subtype. After ischemic stroke, observed 
Figure 2 Cumulative mortality in 30-day survivors of a TIA or ischemic stroke, 
stratified by sex (A) or age groups (B).
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mortality was increased compared to expected in all subgroups. This was also true 
for all subgroups of TIA, except for atherothrombotic stroke subgroups. The latter 
analyses were not performed for ICH because of too small numbers of the 30-day 
survivors in this group. 
Table 3 shows the association of TOAST subtype with mortality for TIA and ischemic 
stroke, after adjusting for age and sex. In the univariate analysis, age and male sex 
were predictors of mortality in ischemic stroke patients (HR 1.1 (95% CI 1.0-1.1) and 
HR 1.5 (95% CI 1.1-2.2) respectively), but not in TIA patients. Taking ischemic stroke 
due to an unknown cause as reference, mortality in ischemic stroke patients was 
predicted by likely atherothrombotic stroke (HR 2.1 (95% CI 1.1-4.0)), cardioembolic 
stroke (HR 3.9 (95% CI 2.1-7.2)) and coexisting cause of stroke (HR 4.5 (95% CI 1.7-
12.3)), and mortality in TIA was predicted by stroke due to rare and coexisting cause 
of stroke (HR 4.7 (1.6-14.2) and HR 9.3 (1.1-76.7) respectively). After adjusting for 
age and sex, cardioembolic stroke and coexisting cause of stroke were associated 
with mortality in patients with ischemic stroke (HR 4.0 (95% CI 2.2-7.3) and HR 3.4 
(95% CI 1.3-9.4) respectively). In patients with TIA, rare and coexisting cause of 
stroke were associated with mortality after adjusting for age and sex (HR 4.8 (95% 
1.5-14.9) and HR 8.7 (95% CI 1.0-73.9) respectively). 
Cause of death is shown in table 4. The cause of death was of vascular origin for 34% 
and 55% after TIA and ischemic stroke respectively. There were no indications that 
a possible cohort or period effect influenced our results. Cox proportional-hazards 
models of mortality after either a TIA, ischemic stroke or ICH, revealed no significant 
effect for period (1980-1989, 1990-1999 and 2000-2010), adjusted for age of onset 
and sex. Thrombolytic therapy has been introduced in our center in 2004, which 
resulted in 16 (2.7%) ischemic stroke patients that received thrombolytic therapy, 
but that did not affect mortality.
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Discussion
We showed that even 20 years following stroke in adults aged 18-50 years, patients 
remain at a significantly higher risk of death compared to the general population. 
After surviving the first 30 days after young ischemic stroke, the cumulative mortality 
is increased compared to expected based on nationwide population mortality data. 
This mortality remained at this higher level even in the second and third decade 
after young stroke. In patients who survived the first 30 days after an ICH, mortality 
gradually coincides with that of expected. Half of the deaths are due to a vascular 
origin, suggesting that the underlying disease causing the stroke at a young age 
continues to be active throughout life.
Our study has the longest follow-up period reported and one of the largest study 
populations in the field of young stroke. Moreover, collecting data all in one site 
allowed us to collect baseline and follow-up information according to identical 
procedures in all patients thereby reducing the risk of information bias. Among 
studies published to date on mortality after stroke in adults not older than 50 years, 
our study is the first to take the approach of indirect standardization to the general 
population to give estimates of the excess mortality risk due to stroke. 
Table 4 Causes of death among 30-day survivors
 Cause of deatha Total
(n = 145)
TIA
(n =29)
Ischemic 
Stroke
(n = 107)
ICH
(n = 9)
Ischemic Stroke 20 (13.8%) 4 (13.8% 16 (15.0%) 0
Intracerebral hemorrhage 8 (5.5%) 1 (3.4%) 5 (4.7%)  2 (22.2%)
Cardiac cause 38 (26.2%) 4 (13.8%) 31 (29.0%) 3 (33.3%)
Other vascularb 9 (6.2%) 1 (3.4%) 7 (6.5%) 1 (11.1%)
Malignancies 34 (23.4%) 12 (41.4%) 21 (19.6%) 1 (11.1%)
Infections 21 (14.5%) 2 (6.9%) 17 (15.9%)  2 (22.2%)
Miscellaneous 15 (10.3%) 5 (17.2%) 10 (9.3%) 0
a Cause of death was missing for 4 (2.1%) patients
b Other vascular deaths were those that were not clearly non-vascular and did not meet the criteria for fatal 
stroke or cardiac cause
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The ischemic stroke group in our study is slightly younger than in some previous 
studies.15, 18, 19 In line with epidemiologic data on young stroke, the proportion 
of women was significantly higher in our study than in those previous studies, 
indicating that our population reflects a true young stroke population.89 Our results 
of cumulative mortality 5 years after an ischemic stroke are in accordance with 
previous studies from Finland,18 Norway,24 Spain13 and Italy17, despite differences in 
age and gender distributions. However, only a few studies report mortality 10 years 
after an ischemic stroke, and these results show substantial variation (range 12%-
17%), probably due to small numbers. 13, 16, 17, 19
Although many diseases are associated with mortality, it is usually reported as the 
crude, observed mortality which is the sum of the background risk of dying in a 
population (independent from the disease) plus the excess risk of dying due to the 
disease. Crude mortality rates can be helpful in monitoring temporal mortality rates 
within a specific population, but they do not reveal this excess mortality attributable 
to the young stroke. Other studies reported increased (observed) mortality among 
men compared to women13, 17 However, in these studies it is not clear whether this 
difference is due to young stroke related differences between men and women and/
or differences in background mortality. Similarly, higher age of stroke onset was 
associated with an increased observed mortality after an ischemic stroke, which is 
in line with some,13, 17, 18 but not in all studies.19
However, the excess mortality relative to background mortality was highest in 
the youngest age category. We showed that cardio-embolic stroke was (among 
ischemic stroke subtypes) the most important predictor of mortality. Patients with 
cardio-embolic stroke suffer more often from cardiac or other comorbidities that 
themselves are associated with high mortality. A previous study on 5-year mortality 
after ischemic stroke in adults < 50 years showed similar results for TOAST subtypes.18 
Another important finding of our study is that all TOAST subtypes of ischemic 
stroke exhibit an increased risk of death compared to that expected in the general 
population.
Our study has some limitations. First, it may be that not all young stroke cases in our 
catchment area were included in our cohort as our cohort is hospital based, rather 
than  community-based.  Only those patients who suffered a fatal stroke, that were 
not admitted to our hospital, would not have been in our study. If any, this would 
have only affected case-fatality rate, but not mortality during follow-up. Those who 
survive usually visit a university medical center during the course of their disease. 
In addition there are no restrictions to be admitted to our hospital and we included 
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all consecutive cases admitted to our hospital. We therefore presume that our study 
population is a representative sample of Dutch stroke patients, aged 18-50 years, 
although formal data is lacking to prove this generalizability.
Second, our study has a long inclusion period, during which diagnostic equipment, 
acute treatment and secondary prevention have improved. However, this is an 
unavoidable feature of a long-term follow-up study. We found no evidence of such a 
cohort effect after statistical testing.
Third, statistical power was limited for the ICH group because of the small number 
of 30 day survivors, and a relatively small proportion of ICH in the overall study 
population (9.5%). Therefore these results should be viewed with caution. 
Nevertheless, the present study is to our knowledge the largest study ever published 
on long-term prognosis after ICH at young age.
Finally, estimates for some subgroups that contain only few patients might be 
unstable, which is shown by wide confidence intervals, and should therefore be 
interpreted with caution.
Our study showed a clear excess in mortality compared with the general population 
(of which half due to a vascular cause), even decades after stroke. This may suggest 
that the underlying (vascular) disease that caused the stroke at relatively young age 
continues to put these patients at an increased risk for vascular disease throughout 
their lives. Although currently data are lacking, this could have important implications 
for the implementation of secondary prevention (both medical and lifestyle) 
treatment strategies. Future studies should address the role of this stringent 
implementation in these young stroke patients 
To conclude, among adults aged 18-50 years, 20-year mortality following first acute 
stroke was relatively high compared with expected mortality.  
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Sex-specific temporal changes in cause 
of death and years of life lost after TIA 
or ischemic stroke in young adults
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Sex specific temporal changes in cause of death and years of life lost after TIA or 
ischaemic stroke in young adults: the FUTURE study
Abstract
Background and objectives
The aim of this study was to investigate sex-specific temporal changes in cause of 
death and years of life lost after first transient ischemic attack (TIA) or ischemic 
stroke in adults aged 18-50 years.
Methods 
We included all 845 consecutive 30-day survivors, of a first-ever TIA (n=261) or 
ischemic stroke (n=584), aged 18-50 years, admitted to our hospital between 1980 
and 2010. Survival status was assessed at April 1, 2013. Observed cause-specific 
mortality was compared with expected mortality, derived from mortality rates in the 
general population with similar age, sex and calendar-year characteristics. 
Results
During a median follow-up of 9.2 years, 146 patients (17.3%) died, such that 29 
years of life was lost by each individual. For all causes of death, observed mortality 
exceeded expected mortality. The absolute excess risk of death (AER) was for 74% 
attributable to a vascular cause (AER 2.8 per 1000 person-years (95% CI 1.8-4.1) 
for stroke and AER 4.3 per 1000 person-years (95% CI 2.9-5.9) for other vascular 
causes). The AER was highest between 10-15 years after stroke and this peak was 
most pronounced in men and mainly attributable to vascular death.
Conclusions
Long-term excess death after stroke in young adults results in many years of life lost, 
mainly attributable to a vascular cause and most pronounced in men. Because of the 
probably life-long high risk of vascular death, attempts to reduce the risk of vascular 
disease after stroke in young adults should extend beyond the acute phase into the 
long-term.
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Introduction
Stroke in adults aged 18 - 50 years is associated with substantial excess mortality 
compared with the general population, even decades after stroke.81 However, it 
is unclear which cause at which moment after stroke underlies this excess risk of 
death. 
Ideally, the information on both the (excess) risk and the cause of mortality is 
available for the decades after stroke in young adults, as especially the long-term 
prognosis is important in these relatively young patients, given that they have a long 
life expectancy during a demanding period of life in which they start to form families 
and make decisive career moves. Information on the cause of mortality is important 
as it may provide opportunities for treatment strategies to perhaps postpone death 
after stroke. 
Apart from investigating cause of death within a young stroke population, its 
comparison with that from the general population in a time-after-event dependent 
fashion, yields information on what causes underlie excess mortality at which 
specific moment after stroke. This is important as it may be used to optimize the 
right therapeutic window for secondary prevention strategies, but may also identify 
time periods after stroke during which patients are vulnerable to other than vascular 
causes of death, each with their own treatment strategy. So far, there are only few 
reports on cause of death after stroke in young adults and they are limited with 
respect to follow-up duration and number of deaths.13, 16-19 Moreover, those studies 
report cause of death within their young stroke population without comparison to 
the general population, without taking time after event into account.
Apart from the dramatic consequences for the relatives of the patients, stroke at a 
young age may have a substantial impact on society as a whole due to premature 
death, although this has never been quantified, for example in terms of years of life 
lost (YLL). 
The aim of this study was to investigate sex specific temporal changes in cause of 
death and years of life lost after first transient ischemic attack (TIA) or ischemic 
stroke in adults aged 18-50 years. 
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Methods
Patients and study design
This study is a part of the “Follow-Up of Transient ischemic attack and stroke 
patients and Unelucidated Risk factor Evaluation” (FUTURE) study, a prospective 
cohort study designed to investigate the etiologies and consequences of a young 
stroke.75 The medical review ethics committee region Arnhem-Nijmegen provided 
approval for the study and granted a waiver of consent to collect information on 
vital status and cause of death. The report was prepared in accordance with the 
STROBE guidelines.112
In short, the FUTURE study comprised all consecutive patients aged 18 through 
50 years with a TIA or stroke admitted to the Radboud University Medical Centre 
Nijmegen from January 1, 1980 until November 1, 2010. In the present study we 
only included patients with a first-ever TIA or ischemic stroke who survived beyond 
the first 30 days. Patients with cerebral venous sinus thrombosis were excluded. 
To minimize bias resulting from changing diagnostic techniques, the World Health 
Organization definition for TIA and stroke was used.77, 100 The definition of TIA 
included a rapidly evolving focal neurological deficit, without positive phenomena 
such as twitches, jerks or myoclonus, with vascular cause only and persisting for 
a period of less than 24 hours. Stroke was defined as focal neurological deficit 
persisting for more than 24 hours.77, 100 Stroke was divided into ischemic and ICH 
categories on the basis of radiological findings. 
Patients were identified through a prospective registry of all consecutive young 
stroke patients that has been maintained at the Department of Neurology, Radboud 
University Medical Centre, beginning in 197825 with a standardized collection of 
baseline and clinical characteristics (including demographics, stroke subtype and 
vascular risk factors).75 
A history of cardiovascular risk factors was defined as the presence of these risk 
factors, either in the patients’ medical history or when identified during admission. 
Cardiovascular risk factors detected during admission were defined as follows: 
diabetes mellitus as a random blood glucose level greater than 11.1 mmol/L or 
two consecutive fasting venous plasma glucose levels of 7.0 mmol/L or greater13; 
hypertension as systolic blood pressure 135 mm Hg or greater, diastolic blood 
pressure 85 mm Hg or greater, or both, measured after the first week of the index 
event; dyslipidemia as treated with lipid-lowering medication and/or a diagnosis of 
dyslipidemia (total cholesterol level 5.0 mmol/L or greater, low-density lipoprotein 
level 3.0 mmol/L or greater, high-density lipoprotein level lower than 1.0 mmol/L); 
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and atrial fibrillation when identified on either an electrocardiogram or during 
continuous electrocardiographic recording. Atrial fibrillation was diagnosed by 
a cardiologist. Smoking was defined as smoking at least 1 cigarette per day in the 
year prior to the event; 3.4% of the smoking data were missing. Excess alcohol 
consumption was defined as consuming more than 200 grams of pure alcohol per 
week. In the framework of our young stroke protocol, patients underwent imaging 
of intracranial and vertebral arteries, when appropriate, cardiac echography was 
also performed. 
Assessment of both the etiology (modified TOAST classification78) and severity 
(National Institutes of Health Stroke Scale (NIHSS)79) was performed retrospectively 
in all cases using a validated approach as previously described,26, 80 because these 
scales did not exist when a substantial number of our patients experienced their 
index event. In comparison to the original TOAST classification,101 the presently used 
classification has an additional category, “likely large-artery atherosclerosis”.78
Cause-specific mortality
The primary outcome was cause-specific mortality. Information on the vital status was 
retrieved from the Dutch Municipal Personal Records database. Patients underwent 
follow-up until death or April 1, 2013, whichever occurred first. Information on cause 
of death was obtained from the general practitioner or other treating physicians and 
medical records and subsequently classified according to the rules and guidelines 
for mortality coding, described in the International Classification of Diseases, Tenth 
Revision.108 
The causes of death were classified as ischemic stroke, intracerebral hemorrhage, 
other vascular, malignancies and miscellaneous. Other vascular deaths were those 
that were not clearly nonvascular and did not meet the criteria for fatal stroke. 
Cause of death was missing for 7 patients (4.8%).
Statistical analysis
Cause-specific cumulative mortality and 95% CIs were estimated using Gray’s 
method,113 treating other causes of death as competing risks because deaths from 
other causes preclude the occurrence of deaths from a specific cause of interest. 
Person-years at risk were calculated for each patient from date of the index stroke 
until death or date of end of follow-up. Patients who did not reach the endpoint 
were censored.
For 30 (3.6%) patients follow-up was not complete. In our analyses, we took 
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these patients into account until the last known recording of their survival 
status. Theoretically, the follow-up of these 30 patients could have contributed 
to a maximum of 451 person-years. But on their last known survival status they 
contributed 205 person-years. This means that a maximum of 246 person years out 
of in total 10380 person-years of follow up are missing, resulting in a follow up rate 
of 98%. 
An explorative analysis was performed to assess whether type of index event (TIA or 
ischemic stroke) influenced or results. 
Cause-specific mortality of the reference population was obtained from mortality 
data of the whole population of the Netherlands, stratified by 5-year age categories, 
sex and calendar year at risk,36 matched to the study population on these factors.110 
Standardized mortality ratios (SMRs) were calculated to compare risk of cause-
specific death in our population with that in the general population. The standardized 
mortality ratio (SMR) was derived as the ratio of observed to expected deaths over 
the duration of the follow-up, and the exact 95% confidence interval was calculated 
according to the Poisson distribution. 
The absolute excess risk (AER) was calculated as the difference between observed 
and expected deaths, divided by the number of person-years at risk and expressed 
per 1000 person-years. Furthermore we calculated the cause-specific AER as a 
proportion of the total AER (AER%).
To assess the AER over time for vascular and nonvascular death, we plotted these 
numbers for 0-5, 6-10, 11-15, 15-20 and 20-30 years of follow-up.
Cause-specific years of life lost (YLL) were calculated by estimating the difference 
between the actual age at death of a subject who died of young stroke and the 
expected age at death according life tables of the whole population of the 
Netherlands, stratified by 1-year age categories, sex and calendar year.
Two-sided P values of less than 0.05 were considered to indicate statistical 
significance. Statistical analysis were done using IBM SPSS Statistics version 20 and R 
version 2.15 (http://www.R-project.org) software packages.
Results
Between January 1, 1980 and November 1, 2010, 845 30-day survivors of a first-ever 
ischemic stroke or TIA were included. There were 261 patients (30.9%) with a TIA 
and 584 patients (69.1%) with an ischemic stroke. The baseline characteristics of the 
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study population are shown in Table 1. 
Mean follow-up was 12.0 (SD 8.6) years (median 9.2 ( IQR 4.9-18.3)) years. During 
follow-up, 146 30-day survivors (17.3%) had died. Mean age at time of death was 
52.6 (SD 10.3) years.  
Table 1 Baseline characteristics stratified by stroke subtype
 Total Men Women
n (% of total) 845 388 (45.9) 457 (54.1)
Mean age at event, years (SD) 40.3 (7.9) 41.8 (7.2) 39.0 (8.2)
Median follow-up, years (IQR) 9.2 (4.9-18.3) 9.8 (5.1-18.3) 8.9 (4.7-18.1)
>15 years FUP, n (%) 279 (33.0) 131 (33.8) 148 (32.4)
>20 years FUP, n (%) 174 (20.6) 79 (20.4) 95 (20.8)
TOAST    
Atherothrombotic stroke 84 (9.9) 55 (14.9) 29 (6.3)
Likely atherothrombotic stroke 127 (15.0) 59 (15.2) 68 (14.9)
Cardioembolic stroke 105 (12.4) 46 (11.9) 59 (12.9)
Lacunar stroke 92 (10.9) 44 (11.3) 48 (10.5)
Rare causes 129 (15.3) 52 (13.4) 77 (16.8)
Coexisting cause 20 (2.4) 7 (1.8) 13 (2.8)
Unknown cause 288 (34.1) 125 (32.2) 163 (35.7)
Median NIHSS at admission (IQR)a 3 (1-7) 3 (1-7) 2 (0-6)
History of cardiovascular risk factors    
Diabetes 46 (5.4) 25 (6.4) 21 (4.6)
Hypertension 231 (27.3) 106 (27.3) 125 (27.4)
Dyslipidemia 206 (31.5) 100 (32.4) 106 (30.6)
Atrial fibrillation 14 (1.7) 7 (1.8) 7 (1.5)
Smokingb 434 (53.2) 209 (55.9) 225 (50.9)
Excess alcohol consumptionc 62 (7.3) 56 (14.4) 6 (1.3)
Any vascular risk factor 491 (78.4) 245 (83.3) 246 (74.1)
Abbreviations: IQR, interquartile range; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of ORG 
10172 in Acute Stroke Treatment.
a Scores range from 0 to 42 with higher scores on the scale indicating worse stroke severity. 0.5% of NIHSS was 
  missing
b Defined as smoking at least 1 cigarette per day in the year prior to the event; 3.4% of the data were missing.
c Defined as consuming more than 200 g of pure alcohol per week. 
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Cause-specific observed 20-year cumulative mortality was 5.3% (95% CI 3.2%-7.5%) 
for stroke, 9.6% (95% CI 6.8%-12.5%) for other vascular disease, 6.4% (95% CI 4.1%-
8.7%) for malignancies and 4.4% (95% CI 2.5%-6.3%) for miscellaneous causes. 
The SMR was significantly increased for all causes of death (Table 2). A substantial 
excess risk (SMR > 5) was apparent for death due to stroke (SMR 15.8 (95% CI 10.9-
22.3)) and other vascular causes (SMR 6.0 (95% CI 4.5-7.8)). The absolute excess risk 
of dying was highest due to stroke (AER 2.8 per 1000 person-years (95% CI 1.8-4.1)) 
or other vascular diseases (AER 4.2 per 1000 person-years (95% CI 2.9-5.9)). 
 The SMR of death due to vascular causes was 6.2 (4.6-8.2) in men and 12.1 (8.5-
16.7) in women. The SMR of death due to nonvascular causes was 1.6 (1.1-2.2) in 
men and 2.1 (1.4-3.0) in women. The proportion of all excess deaths attributed to a 
vascular cause was 78% in men and 69% in women. 
The absolute excess risk of all cause death was highest at 10-15 years after the 
index event (AER 15.3 (95% CI 9.0-23.5)) Figure 1) and was mainly attributable to a 
vascular cause (84% of total AER at 10-15 years) and most pronounced in men (AER 
18.6 (95% CI 9.8-31.4)).
The mean YLL for each patient that died was 26.1 years (95% CI 24.4-27.8) for men 
and 32.1 years (95% CI 29.6-34.7) for women. Cause-specific mean YLL is shown in 
Figure 2. 
Table 2 Cause-specific mortality after TIA or ischemic stroke in young adults 
compared with mortality in the general population
Observed 
n (%)a
Expected
n
SMR (95% CI) AER (95% CI)b %AER
All cause 139 (100) 42.9 3.2 (2.7-3.8) 9.6 (7.4-12.1) 100%
Vascular 81 (58.3) 10.3 7.9 (6.3-9.7) 7.1 (5.4-9.0) 74%
Stroke 30 (21.6) 1.9 15.8 (10.9-22.3) 2.8 (1.8-4.1) 29%
Other vascular 51 (36.7) 8.5 6.0 (4.5-7.8) 4.3 (2.9-5.9) 45%
Nonvascular 58 (41.7) 32.6 1.8 (1.4-2.3) 2.5 (1.1-4.2) 26%
Malignancies 35 (25.2) 19.7 1.8 (1.3-2.4) 1.5 (0.5-2.9) 16%
Miscellaneous 23 (16.5) 12.9 1.8 (1.2-2.6) 1.0 (0.2-2.2) 10%
Abbreviations: AER, absolute excess risk; %AER, cause-specific AER as proportion of AER of all cause death; 
SMR, standardized mortality ratio
aCause of death was missing in 7 (4.8%) patients
b Per 1000 person-year
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Figure 1 Absolute excess risk attributable to a vascular or 
nonvascular cause stratified by sex
Curves represent absolute excess risk (AER) which was calculated as the difference between 
observed mortality after young stroke and expected deaths, derived from data for the general 
population matched in age, sex, and calendar-year characteristics. The AERs were plotted by 
5-years intervals of follow-up
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Figure 3 shows the contribution to the total YLL by cause of death. Total YLL in men 
was 2038 years and this was for 60% attributable to a vascular cause. In women, 
total YLL was 1960 years of which 53% was attributable to a vascular cause. 
Figure 2 Cause-specific mean number of years of life lost, stratified by sex
Bars represent cause-specific mean number of years of life lost (YLL). YLL were calculated by estimating the 
difference between the actual age at death of a subject who died of young stroke and the expected age at 
death, derived from data for the general population matched in age, sex, and calendar-year characteristics.
Figure 3 Contribution of causes of death to total years of life lost, 
stratified by sex
Proportions represent the contribution of each cause of death to the total number of years of life 
lost in all deaths, stratified by sex.
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There were no indications that type of index event influenced our results. Both the 
AER and the mean YLL of vascular and nonvascular death did not significantly differ 
between TIA and stroke. 
Discussion
During a mean follow-up of 12 years, about 17% of the 30-day survivors of a first-
ever ischemic stroke or TIA had died and the corresponding excess risk of death 
persisted for decades after stroke. The AER was for 74% attributable to vascular 
death and the highest risk was between 10-15 years after the index event, which 
was most pronounced in men. Death occurred prematurely and led to 29 years of 
life lost, with the largest number of YLL in men. 
Strengths of our study include the long follow-up period, one of the largest study 
populations in the field of young stroke with a high follow-up rate of 98% and the 
comparison with nationwide age- and sex-matched cause-specific mortality rates. 
Moreover, collecting data all in one site allowed us to collect baseline and follow-up 
information according to identical procedures in all patients, thereby reducing the 
risk of information bias.
Previous studies provided information on cause of death within their population, but 
did not provide information on the excess risk of death and its underlying causes.13, 
16-19 Moreover, they did not quantify the possible social and economical impact in 
terms of YLL due to early death after stroke. In our population about one third of life 
was lost by each individual that died, which will have a major social impact as these 
young adults are in the age that many of them will have young families. Furthermore 
this population is part of the working population, thus this major number of YLL will 
also result in economic loss.
Both the number of excess deaths and number of YLL due to vascular deaths were 
higher in men than in women. These findings suggest that men are most vulnerable 
to death after young stroke due to a vascular cause. One explanation could be that 
traditional vascular risk factors associated with vascular death are more prevalent 
in young men with stroke than in women.12, 14 Conversely, the lower excess risk in 
women could be explained by the possible protective effect of estrogen exposure, 
as premenopausal women seem to have a much lower risk of vascular disease 
than postmenopausal women or men with similar ages.89 As the median age of 
menopause is about 52 years,114 the majority of the women in our population were 
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still premenopausal women with the attendant low risk of vascular disease. 
Excess risk of all cause death was highest between 10-15 years after the index event 
and this was mainly attributable to vascular death in men during these years. As 
excess risk of vascular death is the difference between “observed” and “expected”, 
an increase of excess risk can either be caused by an increase of “observed” vascular 
death (index population) or by a decrease of this risk in the reference population. This 
latter explanation is unlikely as the risk of vascular death in the reference population 
rises with age, thus the increase in excess risk at 10-15 years after stroke, is fully 
attributable to an increased risk of vascular death in men at 10-15 years after young 
stroke. A possible explanation for this increased risk could be that especially these 
young men are more vulnerable to deleterious effects of vascular risk factors at this 
age that are usually more prevalent and severe than in women and perhaps due 
to lack of estrogen exposure. The subsequent convergence of the risk of (vascular) 
mortality of patients after about 20 years after the event and the general population 
may be due to an increase of vascular disease in the reference population during 
aging.
One quarter of all excess deaths was attributable to a nonvascular cause of which 
malignancies contributed the most. One explanation for this is that malignancies 
in medical history itself were both a cause for the index stroke, but also for in the 
increased risk of death on the long term. This is supported by the fact that the excess 
risk disappeared after exclusion of those who had a history of malignancies. Another 
explanation may be that some malignancies and stroke share risk factors including 
long-term excessive smoking and alcohol intake habits.
A potential limitation of our study includes the lack of detailed data on secondary 
preventive medication during the years after stroke. About 90% of all patients used 
preventive medication at discharge but some patients will have stopped or (re)
started medication during 30 years of follow-up, thus in the present study we cannot 
reliably assess its effect on the risk of vascular death. 
Furthermore it may be that not all cases of young stroke in our catchment area were 
included in our cohort, because our cohort is a single-centre hospital based study, 
rather than community-based. Only those patients who sustained a fatal stroke, 
who were not admitted to our hospital, would not have been included in our study. 
If there were any effect, this would have affected only case-fatality rate, but not 
mortality, during follow-up. Patients who survive usually visit a university medical 
centre during the course of their disease. In addition there are no restrictions to be 
admitted to our hospital and we included all consecutive cases admitted. 
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Moreover, the age- and sex standardized mortality data of our catchment area 
are similar to the age and sex-standardized mortality data of the Netherlands. The 
same is true for the prevalence of stroke; the age- and sex-standardized prevalence 
of stroke in our region equals that of the age and sex-standardized prevalence of 
stroke in the Netherlands.19 We therefore presume that our study population is a 
representative sample of Dutch patients with young stroke.
Another limitation may be that the distribution of TIA and ischemic stroke in our 
population might have influenced our results. Risk of vascular death might have 
been underestimated in our study, since in general prognosis after ischemic stroke 
is worse compared to TIA. However, previously we demonstrated that risk of 
recurrent vascular events was not different between patients with TIA and ischemic 
stroke in our population,102 moreover stratification by index event did not alter our 
conclusions.
Young stroke survivors are at substantial excess risk of death, predominantly 
due to a vascular cause. This was most outspoken in men, especially during the 
first 15 years after stroke, and was accompanied by major loss of YLL. Given this 
vascular predominance as a cause of death one could argue that optimal secondary 
prevention might prevent, at least in part, this excess of vascular death. However, 
this reasoning must be done with care as young (under age of 50 years) patients 
have been excluded from virtual any secondary prevention trial. Hence, our findings 
can be viewed as an encouragement in the development of personalized secondary 
prevention (trials) in young stroke survivors.
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Abstract
Background and objectives
Long-term data on recurrent vascular events after young stroke are limited. Our 
objective was to examine the long-term risk of recurrent vascular events after young 
stroke.
Methods
We prospectively included 724 consecutive patients with a first-ever transient 
ischemic attack (TIA), ischemic stroke, or intracerebral hemorrhage (ICH), aged 18-
50 years admitted to our hospital between January 1, 1980 till November 1, 2010. 
Outcomes were (1) stroke; (2) myocardial infarction or cardiac or peripheral arterial 
revascularization procedures; (3) composite event of these, whichever occurred 
first. 
Results
After a mean follow-up of 9.1 years (SD 8.2; range 0-31.0), 142 patients (19.6%) had 
at least one recurrent vascular event. Cumulative 20-year risk of stroke was 17.3% 
(95% CI 9.5%-25.1%) after TIA, 19.4% (95% CI 14.6%-24.3%) after ischemic stroke 
and 9.8% (95% 1.0%-18.7%) after ICH. Cumulative 20-year risk of any vascular event 
was 27.7% (95% CI 18.5%-37.0%) after TIA and 32.8% (95% CI 26.7%-38.9%) after 
ischemic stroke. Age and male sex were associated with other arterial events, but 
not with stroke. Among TOAST subtypes, adjusted for age, sex and decennium of 
inclusion, atherothrombotic stroke, cardioembolic stroke, and lacunar stroke, were 
associated with recurrent stroke (HR 2.72 (95% CI 1.34-5.52), HR 2.49 (95% CI 1.23-
5.07) and HR 2.92 (95% CI 1.45-5.88) respectively).
Conclusions
Patients with young stroke remain at substantial risk of recurrent vascular events for 
even decades, suggesting that the underlying disease that caused stroke at a young 
age continuous to put these patients at a high risk for vascular disease throughout 
their lives.
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Introduction
The incidence of stroke in younger adults (<55 years of age) is increasing.7 Stroke at 
young age has a large and long-lasting impact on a patient’s quality of life due to the 
long life expectancy and the socio-economical demanding phase of life during which 
a young stroke usually occurs. This impact is not solely determined by the index 
stroke, but also by future (cerebro)vascular events after the initial stroke.
Some previous studies showed that young stroke patients have a substantial risk 
of recurrent vascular events within the first years following their stroke at a young 
age,10, 13, 16, 17, 21, 22, 24 but there are only very limited data on prognosis beyond 5 years 
after the initial stroke in the young. We previously showed that young stroke patients 
have a clear excess in long-term mortality compared with the general population, 
even decades after stroke.81 The majority of deaths in this study were due to a 
vascular cause which suggests that the underlying (vascular) disease that caused 
the stroke at relatively young age continues to put these patients at an increased risk 
for vascular disease throughout their lives. 
Young stroke patients face many uncertainties about their future, in particular with 
respect to long term recurrence risk of (cerebro)vascular events. Especially this long-
term prognosis is important in younger people as they usually have a long life to 
live after their stroke in which they start to form families, have an active social life 
and make decisive career moves. In addition most of those studies only investigated 
patients with an ischemic stroke while stroke is usually considered an umbrella term 
for a transient ischemic attack (TIA), ischemic stroke, or intracerebral hemorrhage 
(ICH). 
The estimation of long-term risk of recurrent vascular events and identifying high-
risk subgroups is a first step in both informing young stroke patients and providing a 
rationale for the never investigated necessity of long-term secondary prevention in 
young stroke survivors.
Therefore, we investigated long-term risk of recurrent stroke and other arterial 
events, in a cohort of consecutive young TIA, ischemic stroke, and ICH patients. 
Methods
Patients and study design
This study is a part of the Follow-Up of Transient ischemic attack and stroke patients 
and Unelucidated Risk factor Evaluation (FUTURE)-study, a prospective cohort study 
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designed to investigate etiologies and consequences of a young stroke. Details of the 
study have been described elsewhere. 75, 81 The Medical Review Ethics Committee 
region Arnhem-Nijmegen provided approval for the study and granted a waiver 
of consent to collect information on those who had died. Participants provided 
written informed consent. The report was prepared in accordance with the STROBE 
guidelines.112
In short, the FUTURE study comprises all patients aged 18-50 years with a TIA, 
ischemic stroke, or ICH, admitted to the Radboud University Medical Centre 
Nijmegen from January 1, 1980 until November 1, 2010. Only patients with first-ever 
TIA or stroke were included consecutively in the present study. Exclusion criteria 
were traumatic hemorrhagic stroke, hemorrhage in known cerebral metastasis or 
primary brain tumor, cerebral venous sinus thrombosis, subarachnoid hemorrhage 
or ICH attributable to known ruptured aneurysm, and retinal infarction. 
To minimize bias resulting from changing diagnostic techniques, the World Health 
Organization definitions for TIA and stroke were used.77, 100 The definition of TIA 
included a rapidly evolving focal neurological deficit, without positive phenomena 
such as twitches, jerks, or myoclonus, with vascular cause only, and persisting for a 
period less than 24 hours. Stroke was defined as focal neurologic deficit persisting 
for more than 24 hours.76, 77 Stroke was subdivided into ICH and ischemic stroke on 
the basis of radiological findings.
Patients were identified through a prospective registry of all consecutive young 
stroke patients that has been maintained at our department beginning in the 1970’s 
with a standardized data collection of baseline and clinical characteristics (including 
demographic data, stroke subtype, and vascular risk factors).81 
A history of cardiovascular risk factors was defined as the presence of these risk 
factors, either in the patients’ medical history or when identified during admission. 
Cardiovascular risk factors detected during admission were defined as follows: 
diabetes mellitus as a random blood glucose level >11.1 mmol/L or two consecutive 
fasting venous plasma glucose levels of ≥7.0 mmol/L13; hypertension as a systolic 
blood pressure ≥135 mm Hg and/or a diastolic blood pressure ≥85 mm Hg measured 
after the first week of the index event; dyslipidemia as treated with lipid-lowering 
medication and/or a diagnosis of dyslipidemia (total cholesterol level ≥5.0 mmol/L, 
low-density lipoprotein level ≥3.0 mmol/L, high-density lipoprotein level <1.0 
mmol/L); and atrial fibrillation when identified on either an electrocardiogram or 
during continuous electrocardiographic recording. Atrial fibrillation was diagnosed 
by a cardiologist. Smoking was defined as smoking at least one cigarette per day in the 
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year prior to the event; 8.0% of the data were missing. Excess alcohol consumption 
was defined as consuming more than 200 grams of pure alcohol per week. 
In the framework of our young stroke protocol, patients underwent imaging of 
intracranial and vertebral arteries, when appropriate, cardiac echography was 
also performed. Assessment of both the etiology (modified TOAST classification78) 
and severity (National Institutes of Health Stroke Scale (NIHSS)79) was performed 
retrospectively in all cases on the basis of medical records, because these scales did 
not exist when a substantial number of our patients experienced their index event. 
The NIHSS was scored using a validated approach as previously described.26, 80 In 
comparison to the original TOAST classification,101 the presently used classification 
has an additional category, “likely large-artery atherosclerosis”.78 Atherothrombotic 
stroke is defined as patients with (1) an ipsilateral internal carotid stenosis >50% (in 
NASCET criteria), or (2) an ipsilateral stenosis >50% of another intra/extracranial 
artery, or (3) mobile thrombus in the aortic arch. Likely atherothrombotic stroke 
is defined as patients with no evidence of atherothrombotic stroke with (1) an 
ipsilateral internal carotid stenosis <50%, or (2) an ipsilateral stenosis <50% of 
another intra/extracranial artery, or (3) aortic arch plaques >4 mm in thickness 
without a mobile component, or (4) a history of myocardial infarction or coronary 
revascularization, (5) a history of documented peripheral arterial disease, or (6) at 
least two risk factors for atherosclerotic disease: arterial hypertension (treated or 
known blood pressure before stroke >135/85 mm Hg or hypertensive retinopathy), 
diabetes mellitus (treated or known blood fasting glucose >7 mmol/dl), current 
smoking (or smoking stopped within the last 6 months), high cholesterol (treated or 
known low-density lipoprotein before the stroke >160 mg/dl)
Follow-up
Information on vital status was retrieved from the Dutch Municipal Personal Records 
database. The Dutch Municipal Personal Records database contains the personal 
details (i.e. names, date of birth, address, vital status) of everyone who lives in the 
Netherlands. Completeness of this database is estimated to be about 97%. 
Patients alive were invited for a follow-up assessment between November 1, 2009 
and January 1, 2012. Patients underwent follow-up until death or until their follow-
up assessment, whichever occurred first. 
Patients were evaluated for recurrent vascular events using a two staged approach. 
First, all patients alive were asked during a structured interview whether they had 
visited a because of a recurrent TIA or stroke, or because of any of the following 
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(but not exclusively) symptoms that might raise the suspicion of the occurrence of 
a stroke: one-sided weakness in face, arm or leg, sensory loss, aphasia, diplopia, 
transient monocular blindness, hemianopsia, neglect, ataxia, dysarthria, dizziness, 
acute apraxia (trouble with dressing, brushing teeth, geographical disorientation etc). 
Furthermore patients were asked whether they ever had visited a physician because 
of a myocardial infarction, or whether they ever underwent coronary artery bypass 
grafting, percutaneous transluminal coronary angioplasty or any other peripheral 
arterial revascularization procedures. In case a patient had died, this information 
was retrieved from the general practitioner by the same structured questionnaires. 
Secondly, when patients (or their general practitioner) confirmed that they had 
a TIA or stroke after their index event, medical records were retrieved from their 
treating physicians and subsequently verified and adjudicated by physicians from 
the appropriate specialty (FEdL, EvD, MvdV). If information concerning a recurrent 
vascular event was not sufficient, it was considered as a possible event and not used 
in the analyses.
Recurrent stroke was defined similar as the index event and myocardial infarction 
was defined by ischemic symptoms with electrocardiographic, cardiac biomarker, or 
pathologic evidence of infarction according to the universal definition of myocardial 
infarction.115
Vascular events
The occurrence of any vascular event was the primary outcome measure, being the 
composite event of fatal or non-fatal stroke (ischemic or hemorrhagic), fatal or non-
fatal myocardial infarction, or cardiovascular procedures (coronary artery bypass 
grafting, percutaneous transluminal coronary angioplasty, carotid endarterectomy, 
or other peripheral arterial revascularization procedures), whichever occurred first.
Separate analyses were done for fatal or non-fatal stroke (ischemic or hemorrhagic) 
and other arterial events (composite event of fatal or non-fatal myocardial infarction 
and cardiovascular procedures). 
Statistical analysis
Cumulative risk of vascular events was estimated by index event separately ,using 
Gray’s method, with death as a competing risk.113 Person-years at risk were calculated 
for each patient from date of the index stroke until recurrent event, death or date of 
end of follow-up. Patients who did not reach any of the endpoints (recurrent vascular 
event or death) were censored. To ensure that the provided plots were reliable for 
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all subgroups, survival plots were curtailed at 20 years;109 all events were retained in 
subsequent analysis. Actual annual risks were calculated from the survival estimates 
obtained by Gray’s method and the mean annual risk was subsequently calculated 
for the periods 2-5 years, 6-10 years, 11-15 years and 16-20 years after stroke.
Age was divided into 3 groups: 18-29 years, 30-39 years, and 40-50 years. To 
determine whether the risk of recurrent stroke or another arterial event after a TIA 
or ischemic stroke was different between the age categories and men vs women, 
cumulative risk of recurrent stroke or another arterial event was estimated with 
Gray’s method for these subgroups. Subsequently, cumulative incidence curves of 
recurrent stroke and other arterial were compared between the age categories and 
by sex using Gray’s test.
By means of the Fine and Gray’s proportional hazard model,116 we calculated hazard 
ratios of baseline variables with 95% CIs for the risk of any vascular event, stroke, or 
other arterial event, with death as a competing risk, after adjusting for age, sex and 
the decennium in which the index event occurred. Two-sided P-values of less than 
0.05 were considered to indicate statistical significance. Statistical analysis were 
done using IBM SPSS Statistics version 20 and R version 2.15 (http://www.R-project.
org) software packages.
Results
Study population
724 patients with first-ever TIA, ischemic stroke, or ICH were included in the 
present analysis (Fig1). Of them, 172 patients (23.8%) had died by the follow-up. 
Baseline characteristics of the study population are shown in Table 1. There were no 
differences in baseline characteristics between participants and those patients who 
refused or were lost to follow-up. Etiologies of intracerebral hemorrhage are shown 
in Table 2. 
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Figure 1 Study population
* Vital status was known at follow-up
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Table 1 Baseline characteristics stratified by stroke subtype
 Total TIA Ischemic 
stroke
ICH
n (% of total) 724 (100) 209 (28.9) 447 (61.7) 68 (9.4)
Mean age at event, years (SD) 40.5 (7.8) 40.6 (8.0) 40.8 (7.6) 38.0 (8.6)
Male 344 (47.5) 94 (45.0) 215 (48.1) 35 (51.5)
Mean follow-up, years (SD) 9.1 (8.2) 8.5 (7.9) 9.8 (8.2) 6.6 (8.1)
>15 years FUP 185 (25.6) 47 (22.5) 125 (28.0) 13 (19.1)
>20 years FUP 104 (14.4) 31 (14.8) 66 (14.8) 7 (10.3)
TOAST     
Atherothrombotic stroke 64 (9.8) 12 (5.7) 52 (11.6)  
Likely atherothrombotic stroke 102 (15.5) 35 (16.7) 67 (15.0)  
Cardioembolic stroke 86 (13.1) 27 (12.9) 59 (13.2)  
Lacunar stroke 65 (9.9) 11 (5.3) 54 (12.1)  
Rare causes 96 (14.6) 23 (11.0) 73 (16.3)  
Multiple causes 17 (2.6) 2 (1.0) 15 (3.4)  
Unknown cause 226 (34.5) 99 (47.4) 127 (28.4)  
Median NIHSS at admission (IQR)a 3 (1-9) 0 (0-1) 5 (2-10) 14 (5-18)
mRS at discharge >2 186 (25.7) 5 (2.4) 135 (30.2) 46 (68.7)b
History of cardiovascular risk 
factorsc
    
Diabetes 43 (5.9) 8 (3.8) 33 (7.4) 2 (2.9)
Hypertension 205 (28.3) 61 (29.2) 131 (29.3) 13 (19.1)
Dyslipidemia 194 (26.8) 73 (34.9) 117 (26.2) 4 (5.9)
Atrial fibrillation 12 (1.7) 3 (1.4) 9 (2.0) 0
Smokingd 338 (50.8) 82 (40.2) 238 (56.5) 18 (43.9)
Excess drinking (> 20 gl)e 53 (7.3) 15 (7.2) 33 (7.4) 5 (7.4)
Abbreviations: IQR, interquartile range; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of ORG 
10172 in Acute Stroke Treatment; mRS, modified Rankin Scale.
Numbers represent n (%) or otherwise stated
a Scores range from 0 to 42 with higher scores on the scale indicating worse stroke severity. 0.6% of NIHSS was 
missing
b mRS at discharge was missing in 1 patient
c At discharge, 97% of all patients with hypertension were treated with medication, including beta blockers, 
angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium blockers, and diuretics; 95% 
of all patients with diabetes were treated with medication, including insulin or oral blood-glucose lowering 
agents; all patients with atrial fibrillation were treated with medication including beta-blockers, digoxin, and oral 
anticoagulants; 98% of all patients with dyslipidemia were treated with medication including statins
d Smoking was defined as smoking at least 1 cigarette a day in the year prior to the event. For the data on 
smoking habits, 8.0% of the data were missing
e Excess alcohol consumption was defined as consuming more than 200 grams of pure alcohol per week
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Recurrent vascular events
During a mean follow-up of 9.1 years (SD 8.2), amounting to 6569 patient-years of 
observation, 142 patients (19.6%) had at least one vascular event. In 42 patients 
(5.8%) more than one vascular event occurred. After a TIA, 35 patients (16.7%) 
suffered from any vascular event and 14 patients (6.7%) had more than one vascular 
event; 22 (10.5%) of previous TIA patients had at least one stroke and 19 (9.1%) of 
them had at least one other arterial event. After an ischemic stroke, 101 patients 
(22.6%) suffered from any vascular event and 28 patients had (6.3%) more than 
one vascular event; 64 (14.3%) of previous ischemic stroke patients had at least one 
recurrent stroke and 47 (10.5%) of them had at least one other arterial event. After 
ICH, 6 patients (8.8%) suffered from any vascular event and one patient (1.5%) had 
more than one event; 5 (7.4%) of previous ICH patients had one recurrent stroke and 
1 (1.5%) of them had three other arterial events.
Recurrent stroke was the most frequent event in the years following TIA or ischemic 
stroke (Figure 2) In patients with initial ICH there was only one patient with ischemic 
stroke and one patient with another arterial event, but four patients with recurrent 
ICH, resulting in a 20-year cumulative risk of any vascular event of 11.6% (95% CI 
2.3%-20.9%) and an incidence rate of 14.6 per 1000 person-years.
Table 2 Etiology of intracerebral hemorrhage (n=68)
n (%)
Hypertension 16 (23.5)
AVM 14 (20.6)
Cavernous angioma 3 (4.4)
Coagulopathy
Medication use 4 (5.9)
Bleeding disorder 4 (5.9)
Substance abuse 1 (1.5)
Septic embolism 1 (1.5)
Unknown
Cryptogenica 10 (14.7)
Multiple causes 3 (4.4)
Incomplete evaluationb 12 (17.6)
a Etiology was cryptogenic after complete evaluation
b Evaluation could not be completed in 10 out 12 (83.3%) patients because 
they died within seven days. Complete evaluation was not performed in the 
remaining two patients because of their very poor clinical condition in the first 
days after the event. These two patients died within nine days after the event.
111
III
Long-term risk of recurrent vascular events
In patients with a TIA, the 20-year cumulative risk of any vascular event, stroke, and 
other arterial event was 27.7% (95% CI 18.5%-37.0%), 17.3% (95% CI 9.5%-25.1%) 
and 17.2% (8.8%-25.7%) respectively; the corresponding incidence rates per 1000 
person years were 22.7, 13.4 and 11.5 respectively.
In patients with initial ischemic stroke, 20-year cumulative risk of any vascular event, 
stroke, and other arterial event was 32.8% (95% CI 26.7%-38.9%), 19.4% (95% CI 
14.6%-24.3%), and 16.4% (11.5%-21.3%) respectively; the corresponding incidence 
rates per 1000 person years were 27.6, 16.1 and 11.7 respectively.
In both patients with initial TIA and ischemic stroke, the annual risk of any vascular 
event was highest during the first year after the index event (7.0% (95% CI 6.9%*7.1%) 
and 6.6% (95% CI 6.6%-6.7%)respectively), and gradually decreased to a constant 
level about 2% after five years following both TIA or ischemic stroke (Figure 2B).
Figure 2 Cumulative risk (A) and annual risk (B) of recurrent events by stroke 
subtype. 
In B, data points represent the annual risks for the first year and the mean annual risk for the periods 2 to 5 
years, 6 to 10 years, 11 to 15 years, and 16 to 20 years after stroke. TIA 5 transient ischemic attack.
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Risk of another arterial event differed between men and women (22.3% (95% CI 
15.9%-28.8%) for men and 10.7% (95% CI 5.5%-16.0%) for women; p =0.004 by 
Gray’s test), whereas there were no differences in risk of a recurrent stroke (19.4% 
(95% CI 13.6%-25.2%) for men and 18.2% (95% CI 12.3%-24.1%) for women; p=0.94 
by Gray’s test) (Figure 3). Risk of another arterial event differed between age groups 
(2.5% (95% CI 0%-7.4%) for 18-29 years, 12.3% (95%CI 5.6%-19.1%) for 30-39 years 
and 21.7% (95% CI 15.5%-27.9%) for 40-50 years; p=0.006 by Gray’s test). There was 
no difference between age groups with respect to risk of a recurrent stroke ((18.6% 
(95% CI 7.6%-29.6%) for 18-29 years, 14.8% (95%CI 7.7%-21.9%) for 30-39 years and 
20.8% (95% CI 15.2%-26.3%) for 40-50 years; p=0.44 by Gray’s test).
Figure 3 Cumulative risk of recurrent stroke or other arterial event in TIA or 
ischemic stroke, stratified by sex (A) or age group (B). 
P-values were obtained by the Gray’s test, which was used to compare the curves of the subgroups
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Baseline risk factors and risk of recurrent vascular events 
After adjusting for age, sex and decennium of inclusion, the composite event was 
associated atherothrombotic stroke, likely atherothrombotic stroke, cardioembolic 
stroke, lacunar stroke, stroke due to multiple causes, stroke severity, diabetes, 
dyslipidemia and smoking (Table 3). Stroke separately was associated with 
atherothrombotic stroke, cardioembolic stroke, lacunar stroke and stroke severity. 
Other arterial events were associated with male sex, atherothrombotic stroke, likely 
atherothrombotic stroke, stroke due to multiple causes, stroke severity, diabetes, 
dyslipidemia and smoking.
Discussion
We showed that after a mean follow-up of more than nine years after a young TIA, 
ischemic stroke, or ICH, about 20% of all patients had experienced at least one incident 
vascular event. 20 Years after young stroke, the cumulative risk of any vascular event 
was 12% after ICH, 28% after TIA and 33% after ischemic stroke. Most ischemic events 
occurred after ischemic stroke, whereas patients with ICH hardly experienced any 
ischemic events. Although a hemorrhagic event was rare during follow-up, it was the 
most frequent type of recurrent vascular events after ICH. Independent of age, sex 
and decennium of inclusion, patients with atherothrombotic, cardioembolic stroke 
or lacunar stroke had the highest risk of recurrent stroke among TOAST subtypes. Risk 
of other arterial events was highest among patients with atherothrombotic stroke, 
likely atherothrombotic stroke and stroke due to multiple causes. Furthermore, a 
medical history of diabetes, dyslipidemia or smoking was associated with other 
arterial events but not with recurrent stroke.
To our knowledge, our study has the longest follow-up period reported and one 
of the largest study populations in the field of investigation of young stroke. 
Moreover, collecting data all in one site allowed us to collect baseline and follow-up 
information according to identical procedures in all patients thereby reducing the 
risk of information bias. 
The ischemic stroke group in our study is slightly younger than in some previous 
studies.15, 18, 19 In line with epidemiologic data on young stroke, the proportion of 
women was significantly higher in our study than in those previous studies, indicating 
that our population reflects a population with true young stroke.89 
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Table 3 Cumulative 20-year risk of any recurrent event in TIA or ischemic 
stroke (n=656), with respect to selected baseline characteristics and 
corresponding age, sex and decennium adjusted hazard ratio’s 
Person-
years
Nr 
events
20-year 
cumulative 
risk
HR (95% CI)a
Age
18-29 683 11 21.0% 0.62 (0.33-1.16)
30-39 1624 32 24.5% 0.69 (0.46-1.05)
40-50 2901 93 36.9% 1 [reference]
Sex
Men 2492 76 36.2% 1.25 (0.89-1.77)
Women 2716 60 26.2% 1 [reference]
Index event
TIA 1545 35 27.7% 1 [reference]
Ischemic stroke 3663 101 32.8% 1.15 (0.78-1.70)
TOAST
Atherothrombotic stroke 610 29 52.8% 3.26 (1.89-5.64)
Likely atherothrombotic stroke 931 25 36.3% 1.70 (1.01-2.87)
Cardioembolic stroke 450 21 40.8% 2.17 (1.24-3.79)
Lacunar stroke 462 15 32.6% 2.02 (1.09-3.75)
Rare causes 656 10 15.0% 0.90 (0.43-1.88)
Multiple causes 80 6 43.1%b 3.16 (1.25-8.02)
Unknown cause 2019 30 21.3% 1 [reference]
NIHSS (median)  0.94 (0.91-0.97)
History of cardiovascular risk factors
diabetes 247 15 45.1% 1.89 (1.12-3.19)
Hypertension 1355 49 35.6% 1.34 (0.94-1.90)
Dyslipidemia 596 34 56.2% 1.68 (1.06-2.68)
Smoking 2924 87 36.8% 1.62 (1.11-2.36)
Excess drinking (> 20 gl) 485 10 30.4% 0.65 (0.35-1.22)
Data were analyzed by means of the Fine and Gray’s proportional hazard model. Stroke = ischemic or 
hemorrhagic stroke. Other arterial event = myocardial infarction or cardiovascular procedures. Composite 
event = stroke or other arterial event. Abbreviations: NIHSS, National Institute of Health Stroke Scale; TOAST, 
Trial of ORG 10172 in Acute Stroke Treatment; HR, hazard ratio. 
a Hazard Ratio’s are adjusted for age of the index event, sex, decennium of the index event 
b 10-year cumulative risk 
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Table 4 Cumulative 20-year risk of recurrent stroke in TIA or ischemic stroke 
(n=656), with respect to selected baseline characteristics and corresponding 
age, sex and decennium adjusted hazard ratio’s 
Person-
years
Nr 
events
20-year 
cumulative 
risk
HR (95% CI)a
Age
18-29 686 10 18.6% 0.96 (0.49-1.88)
30-39 1700 20 14.8% 0.72 (0.43-1.22)
40-50 3223 56 20.8% 1 [reference]
Sex
Men 2743 43 19.4% 1.03 (0.67-1.58)
Women 2866 43 18.2% 1 [reference]
Index event
TIA 1639 22 17.3% 1 [reference]
Ischemic stroke 3970 64 19.4% 1.22 (0.74-2.00)
TOAST
Atherothrombotic stroke 745 15 24.8% 2.68 (1.30-5.49)
Likely atherothrombotic stroke 1018 14 21.2% 1.54 (0.78-3.03)
Cardioembolic stroke 490 13 24.2% 2.03 (1.01-4.09)
Lacunar stroke 470 14 30.3% 3.12 (1.58-6.16)
Rare causes 666 8 10.6% 1.13 (0.49-2.64)
Multiple causes 114 3 25.1%b 2.08 (0.61-7.04)
Unknown cause 2106 19 12.1% 1 [reference]
NIHSS (median) 0.94 (0.91-0.97)
History of cardiovascular risk factors
diabetes 307 8 20.8% 1.44 (0.71-2.90)
Hypertension 1528 29 21.8% 1.18 (0.76-1.83)
Dyslipidemia 675 21 33.3% 1.25 (0.72-2.19)
Smoking 3250 52 21.1% 1.39 (0.88-2.21)
Excess drinking (> 20 gl) 517 7 20.3% 0.93 (0.43-2.00)
Data were analyzed by means of the Fine and Gray’s proportional hazard model. Stroke = ischemic or 
hemorrhagic stroke. Other arterial event = myocardial infarction or cardiovascular procedures. Composite 
event = stroke or other arterial event. Abbreviations: NIHSS, National Institute of Health Stroke Scale; TOAST, 
Trial of ORG 10172 in Acute Stroke Treatment; HR, hazard ratio. 
a Hazard Ratio’s are adjusted for age of the index event, sex, decennium of the index event 
b 10-year cumulative risk 
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Table 5 Cumulative 20-year risk of other arterial events in TIA or ischemic 
stroke (n=656), with respect to selected baseline characteristics and 
corresponding age, sex and decennium adjusted hazard ratio’s 
Person-
years
Nr 
events
20-year 
cumulative 
risk
HR (95% CI)a
Age
18-29 763 1 24.9% 0.11 (0.02-0.84)
30-39 1750 16 12.3% 0.68 (0.38-1.22)
40-50 3148 49 21.7% 1 [reference]
Sex
Men 2693 44 22.3% 1.77 (1.04-3.02)
Women 2968 22 10.7% 1 [reference]
Index event
TIA 1653 19 17.2% 1 [reference]
Ischemic stroke 4008 47 16.4% 0.91 (0.54-1.53)
TOAST
Atherothrombotic stroke 672 20 36.1% 3.86 (1.84-8.09)
Likely atherothrombotic stroke 1020 16 22.8% 2.19 (1.04-4.63)
Cardioembolic stroke 542 10 20.0% 2.21 (0.97-5.04)
Lacunar stroke 527 1 2.4% 0.26 (0.03-1.98)
Rare causes 692 2 4.5% 0.46 (0.10-2.07)
Multiple causes 81 4 30.2%b 4.60 (1.35-15.69)
Unknown cause 2127 13 10.8% 1 [reference]
NIHSS (median) 0.93 (0.88-0.98)
History of cardiovascular risk factors
diabetes 259 11 32.4% 2.91 (1.53-5.57)
Hypertension 1472 26 19.0% 1.45 (0.87-2.42)
Dyslipidemia 640 18 46.3% 3.01 (1.52-5.95)
Smoking 3221 46 20.4% 1.99 (1.08-3.65)
Excess drinking (> 20 gl) 488 8 20.2% 0.97 (0.47-2.01)
Data were analyzed by means of the Fine and Gray’s proportional hazard model. Stroke = ischemic or 
hemorrhagic stroke. Other arterial event = myocardial infarction or cardiovascular procedures. Composite 
event = stroke or other arterial event. Abbreviations: NIHSS, National Institute of Health Stroke Scale; TOAST, 
Trial of ORG 10172 in Acute Stroke Treatment; HR, hazard ratio. 
a Hazard Ratio’s are adjusted for age of the index event, sex, decennium of the index event 
b 10-year cumulative risk 
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Long-term risk of recurrent vascular events
Risk of stroke after TIA or ischemic stroke was comparable between patients aged 
18-29, 30-39, and 40-50, whereas the risk of another arterial event was significantly 
lower in younger patients compared with the oldest patients. Although these findings 
have to be interpreted with caution as there were only few cases with a recurrent 
stroke in each age stratum, it is remarkable that the young patients have the same 
risk of stroke recurrence as the oldest patients. This may be explained by the fact that 
the age category from 18-30 years included 10 patients who experienced a recurrent 
stroke; of whom eight patients suffered from either cardiac valve abnormalities or 
prothrombotic disease (with only few traditional cardiovascular risk factors). This 
might have caused (cardiac) emboli that are more likely to result in ischemic stroke, 
rather than in myocardial infarction.
The five-year risk of recurrent stroke after ischemic stroke in our study was similar 
to a Finnish study.21 However, our study demonstrated a persistent increase in 
cumulative risk of recurrent stroke, also after the initial five years, towards almost 
20% in the subsequent 15 years, thereby illustrating the importance of a long-term 
follow-up; especially among young stroke survivors as they have this long life to live 
after stroke. 
The 5-year cumulative risk of recurrent stroke after ischemic stroke in young adults 
in the present study is lower (10%) than that reported after pediatric ischemic stroke 
(19%)117 and the older stroke population (26%).118 Arteriopathy (included in TOAST 
subtype “rare causes”) is a well known risk factor for recurrent stroke in children,119 
but this specific TOAST subtype was not related to an increased risk of recurrent 
stroke in our study. In our study atherothrombotic, cardioembolic and lacunar stroke 
subtypes were associated with recurrent stroke, which are stroke subtypes, in which 
the traditional vascular risk factors associated with stroke in older patients, are 
commonly reported.
This, suggests that stroke in young adults in general has more in common with 
stroke among the elderly and perhaps even indicates a certain vulnerability of these 
patients at already relatively young age for cardiovascular risk factors.
In the present study, in some TOAST subtypes the risk of recurrent stroke, other 
arterial events or the composite event, was two to four times as high as risk in 
patients with a TIA or ischemic stroke of unknown cause. This identification of a high 
risk young stroke subpopulation may offer opportunities for individualized long-
term secondary prevention strategy. Although our study can identify these high risk 
subgroups, it cannot investigate the effect of (prolonged) secondary prevention in 
these subgroups.
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To our knowledge, only one previous study investigated factors that are associated 
with recurrent vascular events after stroke in young adults using time dependent 
analysis of outcome and taking in account covariates, but limited to ischemic stroke 
and a follow-up of 5 years.21 In that study, independent predictors of recurrent vascular 
events were age, heart failure, previous TIA, diabetes, and atherothrombotic stroke. 
Other studies in young adults after stroke that investigated risk factors of recurrent 
stroke or other vascular events used univariate analysis without adjustment for 
possible confounders or used statistical approaches that did not take the number of 
follow-up years into account.10, 13, 16, 19, 20, 22, 24
Our study has some limitations. First, it may be that not all cases of young stroke 
in our catchment area were included in our cohort, because our cohort is hospital-
based, rather than community-based. Only those patients who sustained a fatal 
stroke, who were not admitted to our hospital, would not have been included in 
our study. If there were any effect, this would have affected only case-fatality rate. 
Patients who survive usually visit a university medical center during the course of 
their disease. In addition there are no restrictions to be admitted to our hospital and 
we included all consecutive cases that were eligible for participation. We therefore 
presume that our study population is a representative sample of Dutch patients with 
young stroke, although formal data are lacking to prove this generalizability.
Second, our study has a long inclusion period, during which diagnostic equipment, 
acute treatment and secondary prevention have improved. However, this is an 
unavoidable feature of a long-term follow-up study. To minimalize its possible effects, 
we adjusted our hazard ratios for recurrent vascular events in TOAST subtypes, by 
decade of inclusion. 
Third, recurrent stroke was detected via self report, in case of a possible event 
additional information was retrieved from their treating physicians. Subsequently 
the event was adjudicated by the specialist of the appropriate field. Still, this might 
have resulted into under detection of stroke as an outcome since some patients may 
not have known they had signs or symptoms of a stroke and therefore did not visit 
their doctor. However, the structured interview did not only contain questions on 
the occurrence of TIA or stroke after the index event, but also included questions on 
signs and symptoms indicative of a TIA or stroke. Therefore, if any, under detection 
of stroke, would most likely be limited.
Fourth, secondary prevention might have influenced our results. In our study about 
89% of TIA or ischemic stroke and 31% of ICH were using secondary preventive 
medication at discharge. Consequently the shown high risk of recurrent vascular 
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events might even be an underestimation attributable to the use of this medication, 
although during 30 years of follow-up some patients will have stopped or (re)started 
secondary preventive medication. 
Fourth, statistical power was limited for the ICH group because of the small 
number of 30 day survivors, and a relatively small proportion of ICH in the overall 
study population (9.4%). Therefore, these results should be viewed with caution. 
Nevertheless, the present study is to our knowledge the largest study ever published 
on long-term risk of recurrent vascular events after ICH at young age. 
Similarly, as is reflected by the wide CIs, estimates for some subgroups that contain 
only few patients might be unstable and should therefore be interpreted with 
caution. 
In conclusion, we showed that patients, who have a stroke at a young age, remain 
at a high risk of recurrent vascular events for many years. This may suggest that 
the underlying (vascular) disease that caused the stroke at relatively young age 
continues to put these patients at a high risk for vascular disease throughout their 
lives. These quantified risks can be used to inform and motivate young patients in 
order to achieve compliant secondary prevention. Moreover, these data may be 
a starting point for trials that are necessary to answer the question whether (all 
of) these young patients should be on secondary prevention for life, since existing 
data provide no evidence, as these young patients have always been excluded from 
secondary prevention trials. 
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Abstract
Background and objectives
To identify clinical determinants of short and long-term prognosis after spontaneous 
intracerebral hemorrhage (ICH) in young adults aged 18-50.
Methods
We investigated 98 consecutive patients with an ICH, aged 18-50 years, admitted 
to our hospital between 1980 and 2010. Collected ICH characteristics included 
presenting symptoms, etiology, location, severity (National Institutes of Health 
Stroke Scale (NIHSS) and Glasgow Coma Scale (GCS)). Outcomes were case-fatality 
(death within 30 days), poor functional outcome (modified Rankin Scale >2), long-
term mortality and recurrent ICH. We assessed discriminatory power of factors 
associated with case-fatality (area under receiver operating curve (AUC)).
Results
Case-fatality was 20.4% (n=20) and well predicted by the GCS (AUC 0.83). Among 
30-day survivors, a poor functional outcome at discharge was present in 51.3%. 
After a mean follow-up of 11.3 years (SD 8.3), another 10 patients (12.8%) had died 
(overall 20-year cumulative mortality 31.4% (95% CI 21.3%-41.5%)). Compared with 
nationwide population data, long-term mortality was only increased in patients 
aged 40-50 years (standardized mortality ratio 4.8 (95% CI 2.3-8.6)). Recurrent ICH 
occurred in 6 patients (10-year cumulative incidence 12.2% (95% CI 1.5%-22.9%)), 
all with the index ICH attributable to structural vascular malformations.
Conclusions
Prognosis after ICH in young adults is poor, mainly due to high case-fatality, that is 
well predicted by the GCS.  An exception are 30-day survivors  < 40 years, who have 
a similar risk of dying as the general population. Recurrence risk is especially present 
in patients with structural vascular malformations, whereas risk seems to be very 
low in other patients.
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Introduction
Spontaneous intracerebral hemorrhage (ICH) accounts for up to 20% of all strokes. ICH 
has a worse prognosis than ischemic stroke with high case-fatality of approximately 
40% and is often disabling.120 ICH in elderly patients is a well-studied topic, but only 
limited data exist on the clinical characteristics and long-term outcome after ICH in 
young adults <50 years.121-123 
We earlier showed that case-fatality among young adults with ICH is much higher than 
in young adults with transient ischemic attack (TIA) or ischemic stroke, conversely 
the risk of mortality after surviving the first 30-days is lower.81 Immediately after 
ICH clinicians often face uncertainties with respect to long-term, during which they 
have to consider different treatment options. To support clinicians in making these 
decisions, it is important to provide them with reliable prognostic information in 
the acute phase. In older ICH patients, case-fatality is predicted by factors including 
male sex, age, ICH location and volume and initial level of consciousness,124 but 
whether these factors are also associated with case-fatality in younger ICH patients 
is unknown. 
After having survived  their initial ICH these young patients subsequently face 
many uncertainties about their future, in particular with respect to the risk of long-
term recurrence of ICH, other cerebrovascular disease and mortality, but also on 
functional outcome This long-term prognosis is particularly important in young 
people as they usually have a long life to live after their ICH in which they start to 
form families, have an active social and professional life. 
Therefore our aim was to identify the clinical determinants of the short and long-
term prognosis after ICH in young adults aged 18-50 years.
Methods 
Patients and study design
This study is a part of the “Follow-Up of Transient ischemic attack and stroke patients 
and Unelucidated Risk factor Evaluation” (FUTURE) study, a prospective cohort study 
on etiologies and consequences of a young stroke. Details of the study have been 
described elsewhere. 75, 81 The medical review ethics committee region Arnhem-
Nijmegen approved the study and granted a waiver of consent to collect information 
on vital status and cause of death. Participants provided written informed consent. 
In short, the FUTURE study comprised all consecutive patients aged 18 through 
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50 years with a TIA or stroke admitted to the Radboud University Medical Centre 
Nijmegen from January 1, 1980 until November 1, 2010.75  Only patients with ICH 
were included in the present study. Exclusion criteria were traumatic hemorrhagic 
stroke, hemorrhage in known cerebral metastasis or primary brain tumor, 
subarachnoid hemorrhage or ICH attributable to ruptured aneurysm. To minimize 
bias resulting from changing diagnostic techniques, the World Health Organization 
definition for stroke was used.77, 100 Stroke was defined as focal neurological deficit 
persisting for more than 24 hours.77, 100 Stroke was subdivided into ischemic and 
hemorrhagic on the basis of radiological findings. Within the framework of our 
young stroke protocol, patients underwent imaging of intracranial arteries.
ICH was classified on the basis of location and presumed etiology.125 Etiology of ICH 
in locations characteristic of hypertensive cause, such as basal ganglia, thalamus, 
cerebellum or brainstem,126 in patients without a known history of hypertension, was 
considered hypertensive when there was no evidence of a vascular malformation or 
other etiology.
Glasgow Coma Scale (GCS) was retrieved from medical records.127 A history of 
cardiovascular risk factors was defined as the presence of these risk factors, either 
in the patients’ medical history or when identified during admission.81 Functional 
outcome at discharge was measured by the modified Rankin Score (mRS).107  A poor 
functional outcome was defined as mRS >2. 
Follow-up assessment
Patients were invited for a follow-up assessment between November 1, 2009 and 
January 1, 2012.102 All data were collected on systematic, structured way. Patients 
underwent follow-up until death or until their follow-up assessment, whichever 
occurred first. 
Patients were evaluated for recurrent ICH using a two staged approach. First, all 
patients alive were asked whether they had visited a physician because of a recurrent 
stroke. In case a patient had died, this information was retrieved from the general 
practitioner by the same structured questionnaires. Secondly, when patients (or 
their general practitioner) confirmed that they had stroke after their index event, 
medical records were retrieved from their treating physicians and subsequently 
verified and adjudicated by experienced neurologists (FEdL, EvD). 
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Cause-specific mortality
Information on the vital status was retrieved from the Dutch Municipal Personal 
Records database. Patients underwent follow-up until death or April 1, 2013, 
whichever occurred first. Information on cause of death was obtained from the 
general practitioner or other treating physicians and medical records and classified 
according to the rules and guidelines for mortality coding, described in the 
International Classification of Diseases, Tenth Revision.108 
Statistical analysis
Clinical characteristics were compared between groups using Student’s t test, Mann-
Whitney U test or chi-square-test whenever appropriate. 
Case-fatality was defined as death within 30 days after the index stroke. Receiver 
operating characteristic curves were generated for clinical characteristics that were 
associated with case-fatality and subsequently the area under the curve (AUC) and 
95% confidence interval (CI) was calculated. 
Cumulative mortality and 95% CI was estimated with Kaplan-Meier analysis. Person-
years at risk were calculated for each patient from date of the index stroke until 
death or follow-up date. Patients who died or did not reach the endpoint were 
censored. For 5 patients (5.1%) follow-up for vital status was not complete. In our 
analyses, we took these patients into account until the last known recording of their 
survival status. 
Expected mortality was obtained from mortality data of the whole population of the 
Netherlands, stratified by age, sex and calendar year at risk,39 matched to the study 
population on these factors.110 Standardized mortality ratios (SMRs) were calculated 
to compare risk of death in our population with that in the general population for 
patients aged <40 years and patients 40-50 years. The standardized mortality ratio 
(SMR) was derived as the ratio of observed to expected deaths over the duration 
of the follow-up, and the exact 95% CI was calculated according to the Poisson 
distribution. 
5- And 10-year cumulative risk of recurrent ICH with 95% CI was estimated, using 
Gray’s method, with death as a competing risk.113 Two-sided P values of less than 
0.05 were considered to indicate statistical significance. Statistical analysis were 
done using IBM SPSS Statistics version 20 and R version 2.15 (http://www.R-project.
org) software packages. 
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Table 1 Baseline characteristics
All patients < 40 years 40-50 years pa
No. (% of total) 98 (100) 52 (53.1) 46 (46.9)
Men, n (%) 49 (50.0) 29 (55.8) 20 (43.5) 0.23
Follow-up, mean (SD), years 9.0 (8.7) 9.8 (8.7) 8.1 (8.7) 0.36
NIHSS score at admission, 
median (IQR)
12 (4-16) 12 (4-17) 11 (4-16) 0.69
GCS at admission, median (IQR) 13 (6-15) 13 (5-15) 13 (6-15) 0.59
History of cardiovascular risk 
factors, n (%)
Hypertension 23 (23.5) 6 (11.5) 17 (37.0) 0.003
Diabetes 2 (2.0) 0 2 (4.3) 0.13
Smokingb 28 (34.6) 16 (34.8) 12 (34.3) 0.96
Excess drinking 7 (7.1) 2 (3.8) 5 (10.9) 0.18
History of TIA 7 (7.1) 4 (7.7) 3 (6.5) 0.82
History of ICH 0 0 0
Location,  n (%)c
Supratentorial 78 (80.4) 43 (84.3) 35 (76.1) 0.31
Hemisphere 0.27
Left 34 (43.6) 16 (37.2) 18 (51.4)
Right 39 (50.0) 25 (58.1) 14 (40.0)
Bilateral 5 (6.4) 2 (4.7) 3 (8.6)
Deep 27 (34.6) 15 (34.9) 12 (34.3) 0.69
Lobar 46 (59.0) 26 (60.5) 20 (57.1) 0.77
Ventricular 5 (6.4) 2 (4.7) 3 (8.6) 0.48
Intraventricular extension 29 (37.2) 16 (37.2) 13 (37.1) 0.99
Infratentorial 19 (19.6) 8 (15.7) 11 (23.9) 0.31
Cerebellum 6 (31.6) 3 (37.5) 3 (27.3)
Brainstem 13 (68.4) 5 (62.5) 8 (72.7)
Abbreviations: NIHSS, National Institute of Health Stroke Scale; IQR, interquartile range; GCS, Glasgow Coma 
Scale.
a p values refer to a comparison between patients aged <40 years and patients aged 40-50
b Smoking status was missing in 17 patients (17.3%)
c Hemorrhage location was missing in 1 patient
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Results
Baseline characteristics
During the 30 year period, 98 young adults with ICH (49 women) were admitted 
to our centre (Figure 1). Mean age was 37.9 years (SD 8.8) for men and 38.0 years 
(SD 8.9) for women.  89 patients (90.8%) were from European descent. Baseline 
characteristics stratified by age group (<40 years versus 40-50 years) are presented 
in Table 1. A history of hypertension was the only baseline characteristic that differed 
between age categories. 
Clinical presentation
Presenting symptoms included severe headache (n=70 (71.4%)), nausea (n=32 
(32.7%)), impaired consciousness (n=64 (65.3%)), seizures (n=13 (13.3%)) and focal 
neurological deficits (n=76 (78.4%)). Presenting symptoms did not differ between 
patients aged <40 years and patients aged 40-50 years. 
Figure 1 Flow-chart of study population
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Etiology of ICH
Arteriovenous malformation (AVM) was the most reported etiology in patients aged 
<40 years, whereas hypertension was the most reported etiology in patients aged 
40-50 years (Table 2). The distribution of etiologies did not differ between men and 
women. Evaluation was incomplete in 14 patients (14.4%), mainly due to the fact 
that 12 patients (out of 14)  died before further evaluation could be performed.
Short-term mortality
20 Patients (20.4%) died within 30 days after their ICH (9 men and 11 women). 
Compared with 30-day survivors, they had a higher initial median NIHSS score (17 
versus 10, p = 0.01) and a lower GCS (median 3 versus 14, p = 0.004), whereas there 
were no differences in age, sex, history of cardiovascular risk factors,  location of the 
hemorrhage and presenting symptoms (other than impaired consciousness). The 
ability to discriminate already at admission between those patients that died within 
30 days and those that survived, was fair for the NIHSS (AUC 0.76 (95% CI 0.64-0.88) 
and good for the GCS (AUC 0.83 (95% CI 0.70-0.96). The optimal cut-off to with the 
best discriminative power was >13 for the NIHSS and <10 for the GCS.  
Table 2 Etiology of ICH
 All patients < 40 yearsa 40-50 years
Hypertension, n (%) 26 (26.8) 10 (19.6) 16 (34.8)
AVM, n (%) 21 (21.6) 17 (33.3) 4 (8.7)
Cavernous angioma, n (%) 5 (5.2) 3 (5.9) 2 (4.3)
Coagulopathy, n (%) 
Medication use 5 (5.2) 3 (5.9) 2 (4.3)
Bleeding disorder 3 (3.1) 2 (3.9) 1 (2.2)
Substance abuse, n (%) 2 (2.1) 1 (2.0) 1 (2.2)
Septic embolism, n (%) 1 (1.0) 0 1 (2.2)
Unknown, n (%) 
Cryptogenic 17 (17.5) 9 (17.6) 8 (17.4)
Multiple causes 3 (3.1) 1 (2.0) 2 (4.3)
Incomplete evaluation 14 (14.4) 5 (9.8) 9 (19.6)
Abbreviations: AVM, arteriovenous malformation
a Etiology was missing in 1 patient
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Chance of survival up to 90 days after stroke differed significantly between patients 
with GCS3, GCS4-9 and GCS10-15 (p<0.001) and most deaths occurred within 10 
days after stroke (Figure 2)
In patients that died within 30 days after the event, etiology was hypertension (n=2), 
AVM (n=2), coagulopathy (due medication use (n=1) or hematological disorder 
(n=2)) or substance abuse (n=1). In the other 12 patients that died within 30 days, 
etiological evaluation could not be completed due to early death. 
Functional outcome at discharge
Among the 78 patients that survived the first 30 days, 40 patients (51.3%) had a 
poor functional outcome (mRS >2) at discharge. Compared to patients with a good 
functional outcome at discharge, patients with a poor functional outcome had a 
higher NIHSS at admission (median 15 versus 3, p <0.001) and more often had an ICH 
due to hypertension (42.5% versus 18.9%, p=0.03),  but there were no differences in 
age, sex, GCS and other presenting symptoms than focal neurological deficits.
Figure 2 Survival up to 90 days after ICH, stratified by GCS
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Death within 30-days or a poor functional outcome at discharge was present in 
all patients with GCS3 at admission, in 88% of patients with GCS4-9 and in 44% of 
patients with GCS10-15 (Figure 3). 
Long-term mortality
Among the 78 patients that survived the first 30-days,  10 patients (12.8%) died 
during a mean follow-up of 11.3 years (SD 8.3); 1 patient aged <40 years and 9 
patients aged 40-50 years; 5 men and 5 women. Among those who died on the 
long-term, 7 had a poor functional outcome at discharge and 3 patients had a good 
functional outcome at discharge. 
The all-cause 20-year cumulative mortality in all ICH patients was 31.4% (95% CI 
21.3%-41.5%)(Figure 4). Cause of death in 30-day survivors was ICH in 4 patients (in 
2 patients due to the initial stroke, but death after 30 days and in 2 patients due to 
recurrent ICH), cardiac or aortic disease in 3 patients, malignancy in 2 patients and 
gastrointestinal disease in 1 patient. Long-term risk of death in 30-day survivors was 
increased compared to the age and sex matched reference population in patients 
Figure 3 30-day mortality and functional outcome at discharge, dependent on 
GCS at admission*
*Functional outcome at discharge was considered in those that survived beyond 30 days and was defined as 
poor for mRS >2 and good for mRS 0-2
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aged 40-50 years (SMR 4.8 (95% CI 2.3-8.6)), but not in patients aged <40 years (SMR 
1.3 (95% CI 0.1-6.4)). The mean years of life lost attributable to early death after ICH 
was 36.5 years (SD 9.9), 46.4 years (SD 6.2) in patients aged <40 years and 31.5 years 
(SD 7.4) in patients aged 40-50 years.
Recurrent ICH
During the follow-up 6 patients suffered a recurrent ICH, of which 2 fatal. The resulting 
5-year cumulative incidence of recurrent ICH was 8.4% (95% CI 0.3%-16.5%) and the 
10-year cumulative incidence was 12.2% (95% CI 1.5%-22.9%). Times from the index 
event to the recurrent event were 2 months, 2.0 years, 2.1 years, 4.3 years, 7.2 years 
and 20.2 years. In all patients with a recurrent ICH, the etiology of the index ICH was 
a vascular malformation (AVM in 5 patients and cavernous angioma in 1 patient). 
The recurrent ICH was a rebleed of the vascular malformation that caused the index 
event in all patients. There was no recurrent ICH in patients in whom hypertension 
was the presumed cause.
Figure 4 Cumulative mortality in all young adults admitted with ICH
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Discussion
We provided the clinical characteristics of ICH in 98 young adults aged 18-50 years, 
its short and long-term outcomes and the predictors of a poor outcome. Case-
fatality was as high as 20% and mortality 20-years after presentation was more 
than 30%. The only characteristics at presentation related to case-fatality were the 
GCS and the severity of neurological deficit (NIHSS) at admission. Case-fatality was 
not different between patients aged <40 years and 40-50 years, but after surviving 
the first 30 days, only patients aged 40-50 years had significantly increased long-
term mortality compared with expected, based on nationwide population mortality 
data.  Recurrent ICH was exclusively reported in patients with structural vascular 
malformations as etiology of the index event.
To our knowledge, our study has the longest follow-up period reported and one 
of the largest study populations in the field of investigation of ICH in young adults. 
Moreover, collecting data all in one site allowed us to collect baseline and follow-up 
information according to identical procedures in all patients thereby reducing the 
risk of information bias. Previous studies that provide a detailed clinical description 
of young patients presenting with ICH are scarce, mostly with only a small number of 
patients, limited follow-up and varying age ranges and ethnicities. 121-123 
In the present study we showed that the etiology differs between those patients 
aged <40 years and 40-50 years; the most reported etiology was AVM in the youngest 
group and hypertension in the oldest group, which is in line with a previous study.123 
Also in children, AVM is the most commonly reported etiology of ICH in children 
with proportions ranging from 31%-55%.128, 129 In contrast, hypertension and amyloid 
angiopathy are the most common reported etiology in older ICH patients with a 
mean age about 70 years .130  Thus although the etiological spectrum of ICH in our 
population seems to be in between that of ICH in children and an older population, 
the shift in etiology by age is nicely illustrated in our population.
Case-fatality in our population was in the middle of the wide range of 8%-39% 
reported in previous studies in young adults.17, 121-123 but higher than that reported 
in children128, 129 and lower than the median case-fatality reported in a recent large 
meta-analysis of mainly older ICH patients (20% versus 40%).120 On top of the high 
case-fatality, functional outcome was poor at discharge in more than half of the 
patients that survived until discharge. As a result, only one in every third patient 
admitted, was discharged with a good functional outcome.
The only measures that were associated with case-fatality in our study were a lower 
GCS and a higher NIHSS. Several grading scores have been developed to predict 
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case-fatality in (elderly) ICH patients and these scores include GCS, age, ICH volume 
and ICH location. 131, 132 We did not assess the ICH volume, but among the other 
components of the scores, only GCS score was strongly associated with case-fatality 
in our study. A recent study that tested the accuracy and clinical usefulness of these 
grading scores in 1175 ICH patients with a median age of 73 years, concluded that, 
although the grading scales were highly predictive of 30-day mortality, GCS alone 
was as predictive and its accuracy was similar as in our study.133 Therefore the GCS 
may be a simple and useful tool to provide families and doctors with an estimation 
of the risk of dying after ICH at either young or older age. 
Patients aged 40-50 years that survived the first 30-days had a four times increased 
risk of death during the decades following stroke compared to the age- and sex-
matched general population, whereas patients aged < 40 years did not have such an 
increased risk. The difference between age categories might be explained by the fact 
that older patients more often presented with hypertension as cause of ICH, which 
is also related to many other diseases. 
The 5 and 10-year cumulative incidence of recurrent ICH was lower than that observed 
in an ICH population with a mean age over 65 years,134, 135 but also lower than the 
5-year cumulative incidence previously reported in children. 129 Recurrent ICH in our 
study was exclusively present in patients with structural vascular malformations and 
this etiology is even more common in children, which may explain the higher risk 
of recurrent ICH in children. On the other hand, the higher risk of recurrent ICH in 
the older population may be explained by the fact that the incidence of ICH in the 
general population increases with age, which has been attributed to high prevalence 
of hypertension, amyloid angiopathy and the use of antithrombotic drugs in older 
patients. 120 
Our study has some limitations. First, it may be that not all cases of young stroke 
in our catchment area were included in our cohort, because our cohort is hospital-
based, rather than community-based. Only those patients who experienced a fatal 
stroke, who were not admitted to our hospital, would not have been included in 
our study. If there were any effect, this would have affected only case-fatality rate. 
Patients who survive usually visit a university medical center during the course of 
their disease. We therefore presume that our study population is a representative 
sample of Dutch patients with young ICH although formal data are lacking to prove 
this generalizability. Second, our study has a long inclusion period, during which 
diagnostic equipment, acute treatment and secondary prevention have improved. 
However, this is an unavoidable feature of a long-term follow-up study. Third, 
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although the present study is to our knowledge the largest study ever published 
on long-term prognosis after ICH at young age, statistical power was limited for 
estimating risk of recurrent ICH and long-term mortality because of the small 
number of 30 day survivors. Therefore, these results should be interpreted with 
caution. Fourth, etiological evaluation was incomplete in 12 of the fatal cases, but 
this is an unavoidable feature of studying ICH patients, as some patients die before 
evaluation can be completed. However, when prognosis of ICH is studied, also these 
fatal cases with unknown etiology, should be taken in to account to avoid selection 
bias. 
In conclusion, we showed that ICH in young adults has an etiological distribution 
between that of ICH in children and older adults, but has in general a poor prognosis, 
which is mainly due to the high case-fatality that is well predicted by the GCS.  An 
exception on this are 30-day survivors < 40 years, who have a similar risk of dying 
compared with the general population.  Recurrence risk is especially present in 
patients with structural vascular malformations, whereas the risk seems to be very 
low in other patients. 
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Abstract
Contrary to trends in most other diseases, average age on which ischemic stroke 
occurs decreases, which is attributable to the absolute increase of “young” stroke 
patients (<50 years).
This review provides a critical overview on the risk factors and etiology of young 
ischemic stroke and addresses its long-term prognosis, including cardiovascular risk, 
functional outcome and psychosocial consequences.
Whereas the role of ‘rare’ risk factors in the pathophysiology of young stroke seems 
overestimated, the role of ‘traditional’ vascular risk factors in the pathophysiology of 
young stroke and its rising incidence may have been underestimated.
Long-term prognosis is of particular interest to young patients, because of their 
usual long life-expectancy and their major role in a demanding phase of life. 
Prognosis is not as favorable as previously thought, neither with respect to mortality 
or cardiovascular disease nor with respect to psychosocial consequences. Therefore, 
secondary prevention after young stroke is probably a life-long endeavor in the 
majority of young stroke survivors. However, due to underrepresentation of young 
patients in the past trials, randomized trials focusing on this age group are needed 
to confirm the benefits of long-term secondary preventive medication. The high 
prevalence of poor functional outcome and psychosocial problems warrants future 
studies, to optimize treatment and rehabilitation for these young patients. 
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Introduction
Stroke is a devastating disease that yearly affects 15 million patients worldwide, 
resulting in death in about a third of all patients and severe disability in two thirds 
of the survivors.136, 137 Approximately 80% of all strokes are ischemic strokes, of 
which roughly 10% occur in individuals <50 years, so called ‘young stroke’.10 In this 
review, literature on these young ischemic stroke patients will be discussed. Age 
limits defining a young stroke differ across studies.6, 10, 16, 75 We chose to define young 
stroke as an ischemic stroke in adults aged 18 through 49 years, as these were most 
used in previous large studies.6, 138, 139 However, to be inclusive, we will also report 
on results from some studies using upper age limits of 45, 50 or 55.14, 75 Risk factors 
and stroke management after a young stroke differ across the world, depending 
amongst others on genetic differences, environmental factors, and the development 
and accessibility of health services. In this review, we will focus on the situation in 
western societies, unless otherwise specified.
There is a remarkable, unprecedented decrease in the average age of onset of 
ischemic stroke in the overall population, that is mainly caused by an increased 
incidence of stroke in young adults.7, 140 Ischemic stroke in young adults is often 
thought to be related to ‘rare’ risk factors and etiology, that are very different from 
the ‘traditional’ vascular risk factors and etiology seen in older stroke patients. 
However, the increase of stroke incidence in young adults has been found to be 
associated with an increased prevalence of some important ‘traditional’ vascular risk 
factors in these young patients,141 including hypertension, hypercholesterolemia, 
diabetes mellitus and obesity.7 The role of these risk factors will be discussed from 
the perspective of the increased incidence of young stroke. 
Not only the identification of risk factors and etiology for the stroke, but also long-
term prognosis after stroke is of particular interest from the perspective of these 
young patients, as they usually have a life expectancy of decades ahead. Suddenly, 
they are confronted with uncertainties about their future in a period of life during 
which they prepare for decisive career moves or planning a family. Therefore, 
information on long-term prognosis should not only include the risk of (vascular) 
disease but also of expected psychosocial consequences related to life after stroke; 
a topic reported by patients among their top ten research priorities.142
Therefore, the aim of this review is to provide a critical overview of the existing 
literature on risk factors and etiology of young ischemic stroke. This section will 
include a methodological discussion on rare risk factors and etiology that have 
traditionally been regarded as specific for a young stroke, followed by a discussion of 
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the growing prevalence of traditional vascular risk factors. Secondly, we will review 
the lifelong consequences, not only in terms of cardiovascular disease recurrence, 
but emphatically also with respect to less often studied, hence less visible, but just 
as relevant consequences, including cognitive and societal performance, mood 
disorders and fatigue. 
Risk factors and etiology  
The view that ischemic stroke in young adults is different from ‘old stroke’ with 
respect to risk factors and etiology has been predominantly based on the many 
publications that report on the high prevalence of unusual, rare conditions and risk 
factors among young stroke patients, albeit that these reports were mainly based on 
case series from tertiary hospitals.8  
The aim of this review is not to summarize this extensive list of rare risk factors 
and etiology, as this can be found in several previous reviews and textbooks,8, 143 
but rather to discuss the available evidence on these risk factors and etiologies 
in strokes in young adults. The term ‘risk factor’ is used to indicate that a certain 
factor was found to be associated with stroke in young adults. However, the mere 
identification of a risk factor does not imply that the etiology is known in all detail. 
Sometimes the risk factor is somewhere in the ‘causal pathway’ of the disease, and 
may give rise to a certain etiology that on its turn is associated with the disease; 
for example, hypertension is a risk factor, atherosclerosis may be the underlying 
causal etiology of the stroke. In this review, we will classify etiology according to 
the TOAST classification, with ‘large artery atherosclerosis’, ‘small vessel disease’, 
‘cardio-embolic ‘, and ‘other determined’ as important etiologic subgroups.144
In table 1, we summarized the prevalence and level of evidence for associations 
between stroke in young adults and five rare risk factors and five etiologies. The 
choice was based on their relatively high prevalence in large western young 
stroke cohorts, compared with even rarer risk factors and etiologies.6, 139 In other 
populations, the distribution of conditions categorized under TOAST category ‘other 
determined etiologies’ differs. For example, in Japan, MoyaMoya disease will be 
diagnosed more frequently in young stroke patients, because the incidence and 
prevalence of this disease is much higher there than it is in other parts of the world, 
such as Europe.145
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Etiologic subgroups, as described in table 1, part B, vary across sex and age 
categories. Extracranial arterial dissections are the most common ‘rare’ etiologic 
subgroup. Although dissections are found throughout all age categories and account 
for only 2% of all ischemic strokes, they account for approximately 20% of strokes in 
patients under 45 years of age. The highest incidence lies in the fifth decade. Men 
and women are about equally affected, although women are on average five years 
younger.146, 147 
Inflammatory arteriopathies, e.g. vasculitis, are a heterogeneous group, including 
mostly multisystemic inflammatory disorders affecting arteries of all sizes, depending 
on the disease.148 Some of the conditions virtually never occur in young adults, as for 
example in giant cell arteriitis one of the criteria is being >50 years of age. However, 
other conditions, such as Takayasu’s disease predominate in young females.148 Of 
note, infectious diseases underlie a considerable proportion of secondary vasculitis. 
In the developed world, hepatitis B and C remain the most common underlying 
infections, whereas HIV is a large problem in the developing world.149 
Within the subgroup of cardio-embolic stroke, cardiomyopathy is one of the most 
prevalent conditions, found in young ischemic stroke patients.6, 139 One would expect 
that cardiomyopathy is associated with strokes earlier in life, because this is often a 
condition with an early age of onset. However, one study that stratified young stroke 
patients by age category found no significant difference in prevalence between 
patients <42 years versus those ≥42 years. In this study, cardiomyopathy was more 
than twice as prevalent in men than in women (15.5% versus 6.1%).139
Antiphospholipid syndrome is an important example of a prothrombotic state, 
related to stroke in young adults. This condition has been predominantly studied in 
women. An increased risk for ischemic stroke was found in women under 50 years 
of age (OR 43.1(95%-CI 12.2-152.0)).150 Although some studies showed a clearer 
relationship in younger women than in older populations, another study showed no 
age differences in a young stroke population.151
Of note, some of the mentioned risk factors in table 1 are seen as being rather 
specific for a young adult, for example illicit drug abuse or the presence of a 
persistent foramen ovale (PFO), while they can actually occur throughout human 
life span. However, in older adults the relative presence of these risk factors is much 
lower than in young adults, since the absolute number of patients with traditional 
cardiovascular risk factors and a proven etiology, such as large artery atherosclerosis, 
small vessel disease or cardioembolic stroke is much higher.
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Table 1 Top 10 most prevalent risk factors (A) and etiologies (B) for a young 
stroke in western populations
TOAST-
classificationa
Prevalence in 
young stroke 
patientsb
Strength of the 
association
Highest level 
of evidencec 
A: Risk factors
Migrained
214-218 
Unknown cause 20-24% ~2.0219 A1; association 
for migraine with 
aura only
Illicit drug use
220-224
Other (Rare) 
causes
9-20% 2.0 for cocaine220
2.3 for cannabise,223
No association for 
amphetamins220
A2: cocaine, 
B: amphetamine, 
cannabis, heroin
Persistent 
foramen ovale
225-228
Possible cardiac 
embolism; low 
risk source
24%, up to 
50% in stroke, 
classified as 
cryptogenic
~1.5 (non-
significant)226
A2, contrasting 
with evidence 
from B-level 
studies
Oral 
contraceptives 
217, 229-234
Other (rare) 
cause/Unknown
10-40% 2.1230 B
Pregnancy/
puerperium
235-239
Other (rare) 
cause/Unknown
7.5% in women 8.7 during 
puerperium, 
not during 
pregnancy237
A2; 
conflicting 
results
B: Etiology
Non-
inflammatory  
arteriopathies
Arterial dissection 
(cervical or 
intracranial)146, 147, 
240-242
Other (Rare) 
causes
10-25% Not found in 
literature
A2
Reversible 
cerebral 
vasoconstriction 
syndrome139, 155, 
243, 244
Other (Rare) 
causes
1-5% Not found in 
literature
B
Inflammatory  
arteriopathies
Inflammatory 
arteriitisf, 148
Other (Rare) 
causes
3-5 % (all 
auto-immune 
vasculitides 
combined)
Not found in 
literature
B or C; 
depending on 
the underlying 
auto-immune 
disorder
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Table 1 Top 10 most prevalent risk factors (A) and etiologies (B) for a young 
stroke in western populations (continued)
TOAST-
classificationa
Prevalence in 
young stroke 
patientsb
Strength 
of the 
association
Highest level of 
evidencec 
B: Etiology
Cardio-embolic
Cardiomyopathy
6, 139, 245
Cardio-
embolism, high 
risk source
2-3% Not found in 
literature
A2
Prothrombotic 
state
Coagulation 
factors
246-252
Other (rare) 
cause/
Unknown
antiphospholipids 
(aPL): 10%g 
2.2253 A2 for 
aPL;Conflicting 
results
B for other 
factors;
Conflicting results
Factor V Leiden: 
3-7.5%
1.0246
Antithrombine III 
deficiency: 5-8%
Protein C 
deficiency: 4-11%
Protein S 
deficiency:6%, 
up to 23% in 
occasional studies
Prothrombin 
mutation: 2-6%
 TOAST-classification, according to Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ, An 
evidence-based causative classification system for acute ischemic stroke, 2005 Nov; 58(5):688-697
b Sum of all prevalences > 100%, because data were extracted from different study populations. In addition, 
conditions are not mutually exclusive in an individual patient.
c Level of evidence, categorized as follows:
A1: systematic review, based on at least two independent A2 level studies
A2: Prospective cohort study of sufficient sample size and duration of follow-up,
adequately adjusted for confounding and selective follow-up sufficiently excluded
B: Prospective cohort study, not meeting the criteria of A2, or retrospective cohort
 study, or case control study.
C: Non-comparative study
D: Expert opinion
d It should be noted that a migrainous stroke is very rare.159 However, reports on the role of migraine as a risk 
factor for stroke are abundant.
e Not significant after correction for tobacco use
f including primary vasculitis and vasculitis secondary to collagen vascular diseases, and other systemic 
conditions (excluding those secondary to infections)148
g up to 46% found in selected populations.
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For most of the risk factors in table 1, only weak associations with respect to young 
stroke have been reported. Moreover, depending on the quality of the study, a risk 
factor may be more or less causal in the origin of a disease. In order to increase the 
likelihood of causality, studies would have to show that the effects of risk factors are, 
amongst other criteria, dose- and time-dependent.152 Double blind randomized trials 
or large prospective cohort studies would be needed to meet these requirements. 
However, associations for most of the reported risk factors are derived from case-
control studies or case series that are prone to different forms of bias, because they 
are hospital-based and often limited with respect to sample size. 
First, information bias needs to be considered, in particular recall bias. Remarkable 
events in the recent past may more often be remembered as a potential trigger 
factor by a patient than by a person who has not suffered from a stroke, such as 
infections. For example respiratory tract infections have been shown to act as trigger 
factors, as were chronic infections, such as chronic bronchitis. Their role as trigger 
factor was supported by the fact that their association with stroke was time- and 
dose dependent. However, the evidence mostly comes from case-control studies 
with methodological limitations.153
Secondly, referral bias may be an issue. Young stroke cases described in the literature 
are often selected from a population that was referred for a second opinion to a 
tertiary academic center. These usually represent a selection of patients in whom 
no etiology could be established upon first investigations. Subsequent additional 
investigations during these second opinions may have revealed incidental or 
presumed abnormal findings (for example a patent foramen ovale), that are not 
necessarily a causal factor. 
Third, confounding can play a role. For example, this may be the case when traditional 
risk factors were not appropriately adjusted for in analysis, which is true for many 
small studies.
Whereas the role of rare risk factors in the pathophysiology of young stroke seems 
overestimated, the role of traditional vascular risk factors in the pathophysiology 
of young stroke may have been underestimated.6, 7, 9-14, 102, 154 For example, the rising 
incidence of stroke in young adults coincides with an increasing prevalence of 
traditional vascular risk factors in these young patients,6, 12, 14, 155 which at least is 
supportive of a relation between the two, although causality needs to be proven. 
Hypertension is reported in 19%-39% of all patients, dyslipidemia in 17%-60%, 
diabetes in 2%-10%, smoking in 42%-57%, and obesity in 10%-20%.6, 10-14, 102 
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Figure 1 illustrates the increase of prevalence of the traditional vascular risk factors 
with age, with a rather sudden rise in prevalence of hypertension and to a lesser 
extent for hypercholesterolemia in patients over 35 years, compared with patients 
under 35 years. Moreover, figure 2 shows that the number of traditional vascular 
risk factors per patient rises with age. Especially in patients over 35 years of age , 
there is only a small fraction of patients without any vascular risk factor. 
Figure 1 Age- and sex-specific prevalence of traditional vascular risk factors in 
young stroke patients
Figure shows the prevalence of different traditional vascular risk factors by age category, for men (part A) and 
women (part B) separately. Data are pooled from 15-Cities study,27 FUTURE study,28 and SIFAP1 study.9
Figure 2 Age-specific proportions of patients according to number of 
traditional vascular risk factors, stratified by sex
Figure shows the prevalence of no, one, or two or more traditional vascular risk factors in different age 
categories, for men (part A) and women (part B) separately. Considered traditional vascular risk factors are 
diabetes, hypertension, smoking and hypercholesterolemia. Data are extracted from SIFAP1 study.9
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Although traditional vascular risk factors are prevalent in young adults, a large 
proportion of these young adults remain without proven causal etiology, such 
as large artery atherosclerosis.155 However, it could very well be that especially 
among those patients with vascular risk factors, the likelihood of diagnosing a 
causal etiology will increase due to detection of earlier stages of atherosclerosis by 
improved diagnostics, including high-resolution plaque and vessel wall imaging.156 
Given the abundant presence of traditional vascular risk factors, further diagnostic 
work-up in these patients may be limited in the presence of proven large artery 
atherosclerosis, although the safety of this strategy needs confirmation in diagnostic 
studies. In patients without any proven etiology, ancillary investigations are indicated 
to further unravel potentially treatable rare risk factors and etiologies.
Cardiovascular prognosis
Mortality
Prognosis in terms of mortality was usually considered to be favorable in young 
stroke patients, given the lower short-term mortality rates, compared with older 
stroke patients.157 However, long-term follow-up studies found a 5-year cumulative 
mortality ranging from 9%-11%, while the 10-year cumulative risk ranged from 12%-
17%.13, 16-19, 81 In 30-day survivors of a young ischemic stroke, 20-year cumulative 
mortality has been reported to be 27%, which was four times higher than that of the 
general population with similar age and sex.81 Figure 3 shows that excess mortality 
is present in all young stroke patients, but especially in those over 35 years of age, in 
whom vascular risk factor were also highly prevalent.
Vascular disease was the main cause of death after five and ten years of follow-up in 
that study, of which more than half was attributable to a vascular cause other than 
stroke.18, 81 This suggests that the underlying (vascular) disease that caused stroke at 
a relatively young age continues to put these patients at an increased long-term risk 
for vascular disease. 
Recurrent vascular events
In the first years following a young stroke, patients are at a substantial risk for 
recurrent stroke (annual risk of 1-3%)10, 16, 21, 22, 24, 102 and to a lesser extent for other 
cardiovascular vascular events (annual risk of 0.5-1% ).21, 24, 102 In the decades following 
these first years, there is a continuous elevated risk of recurrent events leading 
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to a cumulative risk of 20% for recurrent stroke and 17% for other cardiovascular 
events.13, 24, 102 
Identification of high risk groups for mortality and recurrent vascular events
High risk groups in terms of recurrent mortality and cardiovascular events were 
identified on the basis of the TOAST classification.144 The atherothrombotic stroke 
category was found to have the highest risk of mortality and recurrent strokes, 
compared with the other TOAST categories.81, 102, 158, 159 
Risk factors that are associated with the highest 5-year risk of recurrent stroke 
included predominantly the traditional vascular risk factors including age >40 years, 
history of TIA, type 1 diabetes and the use of antihypertensive medication.21 The 
studies available found that the more traditional cardiovascular risk factors were 
present, the higher the risk of mortality18, 19, 160 and of recurrent vascular events21, 102 
(figure 4).
Figure 3 Long-term cumulative mortality in young stroke patients and the 
general population with similar age, sex and calendar-year characteristics
Figure shows the excess mortality of young stroke patients, compared with the general population, stratified by 
age <35 or ≥ 35 years. AER: absolute excess risk (of death). Based on data from the FUTURE study.37
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Cardioembolic strokes also exhibited higher risks of mortality and recurrent vascular 
events.81, 102
Apart from differences between etiologic subgroups regarding cardiovascular 
prognosis, there also seem to be racial disparities. In a short-term follow-up study 
of young stroke patients between 18 and 45 years of age, Blacks had the highest 
30-day risk of mortality of 10%, about fourfold the risk of Asians. Whites had an 
approximately 3.5 times increased risk of 30-day mortality, compared with Asians. 
These differences were independent of the presence of traditional vascular risk 
factors.161
These findings indicate that prognosis in terms of long-term risk of cardiovascular 
disease after a young stroke is not as favorable as previously thought .16, 17, 20, 160 It 
seems that young stroke patients, especially those who resemble older stroke 
patients with respect to the presence of traditional vascular risk factors and etiology, 
also show similarity with respect to long-term cardiovascular mortality and disease. 
Of note, the prognosis of stroke patients in the ‘other determined’ category, including 
for example arterial dissection, seemed relatively favorable compared with other 
categories.102, 147, 158 However, one has to keep in mind that this category includes 
a mixture of conditions, each with a different course of the disease and treatment 
options, and thus with variable prognoses.  
Figure 4 Risk of death or recurrent vascular events stratified by number of 
traditional vascular risk factors
Figure shows the risk of mortality (part A) and recurrent vascular events (Part B), stratified by the number of 
risk factors present. Risks are adjusted for age and sex. Considered traditional vascular risk factors are diabetes, 
hypertension, smoking and hypercholesterolemia. Based on data from the FUTURE study.28, 37
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Secondary prevention
Young stroke patients are often underrepresented in large secondary prevention 
trials on anti-platelet drugs, statins and blood pressure lowering agents.159 Despite 
this, it is common practice to treat young stroke patients in accordance with 
guidelines based on extrapolated data from elderly stroke patients.162 This might be 
a sensible approach, since a considerable proportion of these young patients have 
the risk factors that are targeted in these trials and some of these trials showed 
greater benefits in younger subjects (<65 years) than in the older ones (≥65 years).163
However, these conclusions are mainly based on post-hoc analyses, as no studies 
were specifically designed to investigate on secondary prevention strategies in young 
stroke adults. Although there is no evidence that long-term secondary prevention is 
particularly harmful in young patients, this does not answer the question whether 
these long-term prevention strategies are truly beneficial in all young adults with a 
stroke, for example in those patients in whom no risk factor or presumed etiology 
could be found. In addition, treatment strategies without proven benefit are not 
particularly cost-effective.
Secondary prevention strategies in some subgroups with a specific risk factor or 
etiology have been investigated in young adults, for example those with PFO or 
antiphospholipid syndrome. For a PFO, current evidence does not show superiority 
of closure, compared with medical treatment, in preventing recurrent strokes in 
adults under 60 years of age.164 Two RCT’s performed post-hoc subgroup analyses 
in patients ≤ 45 years of age (approximately 45% of the study cohort), which 
showed no beneficial effects of closure in this subgroup.165, 166 For patients with 
an antiphospholipid syndrome, guidelines from the American Heart Association/
American Stroke Association recommend treatment with oral anticoagulants, with 
an INR between 2.0 and 3.0.167 However, an expert panel could not reach consensus 
and noted that evidence for higher or lower INR intensities or other strategies, such 
as antiplatelet therapy, was equally low.168 
In order to answer the question which patients benefit most from secondary 
prevention strategies, future (multicenter) trials should rather include patients on 
the basis of etiological subgroups, without excluding them on the basis of their 
young age. 
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Physical impairments and complications
Underlying risk factors and etiology, related to the stroke have a significant impact on 
cardiovascular mortality and morbidity. However, with respect to functional outcome 
and psychosocial consequences, prognosis will more likely be determined by a 
combination of factors, such as etiology, but also by stroke severity and subsequent 
cerebral damage, co morbidity, demands from the patients’ environment and 
patients’ coping strategies. The following parts provide an overview of prognosis in 
terms of physical problems (functional outcome, pain and epilepsy) and psychosocial 
consequences after a young stroke (cognitive impairment, depression, anxiety, 
fatigue, sexual dysfunction, and return to work).  
Functional outcome 
Neurological deficits due to a stroke are often registered during hospital admission 
and discharge, as a measure of stroke severity (National Institute of Health Stroke 
Scale (NIHSS)). However, as no studies describe these neurological deficits the years 
after discharge, the frequency of neurological deficit over time is not known. 
Functional outcome is rather assessed in terms of disability, most commonly with the 
modified Rankin Scale (mRS), a scale that predominantly assesses motor function. 
Using this scale, functional outcome is usually found to be better in younger than 
in older adults, after short-term follow-up.169 However, for young adults, not only 
the short-term, but especially information on the long-term physical disability is 
important, because of their long life-expectancy. There are only few studies that 
report long-term functional outcome after young ischemic stroke. Proportions of 
poor functional outcome (mRS>2) in young stroke survivors range from 6% to 20% 
after a mean follow-up duration of 3 to 12 years,13, 20, 170, 171 compared with a poor 
functional outcome after short-term follow-up in 40% of the older stroke survivors.172
However, being independent in basic activities of daily living may not necessarily 
mean a good outcome for young patients, in terms of handicaps. The ability to live 
independently as a young adult requires independence in performing more complex 
tasks as well; demands from society on these young patients might be higher than in 
the elderly, because of occupational obligations and often their role as a care-giver 
for a young family. Previous studies did not assess ‘handicap’ as outcome measure.
Moreover, one has to keep in mind that the survivors with a poor functional outcome 
have to cope with this consequence for a considerable number of years, given their 
in general long life-expectancy.
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Epilepsy
The prevalence of post-stroke epilepsy is reported to be between 2.4% and 14.4% 
of young ischemic stroke patients.13, 20, 24, 173-175 The highest prevalence was found in 
a study that included patients ≤50 years,175 whereas most other studies included 
patients up to 45 years. The lowest prevalence was found in a study that only 
included cryptogenic stroke.173 A more severe stroke and involvement of cortical 
structures were associated with epilepsy with or without recurrent seizures.24, 175
Post-stroke epilepsy was associated with a poor functional outcome even until a 
decade of follow-up as measured with the mRS.171.
Pain
The prevalence of post-stroke pain is frequently studied in the older stroke 
population and is reported to be as low as 1% up to as high as almost 50%.176-179 
The range is probably explained by the wide variation in methods used to assess 
post-stroke pain. Moreover, post-stroke pain originates from multiple sources, for 
example central pain from both thalamic and extra-thalamic lesions and peripheral 
pain from musculoskeletal abnormalities, such as joint contractures.176 No studies 
specifically addressed the prevalence of pain after stroke in young adults. Post-stroke 
pain appeared to be associated with a higher mortality in young stroke patients than 
those without.180 
Psychosocial consequences
Cognitive impairment
Cognitive performance is an important determinant of a young stroke patients’ 
social functioning.181 One year after stroke, up to 60% of young stroke patients, had 
a lower cognitive performance compared with stroke-free controls, depending on 
the cognitive domain tested.182, 183 Particularly in younger patients cognitive recovery 
might very well continue beyond one year after stroke. However, one study reported 
that, after a mean follow-up of 11 years, still 50% of young stroke patients had to cope 
with impairment or below average performance on at least one cognitive domain.184 
While the pattern of vascular cognitive impairment in the elderly usually shows 
prominent frontal executive impairment,185 young stroke patients in general show 
a deficits of many cognitive domains, including visuoconstruction, delayed verbal 
memory, attention, and executive function. This was especially true for patients with 
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left-hemispheric lesions, except for visuoconstruction, which was more impaired 
after right-hemispheric strokes.184 These findings suggest that cognitive impairment 
in young stroke patients displays a more global pattern than one would expect 
on the basis of a focal lesion.184 This may be the result of a more diffuse network 
dysfunction, remote from the site of the lesion.184, 186 
Aphasia was not specifically tested in long-term follow-up studies.184 One study 
that assessed language disturbances in the subacute phase after stroke found that 
young patients (<51 years) more often had a non-fluent aphasia, whereas the older 
patients more often suffered from fluent aphasia, related to the higher proportion 
of posterior infarcts in these older patients.187
Cognitive impairment may have life-changing consequences for young adults. For 
example, return to work may be impaired due to memory problems.138 A short-term 
follow-up studies found that the number of cognitive deficits predicted later inability 
to return to work.188 This is not surprising, as disturbances in multiple domains may 
interact, and the ability to compensate for impairments is diminished. For example, 
visual field defects may lead to reading disorders, and alexia may exaggerate this 
effect.189 
Depression 
Depressive symptoms are present in 28-46% of young stroke patients16, 138, 190 after 
follow-up durations of six to twelve years. Depressive symptoms may have a large 
impact on recovery and daily life after stroke. They have been associated with a poor 
functional outcome in an unadjusted analysis, but this association might have been 
confounded, for example by recurrent vascular events.138 
Stroke patients were also found to have an increased risk of suicide (up to 7%), or 
suicidal ideations (6-15%) in the acute as in the chronic phase, especially when 
patients had current or past mood disorders.191, 192 Young adults seemed to be at 
particular risk.192
In the general population, younger patients were more often classified as having a 
‘non-vascular depression’ profile, in whom a higher risk of suicide was found and 
more psychotic features, as opposed to older patients with more often a ‘vascular 
depression’ profile, with more functional disability and anhedonia.193 The small study 
sample resulted in large confidence intervals, and findings need further confirmation 
in large stroke cohorts. One might expect that the proportions of the ‘vascular’ and 
‘non-vascular depression’ profile will not differ very much between young versus 
older patients in a stroke cohort, since the younger patients have a vascular lesion as 
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well as the elderly subjects. On the other hand, the elderly subjects may still exhibit 
more often a vascular depression profile, as they might have more accumulated 
vascular damage during their lives.
Depressive symptoms should not be confused with emotionalism (e.g. emotional 
expressions outside a patient’s normal control), which was reported in 22.5% of the 
general stroke population the first month post-stroke.194 Although the two conditions 
can co-occur in one patient and depressed mood was more likely to be present in 
patients with emotionalism, most patients with emotionalism were found not to be 
depressed.194 No studies on this subject were conducted specifically in young stroke 
patients.
Anxiety
Anxiety is present in 19% of patients with a young ischemic stroke after twelve years 
of follow-up.138 No studies exist on its influence on daily life.
Fatigue
Post-stroke fatigue is present in about 50% of young stroke patients195 and appears 
to be associated with poor functional outcome195 and inability to regain pre-stroke 
activities.196, 197 However, most of previous studies that assessed this complaint were 
limited with respect to sample size197 or follow-up duration.196, 197 
Some short-term follow-up studies in older stroke patients found fatigue to be 
associated with certain lesion localizations.198,199 However, in young stroke patients, 
fatigue may very well be the result of an imbalance between demands from the 
society and reduced cognitive or physical capacity after stroke. Moreover, factors 
that underlie fatigue in the short-term after stroke may differ from those in the long-
term, but these factors remain to be clarified. 
Sexual dysfunction 
One short-term follow-up study on sexual dysfunction, focusing on young stroke 
patients (between 18 and 45 years), found diminished sexual function in 22.5% of 
patients.174 In the general stroke population, sexual dysfunction is caused by multiple 
factors, varying from neurological deficits (for example hemisensory neglect200 or 
aphasia) to psychological problems such as depression.201 The contribution of each 
factor and their effect after long-term follow-up in a young stroke population is 
unknown.
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Hypersexuality may also be a problem after a young stroke. One study found this 
problem in only one out of 71 young stroke patients, which may have been an 
underestimation, since the opinion of patients’ partners was not investigated.174 This 
is thought to result from disinhibition due to lesions in the frontostriatal circuits, but 
also after ischemic stroke in the temporal lobe.202 
Return to work
Although return to work after young stroke is an important determinant of life 
satisfaction203, 204 , or even a necessity for many people to provide for themselves, 
only few studies investigated the return to work after a young stroke. The studies 
performed reported that only 50% to 80% of stroke patients returned to work after 
a maximum follow up of four years.197, 205-208 However, most young-stroke patients 
will be of vocational age during more than a decade of their remaining life, which 
stresses the need for future studies that report on the very long-term prognosis with 
respect to return to work. There is only one study that reported after a follow-up 
of almost twelve years, when still only 40% of patients had returned to a full-time 
employment. However, these data need to be regarded with caution, since it was a 
retrospective study with a relatively low response rate.138
Not being able to return to work will not only result in individual loss to patients, 
but also in an economic burden to society, due to loss of productive years of 
employment.209 
Screening and treatment of psychosocial consequences
Cognitive impairment, mood disorders and fatigue seem very common in young 
stroke patients, and functional outcome is poor in a substantial proportion of these 
young adults. However, if not actively screened for, these consequences often go 
unnoticed by care givers, possibly leading to frustrations in young stroke patients, 
when they are not able to return to their pre-stroke activities.210 The first step in 
treatment of these invisible psychosocial issues, is their recognition.
The next step is starting a treatment. Currently, some treatment strategies exist, 
primarily consisting of occupational therapy211 or medical treatment, for example 
with antidepressants,212, 213 but these strategies are suboptimal.211 
Directions for future research
Currently, only limited data exist on long-term psychosocial consequences after a 
stroke in young adults and their impact on daily life functioning. 
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Several questions on these subjects remain to be answered.
First of all, future studies should focus on the influence of these psychosocial 
consequences on daily life and try to find clinical and demographic factors that can 
predict future psychosocial consequences. Large, prospective cohort studies are 
needed for this purpose. 
These predictors may give some insight in underlying pathophysiological mechanisms 
that lead to these psychosocial consequences, although imaging studies, post-
mortem studies or animal models would provide us with more fundamental insights.
Second, treatment strategies should be developed and their effects need to be 
quantified in clinical trials. Since a younger age comes with different rehabilitation 
goals210 specific programs need to be developed, adjusted to these young patients 
specific needs.
Conclusions and recommendations
Over the years, stroke <50 years (‘young stroke’) has been viewed as a disease with 
different risk factors and etiology and usually a better prognosis than stroke in older 
patients. However, after critical review of available literature, this view may be 
challenged.
Traditional vascular risk factors in young adults with stroke have been somewhat 
neglected in the literature, which seems unjustified given their high prevalence,159 
especially in young patients between 35 and 50 years of age. This high prevalence 
coincides with a rising incidence of stroke in young adults. This suggests that 
traditional vascular risk factors may contribute more to underlying etiology in young 
stroke patients than previously thought, although the presence of these risk factors 
is not always related to causal etiologies such as large artery atherosclerosis, as 
assessed with current diagnostic tools.
Young stroke patients are at increased risk of cardiovascular mortality and morbidity 
compared to the general population, sometimes even approaching the risks observed 
in the older stroke population. The patients classified as atherothrombotic strokes, 
with highly prevalent traditional risk factors, have the highest risk. In these patients, 
it seems plausible to start life-long treatment with secondary prevention. However, 
future trials are needed to establish which patients will benefit from different forms 
of secondary prevention. These trials should rather include patients on the basis of 
etiological subgroups, instead of inclusion of patients based on their age.
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Although many ‘young’ stroke patients are ‘old’ with respect to etiology and 
prognosis, they are ‘young’ when psychosocial consequences come into play, as most 
patients have a life expectancy of decades ahead that includes phases of their lives 
in which important life-changing decisions have to be made. Treatment strategies, 
tailored to the needs of young patients need to be developed to fulfill these needs.
Stroke in young adults is an acute disease, but with increasingly recognized life-long 
consequences. Treatment and guidance, accompanied by a life-long perspective 
should be offered to each young stroke survivor in order to remain the highest 
possible quality of post-stroke life. 
Key points
• Traditional vascular risk factors are more common in young stroke patients than 
previously thought, especially in those over 35 years of age, therein resembling ‘old’ 
stroke. 
• Long-term secondary prevention after stroke in young adults seems as important 
as in older adults, although future trials should establish which patients benefit from 
different treatment strategies, based on underlying risk factors and etiology.
• Poor functional outcome and psychosocial problems are common among the 
whole population of young stroke patients <50 years of age.
• Long-term prevalence and influence on daily life of psychosocial consequences 
need to be further investigated, to optimize specific young stroke rehabilitation 
programs.
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Summary
Stroke is one of the leading causes of death with an annual 6 million fatal events 
worldwide. Stroke mainly affects elderly people, however approximately 10% occurs 
in patients younger than 50 years. Despite this considerable proportion, only very 
limited data exist on long-term prognosis after stroke in adults aged 18-50 years. 
It is exactly this long-term prognosis that is particularly important in adults in these 
ages, given that they have a long life expectancy during a demanding period of life in 
which they start to form families, have an active social life and make decisive career 
moves.
In this thesis the long-term prognosis after stroke in young adults is described.
In part I of this thesis we describe the rationale and design of the FUTURE study; 
a prospective cohort study designed to investigate etiologies and long-term 
consequences of a TIA, ischemic stroke, or intracerebral hemorrhage in 1008 adults, 
aged 18-50 years , admitted to the Radboud University Medical Centre Nijmegen 
between January 1, 1980 and November 1, 2010 (chapter 2).
Risk factors associated with stroke in young adults
Part II of this thesis reports on risk factors that are associated with young stroke and 
recurrent vascular events. 
In chapter 3 we report on the prevalence of Fabry disease in young stroke patients. 
We could not identify any patient with Fabry Disease. We detected some genetic 
variants of unclear clinical significance that were considered in previous studies to 
be probably causative for Fabry Disease. For the first time, we investigated the long-
term risk of vascular disease in patients with these variants of unclear significance 
and these results demonstrated that these genetic variants of unclear clinical 
significance were not likely Fabry Disease causing variants. 
In chapter 4 we studied the incidence of diabetes after stroke in young adults, in 
addition to the prevalence of impaired fasting glucose. 8% Of young stroke survivors 
developed diabetes during a mean follow-up of 10 years after stroke, which is more 
than two times higher than expected compared with persons from a Dutch general 
practitioner registry with similar age and sex. Incident diabetes after TIA or ischemic 
stroke was associated with age, likely atherothrombotic stroke and family history 
of diabetes, which are among the well established risk factors for diabetes in the 
general population. Furthermore, 21% of the remaining patients had impaired 
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fasting glucose. Both patients with diabetes and patients with IFG were far more 
likely to have experienced any arterial event during follow-up than those with 
normal fasting blood glucose values.
Long-term prognosis after stroke in young adults
Part III of this thesis reports on the long-term prognosis after stroke. 
Chapter 5 reports on the long-term mortality. Even 20 years following stroke in adults 
aged 18-50 years, patients remained at a significantly higher risk of death compared 
to the general population. After surviving the first 30 days after young TIA or stroke, 
the cumulative mortality was 2-4 times increased compared to expected based on 
nationwide population mortality data. This mortality remained at this higher level 
even in the second and third decade after young stroke. 
In chapter 6 we showed that the substantial excess risk of death was mainly 
attributable to a vascular cause. This high excess risk of vascular death was most 
outspoken in men, especially during the first 15 years after stroke, and was 
accompanied by a large number of years of life lost.  
Chapter 7 describes the long-term risk of recurrent vascular events. The risk of 
recurrent vascular events remained high for at least decades after stroke. 20 
Years after young stroke, the cumulative risk of any vascular event was 12% after 
ICH, 28% after TIA and 33% after ischemic stroke. Independent of age, sex and 
decennium of inclusion, patients with atherothrombotic, cardioembolic stroke or 
lacunar stroke had a 2-3 times higher risk of recurrent stroke than in patients with 
stroke of unknown cause. Risk of other arterial events was 2-4 times higher among 
patients with atherothrombotic stroke, likely atherothrombotic stroke and stroke 
due to multiple causes than in patients with stroke of unknown cause. Furthermore, 
a medical history of diabetes, dyslipidemia or smoking was associated with other 
arterial events but not with recurrent stroke.  
Chapter 8 describes the clinical characteristics of intracerebral hemorrhage in young 
adults. Furthermore, the clinical determinants of short- and long-term prognosis 
are reported. Among adults younger than 40 years, the most reported etiology was 
a structural vascular malformation, whereas hypertension was the most reported 
etiology in adults older than 40 years. Furthermore we showed that intracerebral 
hemorrhage in general has a poor prognosis, which is mainly due to the high case-
fatality that is well predicted by the Glasgow Coma Scale. 30-Day survivors older 
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than 40 years had an increased risk death compared to the general population 
with similar age and sex, whereas this risk was not increased in younger adults. 
Recurrent intracerebral hemorrhage occurred only in patients with structural 
vascular malformations.
A long-term perspective on stroke in young adults
In part IV of this thesis, chapter 9 provides a long-term perspective on stroke in young 
adults. In this chapter the causes and consequences of young stroke are reviewed. 
We found that the evidence for a causal role of the rare causes for young stroke is 
only limited, in contrast to the increasing evidence that the traditional vascular risk 
factors may explain a considerable proportion of young stroke. We concluded that 
in the majority of young adults, the stroke may simply be a consequence of “old 
stroke” risk factors in young people, which challenges the view that “young stroke” 
exists as a separate stroke subtype with respect to etiology. Long-term prognosis 
is especially important in young adults, because of the demanding phase of life. 
However, there exist only limited data on long-term prognosis with respect to 
psychosocial consequences.
Conclusion
The studies described in this thesis showed that young stroke patients have a much 
poorer prognosis than previously thought. Young stroke is an acute disease, with 
life-long consequences. Young adults with stroke remain at a probably life-long 
increased risk of vascular disease and premature death, which stressed the need 
for probably life-long adequate monitoring and control of risk factors and life style. 
Future prospective studies are needed that address the role of implementation of 
stringent secondary prevention (both medical and lifestyle) treatment strategies in 
these young stroke patients.
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The overall objective of this thesis was to provide more insight in the long-term 
prognosis after stroke in young adults. The studies described in this thesis are based 
on data from the FUTURE study, a prospective cohort study on the etiology and long-
term consequences of stroke in 1005 young adults, aged 18 through 50 years. In this 
chapter the most important methodological considerations and main findings of the 
studies in this thesis will be discussed. Finally some potential clinical implications 
will be addressed and suggestions for future research will be provided.
Methodological considerations
Study design
The FUTURE study is a longitudinal cohort study, thereby permitting the assessment 
of exposures and outcomes in individuals over time. The design of the FUTURE 
study can be described as prospective, with a few elements that may be considered 
as retrospective, depending on its definition. A central feature of a prospective 
study design is that exposure information is recorded before the occurrence of the 
outcome and that consequently the measurement of the exposure could not be 
influenced by the outcome measure.254 In this thesis, there are two studies in which 
the exposure is measured after the occurrence of the outcome namely the studies 
on Fabry Disease and diabetes in relation to recurrent vascular events (chapters 3 
and 4 respectively). In these studies it is unlikely that the assessment of the exposure 
(Fabry Disease or Diabetes) is influenced by the occurrence of recurrent vascular 
events, since screening was performed in all patients in an identical manner without 
any knowledge on the outcome under study. However, in the study on diabetes and 
recurrent vascular events the time order of exposure and outcome is difficult to 
determine and therefore, the design of this particular study may be considered as 
cross-sectional.
Internal validity
Internal validity is a property of a study which reflects the extent to which the 
associations measured in a study are truly caused by the exposure. Non-causal 
reasons for an association between exposure and outcome can be divided into 
systematic errors and random errors. The systematic errors that threaten the 
internal validity of a study are generally classified in three categories: selection bias, 
information bias and confounding. Random errors determine the precision of a study
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Selection bias can occur through procedures used to select subjects and factors 
that influence study participation. In the presence of selection bias, the relation 
between exposure and disease is different for participants and those who do 
not.254 In our studies on the long-term risk of recurrent events and the prognosis 
after intracerebral hemorrhage, baseline characteristics did not differ between 
those patients included in the analyses and those that were potentially eligible 
for the study, but were not included in the analyses for any reason, which makes 
the presence of selection bias unlikely. The same was true for the studies on Fabry 
disease and diabetes, however these studies included only patients that survived 
until follow-up. It may be that mortality is higher among patients with Fabry disease 
or incident diabetes and that therefore the prevalence of Fabry disease or incidence 
of diabetes is underestimated. Furthermore, there is a possibility that patients with 
Fabry Disease or incident diabetes suffer from recurrent vascular events that are 
more often fatal, than those patients without these conditions.
In longitudinal studies, differential loss to follow-up is important to consider. In the 
studies on long-term mortality, the follow-up rate was as high as 97%, which makes 
the influence of possible differential loss to follow-up very unlikely.
Information bias may occur by not properly defined exposures or outcomes 
or improper methods to collect data, which may lead to misclassification of 
these variables.254 Misclassification is called differential when the degree of 
misclassification differs between the groups that are compared and non-differential 
otherwise. Non-differential misclassification results in an underestimation of the 
true association, whereas differential misclassification can either overestimate or 
underestimate the true association, depending on the situation. The FUTURE study 
has a long inclusion period, during which diagnostic equipment, acute treatment 
and secondary prevention have improved, which may have led to non-differential 
misclassification. However, this is an unavoidable feature of a long-term follow-up 
study. In the studies on long-term mortality and its underlying cause (chapter 5 and 
6 respectively), we found no evidence of such a cohort effect after statistical testing. 
To minimize its possible effects in the study on long-term risk of recurrent vascular 
events (chapter 4), we adjusted our hazard ratios for recurrent vascular events in 
TOAST subtypes, by decade of inclusion.
The incidence of recurrent vascular events (chapter 7) could have been underestimated 
by both self-report and the long follow-up period. We tried to overcome the effects 
of self-report by verification of the diagnosis by a specialist of the appropriate field 
on the basis of retrieved medical records. Another source of bias to be considered in 
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studies with a long follow-up period is recall bias. The influence of recall bias in the 
study on recurrent vascular events is probably only small as 5-year cumulative risk of 
any recurrent vascular event did not differ between patients stratified by decennium 
of inclusion (1980-1989, 1990-1999 and 2000-2010).
Finally, confounding refers to a situation in which an association is observed 
between a determinant and outcome and that this association is caused as a result 
of a third variable that correlates with both the determinant and the outcome. 
This third variable should not be in the causal chain.254 Important confounders that 
we adjusted for in the association between TOAST subtypes and long-term risk of 
recurrent vascular events and mortality, were age and sex. In these analyses, we 
intentionally did not adjust for vascular risk factors because they are part of the 
TOAST classification.
Precision is a measure of random error, which is the result of fluctuations around a 
true value.254 A reduction in random error increases precision. One of the strategies 
to improve precision is increasing the size of a study. The FUTURE study is one of 
the largest studies on stroke in young adults. However, some analyses included 
subgroups that contained only a small number of patients, resulting in large random 
variation in the estimations, as was reflected by wide confidence intervals around 
these specific estimations. This was especially the case for patients with intracerebral 
hemorrhage because of the small number of 30 day survivors in combination with a 
relatively small proportion of ICH in the overall study population (9.4%). Therefore, 
these results should be interpreted with caution. Nevertheless, the present study is 
to our knowledge the largest study ever published on long-term prognosis after ICH 
at young age.
External validity
External validity reflects the extent to which the results of a study can be generalized 
beyond the study sample. The FUTURE study is a single-center, hospital-based study, 
rather than community-based and therefore it may be that not all cases of young 
stroke in our catchment area were included in our cohort. However, only those 
patients who sustained a fatal stroke, who were not admitted to our hospital, would 
not have been included in our study. However immediate death after stroke is rare 
and patients who survive usually visit a university medical center during the course 
of their disease. In addition, there are no restrictions to be admitted to our hospital 
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and we included all consecutive cases admitted. We therefore presume that our 
study population is a representative sample of Dutch patients with young stroke, 
although formal data are lacking to prove this generalizability.
General discussion of main findings
Long-term prognosis after stroke
Prognosis after stroke in young adults has always been considered favorable. 
However, the studies in this thesis show that prognosis after stroke in young 
adults is in general not that favorable after all. Patients remain at a probably life-
long increased risk of vascular disease and vascular death. This suggests that the 
underlying vascular disease that caused stroke at a relatively young age continues to 
put these patients at an increased long-term risk for vascular disease. Presumably 
this is because this underlying vascular disease in some individuals has not been 
diagnosed accurately or managed successfully and consequently remains active. 
The conclusion that can be drawn of the studies is that young stroke is an acute 
disease, with life-long consequences.
Strong elements of the studies in this thesis that revealed this new view on prognosis 
after young stroke are the long follow-up duration, the high follow-up rate and the 
large sample size. Most previous studies on mortality or recurrent stroke had a 
follow-up duration limited to a few years,10, 13, 15-18, 20-22, 24 but our studies demonstrated 
a persistent increase in cumulative risk of recurrent stroke and mortality, also after 
the initial few years. Furthermore, we showed for the first time that young adults 
with stroke remain at a significantly higher risk of death compared to the general 
population. This was done by comparing mortality after young stroke with that of 
the general population with similar age, sex and calendar-year characteristics, using 
the approach of indirect standardization.
Secondary prevention might have influenced our results. In our study about 89% of 
TIA or ischemic stroke and 31% of ICH were using secondary preventive medication 
at discharge. Consequently the shown high risk of recurrent vascular disease and 
vascular death might even be an underestimation attributable to the use of this 
medication, although during 30 years of follow-up some patients will have stopped 
or (re)started secondary preventive medication.
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Identification of high-risk groups
In the FUTURE study, the highest risk of recurrent vascular events and death was 
present in patients with atherothrombotic, cardioembolic stroke or lacunar stroke, 
which are stroke subtypes associated with the traditional vascular risk factors as 
observed in older stroke patients. These findings suggest that stroke in young 
adults in general has more in common with stroke among the elderly and perhaps 
indicates a certain vulnerability of these patients at already relatively young age for 
cardiovascular risk factors. These suggestions are in accordance with the conclusions 
of our review on the available literature on risk factors and prognosis of ischemic 
stroke in young adults. Screening for traditional vascular risk factors is generally 
only recommended in the acute phase after stroke,94 thus risk factors that emerge 
after a young stroke may go undetected in many patients. One of these risk factors 
is diabetes and in this thesis we demonstrated that impaired fasting glucose and 
diabetes after stroke in young patients are frequently present and associated with 
recurrent vascular events, but may remain unnoticed in many patients.
Clinical relevance
Extrapolating the findings of the studies in this thesis suggest that secondary 
prevention after stroke in young adults is a long-term, and probably lifelong, 
endeavor and that efforts to reduce the burden of stroke among young adults should 
extend beyond acute treatment and early secondary prevention into the long term. 
The FUTURE study and the review in chapter 9 revealed that traditional vascular 
risk factors are very prevalent in young adults with stroke and that these risk factors 
are associated with a high long-term risk of vascular disease. Young stroke patients 
with these risk factors should be recognized by clinicians as a high-risk group. These 
traditional risk factors should be diagnosed accurately at presentation, treated 
appropriately and carefully monitored over the long-term. Current protocols and 
guidelines only recommend screening of young stroke patients in the acute phase 
and only few months thereafter. However, as previously undiagnosed risk factors 
may emerge after stroke, risk factors also may need to be sought and controlled in 
the long-term. The identification of a high risk young stroke subpopulation may offer 
opportunities for individualized long-term secondary prevention strategy. Although 
the FUTURE study can identify these high risk subgroups, it cannot investigate the 
effect of (prolonged) secondary prevention in these subgroups.
176
Chapter 11
Besides clinicians, also young stroke patients themselves need to be aware of the 
high long-term risk of vascular disease. The quantified risks in this thesis can be used 
to inform them and in order to play their role as director of their own treatment and 
care.
Future directions
The incidence of stroke in young adults is rising,7 and as a consequence also its 
financial, physical and psychosocial burden to patients, family and society, which 
should be recognized in setting national health priorities. Future research is needed 
to reduce the increasing burden of young stroke. An important topic of future 
research should be secondary prevention in these young adults.
Secondary prevention after stroke in young patients has never been formally 
investigated. The question remains unanswered whether these patients should take 
these medications for the rest of their lives, especially when no vascular risk factors 
have been detected. Randomized controlled trials comparing patients that stop or 
continue medication after specified time, are necessary to answer the question 
whether (all of) these young patients should be on secondary prevention (both 
medical and lifestyle) for life. These studies should evaluate the effectiveness, safety, 
and cost of interventions to prevent recurrent cardiovascular events in these young 
patients.
Stroke patients are treated by a “one size fits all approach”. However, stroke patients 
constitute a heterogeneous group with respect to underlying etiology and long-
term risk of recurrent vascular events and death. Moreover, secondary preventive 
treatment is known to fail in a substantial part of the patients.255-257 Therefore, stroke 
patients might benefit from a personalized medicine strategy. An important example 
of such an approach is evolving in area of genetics research. 
Genetic factors are known to play a role in both the efficacy of secondary prevention 
used in stroke patients, but also in the susceptibility of side effects.258 Despite of this 
knowledge, all stroke patients are treated the same, irrespective of their genotypes. 
Many stroke patients are likely to benefit from a personalized secondary preventive 
strategy based on their genotype, but future studies are needed to investigate 
formally the role of such a secondary preventive strategy in these patients. First the 
exact extent of genetic variation associated with differential response to secondary 
preventive medication in stroke patients should be investigated, stratified by high-
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risk groups of recurrent events. Thereafter, the cost-effectiveness of a genetic 
personalized medicine approach in stroke patients should be investigated in a 
prospective study.
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Dutch summary | Nederlandse samenvatting
Beroerte is een van de meest voorkomende doodsoorzaken en is jaarlijks fataal in 
6 miljoen mensen wereldwijd. Beroerte treft voornamelijk oudere mensen, echter 
ongeveer 10% van de patiënten die een beroerte krijgt is jonger dan 50 jaar.  Dit 
wordt in de Engelse literatuur ook wel “young stroke” genoemd. Ondanks dit 
aanzienlijke aandeel young stroke is er slechts weinig bekend over de lange termijn 
prognose na een beroerte in volwassenen tussen 18 en 50 jaar. Juist deze lange 
termijn prognose is heel belangrijk voor volwassenen met deze leeftijden, aangezien 
zij normaal gesproken een lange levensverwachting hebben, gedurende een 
veeleisende periode van het leven. In deze periode zijn velen bezig met het stichten 
van een gezin, hebben een actief sociaal leven en maken belangrijke stappen in hun 
carrière.
In dit proefschrift wordt de lange termijn prognose na een young stroke beschreven.
In deel I van dit proefschrift worden de gedachte achter en de opzet van de FUTURE 
studie beschreven. FUTURE is een prospectieve cohort studie die ontworpen is om 
de oorzaken en lange termijn gevolgen te onderzoeken van een TIA, herseninfarct 
of hersenbloeding in 1008 volwassenen, in de leeftijd 18-50 jaar, behandeld in het 
RadboudUMC, tussen 1 januari 1980 en 1 november 2010.
Risicofactoren die geassocieerd zijn met young stroke
Deel II van dit proefschrift beschrijft risico factoren die geassocieerd zijn met young 
stroke en recidiverende vasculaire gebeurtenissen. Hoofdstuk 3 gaat over de 
prevalentie van de ziekte van Fabry in young stroke patiënten. In onze studie konden 
we geen patiënt met de ziekte van Fabry identificeren. We detecteerden wel enkele 
genetische varianten waarvan de klinische significantie onbekend is, maar die in 
eerdere studies werden beschouwd als waarschijnlijk causaal voor de ziekte van 
Fabry. Voor de eerste keer hebben wij het lange termijn risico op vasculaire ziekte 
onderzocht in deze patiënten met genetische varianten met onbekende klinische 
betekenis. Onze resultaten laten zien dat het onwaarschijnlijk is dat deze varianten 
de ziekte van Fabry veroorzaken.
In hoofdstuk 4 werd de incidentie van diabetes en de prevalentie van gestoorde 
glucose tolerantie na een young stroke onderzocht. 8% Van de patiënten die een 
young stroke overleefde, ontwikkelde diabetes gedurende een gemiddelde tijdsduur 
van 10 jaar na de beroerte. Dit is meer dan twee keer hoger dan verwacht op basis 
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van gegevens van mensen met dezelfde leeftijd en geslacht in een Nederlandse 
huisartsen registratie. De incidentie van diabetes na een TIA of herseninfarct is 
geassocieerd met leeftijd, beroerte met waarschijnlijk atherotrombotische oorzaak 
en diabetes in de familiaire voorgeschiedenis. Deze factoren behoren allemaal 
tot de bekende risicofactoren voor het ontwikkelen van diabetes in de algemene 
bevolking. 21% van de overige patiënten had een gestoorde glucose tolerantie. Het 
ondergaan van een nieuwe arteriële gebeurtenis gedurende de studieduur was veel 
meer waarschijnlijk in zowel de patiënten met diabetes als de patiënten met de 
gestoorde glucose tolerantie dan in de patiënten die normale bloed glucose spiegels 
hadden.
Lange termijn prognose na een young stroke
In deel III wordt de lange termijn prognose na een beroerte beschreven. 
In hoofdstuk 5 werd het lange termijn sterfte risico onderzocht. Zelfs 20 jaar na een 
beroerte in volwassenen in de leeftijd van 18-50 jaar, bleven patiënten een significant 
verhoogd sterfte risico houden in vergelijking met de algemene bevolking. Na het 
overleven van de eerste 30 dagen na een TIA of beroerte op jonge leeftijd, was het 
cumulatieve sterfte risico na 20 jaar 2-4 keer hoger dan verwacht, gebaseerd op 
overlevingstabellen van de Nederlandse bevolking. Dit verhoogd sterfte risico bleef 
aanwezig tot zelfs in het 2e en 3e decennium na de young stroke. 
In hoofdstuk 6 laten we zien dat de substantiële oversterfte voornamelijk een 
vasculaire oorzaak heeft. Deze hoge oversterfte was vooral aanwezig in mannen 
gedurende de eerste 15 jaar na de beroerte en veroorzaakte een groot verlies aan 
levensjaren.
Hoofdstuk 7 beschrijft het lange termijn risico op een recidiverende vasculaire 
gebeurtenis en dit risico bleef hoog gedurende minstens decennia na de beroerte. 
20 Jaar na de beroerte op jonge leeftijd was het cumulatieve risico op het ondergaan 
van een nieuwe vasculaire gebeurtenis 12% na een hersenbloeding, 28% na een 
TIA en 33% na een herseninfarct. Onafhankelijk van leeftijd, geslacht en decennium 
van inclusie, hadden patiënten met een atherotrombotische, cardio-embolische 
of lacunaire beroerte een 2-3 keer hoger risico op een recidiverende beroerte 
dan in patiënten met een beroerte door onbekende oorzaak. Het risico op andere 
arteriële gebeurtenissen dan een beroerte, was 204 keer verhoogd in patiënten 
met een (waarschijnlijk) atherotrombotische beroerte en beroerte met meerdere 
183
V
Dutch summary | Nederlandse samenvatting
oorzaken in vergelijking met patiënten met een beroerte door onbekende oorzaak. 
Verder waren diabetes in de voorgeschiedenis, gestoorde vetstofwisseling en roken 
geassocieerd met andere arteriële gebeurtenissen maar niet met een recidiverende 
beroerte.
Hoofdstuk 8 beschrijft de klinische karakteristieken van een hersenbloeding in jonge 
volwassenen en de klinische determinanten van de korte en lange termijnprognose. 
De meest gerapporteerde oorzaak van de hersenbloeding was structurele 
vaatafwijking in patiënten jonger dan 40 jaar en hypertensie in patiënten ouder 
dan 40 jaar. Verder lieten we zien dat een hersenbloeding over het algemeen 
een slechte prognose heeft en dat dit voornamelijk komt door het hoge aandeel 
fatale hersenbloedingen. Het 30-dagen sterfte risico wordt goed voorspeld door de 
Glasgow Coma Scale. Patiënten die ouder waren dan 40 jaar en de eerste 30 dagen 
na de hersenbloeding overleefden hadden een verhoogd sterfte risico in vergelijking 
met de algemene bevolking met gelijke leeftijd en geslacht, terwijl dit risico niet 
verhoogd was in patiënten jonger dan 40 jaar. Recidiverende hersenbloeding 
gebeurde alleen in patiënten met structurele vaatafwijkingen.
Een lange termijn perspectief op young stroke
In deel IV van dit proefschrift, beschrijft hoofdstuk 9 het lange termijn perspectief 
van beroerte in jonge volwassenen. In dit hoofdstuk worden de oorzaken en conse-
quenties van beroerte op jonge leeftijd samengevat. We vonden dat het bewijs be-
perkt is voor een causale rol voor de zeldzame oorzaken van een beroerte op jonge 
leeftijd. Daarentegen is er toenemend bewijs dat traditionele vasculaire risicofac-
toren mogelijk een aanzienlijk deel van de beroertes op jonge leeftijd verklaren. 
We concludeerden dat in het merendeel van de jonge volwassenen, de beroerte 
een consequentie is van “oude beroerte”-risicofactoren in jonge mensen. Daarmee 
wordt de opvatting in twijfel getrokken dat “beroerte op jonge leeftijd” bestaat als 
een afzonderlijk etiologisch subtype onder beroertes. De lange termijn prognose is 
vooral belangrijk in jonge volwassenen vanwege de veeleisende levensfase. Echter 
de beschikbare gegevens over lange termijn prognose met betrekking tot psycho-
sociale consequenties zijn zeer beperkt.
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Conclusie
De studies die beschreven zijn in dit proefschrift laten zien dat patiënten met een 
beroerte op jonge leeftijd een veel slechtere prognose hebben dan voorheen 
gedacht werd. Beroerte op jonge leeftijd is een acute ziekte, met levenslange 
gevolgen. Patiënten met een beroerte op jonge leeftijd blijven een waarschijnlijk 
levenslang verhoogd risico houden op vasculaire ziekte en voortijdig overlijden. Dit 
benadrukt de noodzaak voor waarschijnlijk levenslange controle van risicofactoren 
en leefstijl. Toekomstige prospectieve studies zijn nodig die de rol onderzoeken van 
de implementatie van strikte secundaire preventie strategieën (zowel medisch als 
leefstijl) in deze patiënten met beroerte op jonge leeftijd.
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List of abbreviations
%AER = cause-specific AER as proportion of AER of all cause death
AER = absolute excess risk 
AUC = area under receiver operating curve
CI = confidence interval
FD = Fabry disease
FUTURE = Follow-Up of Transient ischemic attack and stroke patients and 
Unelucidated Risk factor Evaluation
Gb3 = globotriaosylceramide
GCS = Glasgow Coma Scale
GLA = α-galactosidase A gene
GVUS = genetic variants of unknown significance
HR = hazard ratio
ICH = intracerebral hemorrhage 
IFG = impaired fasting glucose
IQR = interquartile range 
IS =  ischemic stroke
Lyso-Gb3 = globotriaosylsphingosine 
mRS = modified Rankin Score
NIHSS = National Institute of Health Stroke Scale
PFO= persistent foramen ovale
SD = standard deviation
SMR = standardized mortality ratio
TIA = transient ischemic attack
TOAST = Trial of ORG 10172 in Acute Stroke Treatment classification
YLL = years of life lost
α-GAL = α-galactosidase A enzyme
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